



# GAINING MOMENTUM

**2025 ANNUAL REPORT**



## A MESSAGE FROM THE CHIEF EXECUTIVE OFFICER

### *To My Fellow Stakeholders,*

I am honored to join Henry Schein as Chief Executive Officer and to help lead this remarkable organization into its next chapter. This Company is built on a strong foundation of purpose, trust, resilience, and values, and those principles will continue to guide us forward.

I want to begin by thanking Stan Bergman for his extraordinary leadership and for building an organization that is both a market leader and trusted partner across health care. Stan's legacy of "doing well by doing good" is deeply embedded in Henry Schein's culture, and I am committed to honoring that legacy while building on it with focus, clarity, and a long-term perspective.

### **Leading an Iconic Company with an Impactful Mission**

Henry Schein's impact is meaningful and far-reaching. Health care is, at its core, profoundly human. The products we deliver, the technologies we support, and the practices we serve ultimately touch patients, families, and communities every day. This sense of purpose is embraced by Team Schein Members across the organization and it will remain a defining strength as we move forward together.

Many have asked why I joined Henry Schein after more than two decades at Thermo Fisher Scientific. The answer is both strategic and personal. Henry Schein is an iconic company with a strong market position, deeply trusted customer relationships, and advanced capabilities that create meaningful value for all stakeholders. The Company's role as an indispensable partner to practice-based health care is truly distinctive, and the opportunity to lead an organization with this scale and impact is compelling.


Beyond strategy, my decision was guided by personal conviction. I believe expanding access to high-quality care is a responsibility we should always be working to advance. Henry Schein's mission, to ensure health care providers have the tools, technology, and support they need to care for their patients, resonates deeply with me. The most successful organizations are those that help their customers succeed, and I am committed to ensuring Henry Schein continues to lead with that principle at the center of everything we do.

### **Financial Results\***

Our 2025 results reflect stable end markets and sequential market share gains. Throughout the year we reported accelerating sales growth and strong momentum in our businesses, ending the year with fourth quarter sales having the strongest sales growth results in 15 quarters. This demonstrates we are effectively executing our **2025-2027 BOLD+1 strategic plan**.

Total net sales reached \$13.2 billion, an increase of 4.0% from 2024. GAAP net income in 2025 was \$398 million, or \$3.27 per diluted share, compared to \$390 million, or \$3.05 per diluted share, in 2024. Non-GAAP net income increased to \$605 million in 2025, or \$4.97 per diluted share, versus \$605 million, or \$4.74 per diluted share, in 2024. Operating cash flow in 2025 was \$712 million in 2025, compared to \$848 million in 2024, which benefited from some delayed collections of customer receivables from 2023, and we completed \$850 million in stock repurchases, including \$250 million from the Accelerated Share Repurchase plan announced in the first quarter.

We gained market share across each of our reporting segments and remain confident in the underlying strength of our business, and we are well-positioned to continue to perform well in 2026.



\* See GAAP to non-GAAP reconciliation on page 8



## Our 2025–2027 BOLD+1 Strategic Plan: Strengthening Our Competitive Advantage

While Henry Schein's historic strength has been product distribution, we have successfully built a portfolio of complementary high-growth, high-margin technology, and owned-brand manufacturing businesses. Our strategy is to integrate these businesses to provide customers with solutions unmatched in the industry.

This BOLD+1 strategy provides us with a path to sustainable growth. Here are some of the achievements of last year:

**Building High-Growth New Businesses** — We have accelerated growth through new specialty product innovations and cloud and digital solutions. This includes new AI integration and revenue cycle management tools to accelerate revenues of technology solutions. We have also entered into the orthopedic market through TriMed, which provides extremities solutions that create synergies with the medical distribution business, and have expanded our Home Solutions platform, now \$400 million in annual revenues, to address the growing home health care market.

For the full-year of 2025, our high-growth, high-margin businesses, which include implants and biomaterials, endodontics, orthodontics, orthopedics, technology and value-added services, accounted for approaching 50% of our total operating income. Including income from our corporate brand product offerings, this increases to almost 60% of total operating income and almost \$3 billion, or 25%, of our sales.

**Increasing Operational Efficiencies through New Value Creation Initiatives** — Adding to the 2024 restructuring plan, which generated more than \$100 million in annual run-rate savings, we have launched a value creation initiative targeting an additional \$200 million in net savings over the next few years through product and pricing optimization and lower cost-to-serve while maintaining our high customer satisfaction ratings.

**Leverage Our Sales Assets to Accelerate Sales Growth** — By implementing dedicated sales channels through our distribution business for Henry Schein Products, such as Endodontics and Orthodontics, and capitalizing on our corporate brand and distribution networks, we are leveraging businesses and solutions to accelerate sales growth across all business segments and broaden customer relationships.

**Advancing Digital Innovation** — Digital innovation is central to our strategy, enhancing both customer capabilities and operational effectiveness. New developments have enhanced the functionality of Dentrix and Dentrix Ascend practice management software solutions. These include Eligibility Pro software that provides practices with important patient information on insurance coverage, Reserve by Google that allows patients to book dental appointments directly from Google's Chrome browser, and integrated AI solutions to improve clinical and operational workflows. Through LinkIT, we can now offer our customers 3-Click Dentistry to enable seamless digital workflow integration within Dentrix from image capture to fabrication. The new HenrySchein.com website has also been successfully launched in the U.S., Canada, U.K., and Ireland with enhanced digital marketing features, personalized experiences, search engine optimization, and streamlined ordering capabilities.

**Delivering Long-Term Value for All Stakeholders** — As we advance our strategy, we remain committed to the “+1” element of BOLD+1, strengthening trusted relationships and delivering sustainable, long-term value for stakeholders of our Mosaic of Success: customers, suppliers, shareholders, society, and Team Schein Members. Sustainability continues to be an important value driver, and in 2025 we completed our net zero transition plan, establishing a clear, data-driven roadmap for measurable decarbonization across our operations while supporting greater operational efficiency and cost discipline. In parallel, we invested in our Team Schein Members by expanding wellness, engagement, and


inclusion initiatives that support performance, strengthen execution, and foster innovation. Grounded in data and disciplined execution, we are building a more resilient and forward-looking company, reinforced by our values of Community, Caring, and Career. Working together, Team Schein is positioned to drive sustainable and profitable growth as we make the world a healthier place.

### Gaining Momentum — the Opportunity Ahead

As our strong foundation demonstrates, Henry Schein has enormous potential. We benefit from our deep customer relationships, trusted brands, valuable technology assets, a culture grounded in clear values, and an exceptional team that has shown remarkable resilience through significant challenges.

The health care market is evolving rapidly, and the pace of innovation continues to accelerate. Artificial intelligence, digital health solutions, and new care delivery models are reshaping how health care is delivered. For Henry Schein, this is not a threat, but a powerful opportunity. Our customers look to us to help them stay at the forefront of health care, and we must continue to challenge ourselves with new ideas and technologies to maintain and build on the trust they place in us. The opportunity in front of us is greater than it has ever been.

Our path forward is clear: deliver a superior customer experience, drive operational excellence, and achieve long-term, sustainable growth. We will continue to move with intention, because great organizations grow by staying curious, innovative, and remaining close to their customers. This is about honoring what already works and our strong legacy, accelerating value creation, and evolving where we can be even better.



### In Closing

I am passionate about building businesses where people, teams, and impact grow stronger. I am joining Team Schein with deep gratitude for the legacy that has been built, and I am excited about what we can accomplish together, as we deliver exceptional value for our shareholders and accelerate our momentum going into 2026.

Along with the entire Henry Schein Board of Directors, I extend my sincere thanks to every Team Schein Member for your dedication and hard work and for so warmly welcoming me into this great company. We remain steadfast in our commitment to deliver long-term value and to advance our mission of assisting health care professionals to deliver quality care, enhance practice efficiency, and increase profitability.

To our shareholders, thank you for your continued confidence in Henry Schein. I look forward to earning your trust and continuing to guide Henry Schein along a path of purpose, integrity, efficiency, and growth.


Sincerely,

Frederick M. Lowery



*Chief Executive Officer,  
Henry Schein Inc. and Director*

March 2026


Forward-looking statements made in this report are subject to the risks specified in the Safe Harbor statement in the Company's Form 10-K filing and forward-looking statement language in our press release filed on Form 8-K on February 24, 2026



## EXECUTIVE MANAGEMENT



## BOARD OF DIRECTORS



## EXECUTIVE MANAGEMENT

<b>Frederick M. Lowery*</b>	Chief Executive Officer, Henry Schein Inc. and Director
<b>Andrea Albertini*</b>	Chief Executive Officer, Global Distribution and Technology
<b>R. Steven Boggan</b>	Chief Executive Officer, Global Oral Reconstruction Group, Americas
<b>Michael S. Ettinger*</b>	Executive Vice President, Chief Operating Officer
<b>David Kochman</b>	Senior Vice President, Chief Corporate Affairs Officer
<b>Mark E. Mlotek*</b>	Executive Vice President, Chief Strategic Officer
<b>James Mullins</b>	Senior Vice President, Global Supply Chain
<b>Kelly Murphy</b>	Senior Vice President, General Counsel
<b>Christopher Pendergast</b>	Senior Vice President, Chief Technology Officer
<b>Tom Popeck*</b>	Chief Executive Officer, Henry Schein Products Group
<b>Christine Sheehy*</b>	Senior Vice President, Chief Human Resources Officer
<b>Ronald N. South*</b>	Senior Vice President, Chief Financial Officer

\*Executive Officers

## BOARD OF DIRECTORS

<b>Stanley M. Bergman</b>	Chairman of the Board, Henry Schein, Inc.
<b>Mohamad Ali</b>	Senior Vice President and Head of IBM Consulting, IBM Corporation
<b>William K. "Dan" Daniel</b>	Executive Advisor, Kohlberg Kravis Roberts & Co. L.P. (KKR)
<b>Deborah Derby</b>	CEO, The Honey Baked Ham Company, LLC; and Former President and CEO, Carrols Restaurant Group, Inc.
<b>Carole T. Faig</b>	Former U.S. Health Sector Leader, EY LLP
<b>Joseph L. Herring</b>	Former Chairman and Chief Executive Officer, Covance Inc.
<b>Robert J. Hombach</b>	Former Executive Vice President, CFO and COO, Baxalta, Inc.
<b>Kurt P. Kuehn</b>	Former Chief Financial Officer, United Parcel Service, Inc.
<b>Philip A. Laskawy</b>	Lead Director, Henry Schein, Inc.; and Retired Chairman and CEO, EY LLP
<b>Max Lin</b>	Partner, Kohlberg Kravis Roberts & Co. L.P. (KKR)
<b>Frederick M. Lowery</b>	Chief Executive Officer, Henry Schein Inc.
<b>Anne H. Margulies</b>	Former Vice President and Chief Information Officer, Harvard University
<b>Scott Serota</b>	Former President and Chief Executive Officer of Blue Cross Blue Shield Association
<b>Bradley T. Sheares, Ph.D.</b>	Former Chief Executive Officer, Reliant Pharmaceuticals, Inc.; and Former President of U.S. Human Health, Merck & Co.
<b>Reed V. Tuckson, M.D., FACP</b>	Managing Director of Tuckson Health Connections, LLC; Co-Founder and Convener, Black Coalition Against COVID-19; and Co-Founder and Board Chairman of the Coalition For Trust in Health & Science

## COMMON STOCK

Henry Schein Common Stock trades on the Nasdaq® Stock Market under the symbol "HSIC."

## STOCKHOLDER REPORTS AND INVESTOR INQUIRIES

For stockholder inquiries, including requests for quarterly and annual reports, contact our Investor Relations department at (631) 843-5500, or email your request to [investor@henryschein.com](mailto:investor@henryschein.com). Printed materials can also be requested through the Company's Website.

## FORM 10-K

Our Annual Report on Form 10-K for the fiscal year ended December 27, 2025 has been filed with the SEC and is available free of charge through our website, [www.henryschein.com](http://www.henryschein.com). Stockholders may also obtain a copy of the Form 10-K upon request via email at [investor@henryschein.com](mailto:investor@henryschein.com). In response to such request, the Company will furnish without charge the Form 10-K, including financial statements, financial schedules, and a list of exhibits.

## INDEPENDENT AUDITORS

BDO USA, P.C.  
200 Park Avenue  
New York, New York 10166

## LEGAL COUNSEL

Proskauer Rose LLP  
Eleven Times Square  
New York, New York 10036

## STOCK TRANSFER AGENT

For address changes, account cancellation, registration changes, and lost stock certificates, please contact:

Continental Stock Transfer & Trust Company  
1 State Street, 30th Floor  
New York, New York 10004  
(212) 509-4000

## NON-GAAP DISCLOSURES

The following table sets forth, for the applicable periods, a reconciliation of operating income and net income attributable to Henry Schein, Inc., and diluted earnings per share presented following generally accepted accounting principles in the United States ("GAAP") to these measures adjusted to reflect the effects of restructuring and related costs, litigation settlements, impairment of intangible and capitalized assets, cyber incident insurance proceeds, net of third-party advisory expenses, acquisition intangible amortization, change in contingent consideration, and costs associated with shareholder advisory matters and select value creation costs.

## USE OF NON-GAAP MEASURES

The information in the table includes financial measures that are not calculated and presented in accordance with GAAP. The table reconciles differences between each of operating income, net income attributable to Henry Schein, Inc., and diluted earnings per share attributable to Henry Schein, Inc., each as presented in accordance with GAAP, and comparable non-GAAP amounts. We eliminated the effect of the items listed below to assist in evaluating the underlying operational performance of our business, excluding such costs, over the periods presented. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.

## NOTES

(1) During 2025, we recorded restructuring and related costs of \$105 million (\$72 million, net of tax and noncontrolling interests). During 2024, we recorded restructuring and related costs of \$110 million (\$79 million, net of tax and noncontrolling interests). During 2023, we recorded restructuring and related costs of \$80 million (\$53 million, net of tax and noncontrolling interests). The effect that these charges had on 2025, 2024, and 2023, earnings per diluted share attributable to Henry Schein, Inc. was \$(0.59), \$(0.62), and \$(0.40), respectively.

(2) During 2025, we recorded a charge of \$5 million (\$4 million, net of tax) related to estimated settlement amounts for litigation at one of our businesses as well as certain opioid related settlements. During 2024, we recorded a charge of \$5 million (\$4 million, net of tax) related to estimated settlement amounts for litigation related to the October 2023 cyber incident and settlement of certain opioid related lawsuits. The effect that this charge had on earnings per diluted share attributed to Henry Schein, Inc. was \$(0.03) and \$(0.03), respectively.

(3) During 2025, 2024, and 2023, we recorded impairment charges on certain intangible assets of \$16 million (\$12 million, net of tax), \$1 million (\$0 million, net of tax), and \$7 million (\$5 million, net of tax and noncontrolling interests), respectively. The effect that these charges had on 2025, 2024, and 2023 earnings per diluted share attributable to Henry Schein, Inc. was \$(0.10), \$(0.00), and \$(0.04), respectively.

(4) Represents impairment of certain capitalized asset costs of \$12 million (\$6 million, net of tax and noncontrolling interests) during 2024 and \$27 million (\$19 million, net of tax) during 2023. The effect that these costs had on 2024 and 2023 diluted earnings per share attributed to Henry Schein, Inc. was \$(0.05) and \$(0.15), respectively.

	YEARS ENDED		
	December 27, 2025	December 28, 2024	December 30, 2023
	(in millions, except per share data)		
Operating income (GAAP)	\$ 653	\$ 621	\$ 615
Operating margin (GAAP)	5.0%	4.9%	5.0%
Non-GAAP Adjustments:			
Restructuring and related costs (1)	\$ 105	\$ 110	\$ 80
Litigation settlements (2)	5	5	--
Impairment of intangible assets (3)	16	1	7
Impairment of capitalized assets (4)	--	12	27
Cyber incident insurance proceeds, net of third-party advisory expenses (5)	(20)	(31)	11
Acquisition intangible amortization (6)	179	184	151
Change in contingent consideration (7)	(2)	45	--
Costs associated with shareholder advisory matters and select value creation consulting costs (8)	36	2	--
Adjusted operating income (Non-GAAP)	\$ 972	\$ 949	\$ 890
Adjusted operating margin (Non-GAAP)	7.4%	7.5%	7.2%
Net income attributable to Henry Schein, Inc. (GAAP)	\$ 398	\$ 390	\$ 416
Adjustments, net of tax and attribution to noncontrolling interests:			
Restructuring and related costs (1)	\$ 72	\$ 79	\$ 53
Litigation settlements (2)	4	4	--
Impairment of intangible assets (3)	12	--	5
Impairment of capitalized assets (4)	--	6	19
Cyber incident insurance proceeds, net of third-party advisory expenses (5)	(15)	(23)	8
Acquisition intangible amortization (6)	109	112	92
Change in contingent consideration (7)	(2)	35	--
Costs associated with shareholder advisory matters and select value creation consulting costs (8)	27	2	--
Adjusted net income attributable to Henry Schein, Inc. (Non-GAAP)	\$ 605	\$ 605	\$ 593
Diluted earnings per share attributable to Henry Schein, Inc. (GAAP)	\$ 3.27	\$ 3.05	\$ 3.16
Diluted earnings per share attributable to Henry Schein, Inc. (Non-GAAP)	\$ 4.97	\$ 4.74	\$ 4.50
Diluted weighted-average common shares outstanding	121,718	127,779	131,748

Note: Amounts may not sum due to rounding.

(5) Represents cyber incident insurance proceeds, net of third-party advisory expenses of \$20 million (\$15 million, net of taxes) and \$31 million (\$23 million, net of taxes) during 2025 and 2024, respectively, and one time professional and other fees of \$11 million (\$8 million, net of taxes) during 2023, related to our Q4 2023 cyber incident. The effect that these costs had on 2025, 2024, and 2023 diluted earnings per share attributed to Henry Schein, Inc. was \$0.12, \$0.18, and \$(0.06), respectively.

(6) During 2025, 2024, and 2023, we recorded amortization expense from acquired intangible assets of \$179 million (\$109 million, net of tax and noncontrolling interests), \$184 million (\$112 million, net of tax and noncontrolling interests), and \$151 million (\$92 million, net of tax and noncontrolling interests), respectively. The effect that these charges had on 2025, 2024, and 2023 earnings per diluted share attributable to Henry Schein, Inc. was \$(0.90), \$(0.88), and \$(0.70), respectively.

(7) Represents a change in the fair value of contingent consideration of (\$2) million (\$2 million, net of taxes) during 2025 related to acquisitions, and \$45 million (\$35 million, net of taxes) during 2024 related to certain 2022 and 2023 acquisitions. The effect that this charge had on 2025 and 2024 earnings per diluted share attributed to Henry Schein, Inc. was \$0.02 and \$(0.27), respectively.

(8) Represents costs associated with shareholder advisory matters and select value creation consulting costs of \$36 million (\$27 million, net of taxes) and \$2 million (\$2 million, net of taxes) recorded during 2025 and 2024, respectively. The effect that this charge had on 2025 and 2024 earnings per diluted share attributed to Henry Schein, Inc. was \$(0.22) and \$(0.01), respectively.

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549  
**FORM 10-K**

(Mark One)

- ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the fiscal year ended December 27, 2025
- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-27078  
**HENRY SCHEIN, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**11-3136595**  
(I.R.S. Employer Identification No.)

**135 Duryea Road**  
**Melville, New York**  
(Address of principal executive offices)  
**11747**  
(Zip Code)

**(631) 843-5500**  
(Registrant's telephone number, including area code)

**Securities registered pursuant to Section 12(b) of the Act:**

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$.01 per share	HSIC	The Nasdaq Global Select Market

**Securities registered pursuant to Section 12(g) of the Act: None**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

YES:  NO:

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

YES:  NO:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES:  NO:

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YES:  NO:

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer:  Accelerated filer:  Non-accelerated filer:  Smaller reporting company:

Emerging growth company:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

YES:  NO:

The aggregate market value of the registrant's voting stock held by non-affiliates of the registrant, computed by reference to the closing sales price as quoted on the Nasdaq Global Select Market on June 28, 2025, was approximately \$8,885,457,000.

As of February 17, 2026, there were 114,704,121 shares of registrant's Common Stock, par value \$.01 per share, outstanding.

**Documents Incorporated by Reference:**

Portions of the Registrant's definitive proxy statement to be filed pursuant to Regulation 14A not later than 120 days after the end of the fiscal year (December 27, 2025) are incorporated by reference in Part III hereof.

## TABLE OF CONTENTS

	<u>Page Number</u>
<b>PART I</b>	
ITEM 1. Business	3
ITEM 1A. Risk Factors	28
ITEM 1B. Unresolved Staff Comments	42
ITEM 1C. Cybersecurity	43
ITEM 2. Properties	45
ITEM 3. Legal Proceedings	45
ITEM 4. Mine Safety Disclosures	45
<b>PART II</b>	
ITEM 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	46
ITEM 6. [Reserved]	47
ITEM 7. Management's Discussion and Analysis of Financial Condition and Results of Operations	48
ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk	67
ITEM 8. Financial Statements and Supplementary Data	69
ITEM 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	137
ITEM 9A. Controls and Procedures	137
ITEM 9B. Other Information	141
ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	141
<b>PART III</b>	
ITEM 10. Directors, Executive Officers and Corporate Governance	141
ITEM 11. Executive Compensation	141
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	142
ITEM 13. Certain Relationships and Related Transactions, and Director Independence	142
ITEM 14. Principal Accounting Fees and Services	142
<b>PART IV</b>	
ITEM 15. Exhibits and Financial Statement Schedules	142
ITEM 16. Form 10-K Summary	149
Signatures	150

## PART I

### ITEM 1. Business

#### General

Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. We believe we are the world's largest provider of health care products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. Our philosophy is grounded in our commitment to serve as trusted advisors and help customers operate a more efficient and successful business so the practitioner can provide better clinical care.

With 94 years of experience distributing health care products, we have built a vast base of small, mid-sized and large customers in the dental and medical markets, serving more than one million customers worldwide across dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics.

We are headquartered in Melville, New York and employ more than 25,000 people. Approximately 48% of our workforce is based in the United States and 52% outside of the United States. Our operations or affiliates are located in 34 countries and territories. Our broad global footprint has evolved over time through organic growth as well as through the contribution from our strategic acquisitions.

We stock a comprehensive selection of more than 300,000 branded and Henry Schein corporate brand products through our network. Our infrastructure, including over 5.4 million square feet of space in 38 strategically located distribution centers and 0.6 million square feet of space in 17 manufacturing facilities around the world, enables us to historically provide rapid and accurate order fulfillment, better serve our customers and increase our operating efficiency. This infrastructure, together with broad product and service offerings at competitive prices, and a strong commitment to customer service, enables us to be a single source of supply for our customers' needs, which we believe is a competitive advantage.

We conduct our business through three reportable segments:

- Global Distribution and Value-Added Services: distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting and other practice services. This segment also markets and sells under our own corporate brand, a portfolio of cost-effective, high-quality consumable merchandise;
- Global Specialty Products: manufacturing, marketing and sales of dental implant and biomaterial products; endodontic, orthodontic and orthopedic products and other health care-related products and services; and
- Global Technology: development and distribution of practice management software, e-services, and other products, which are distributed to health care providers.

#### Recent Developments

See "Management's Discussion and Analysis of Financial Condition and Results of Operations – Recent Developments" herein for a discussion related to recent Company developments.

## **Industry**

The distribution and value-added services industry, as it relates to office-based health care practitioners, is fragmented and diverse. The industry spans a wide spectrum, from sole practitioners or small independent offices to mid-size and large group practices. These larger organizations may include just a few clinicians or scale to several hundred practices, often owned and operated by dental support organizations (DSOs) or integrated delivery networks (IDNs).

Due in part to the limited capacity of office-based health care practitioners to store and manage large quantities of supplies in their offices, the distribution of health care supplies and small equipment to office-based health care practitioners has been characterized by frequent, small quantity orders, and a need for rapid, reliable and substantially complete order fulfillment. The purchasing decisions within an office-based health care practice are typically made by the practitioner, hygienist or office manager. Supplies and small equipment are generally purchased from more than one distributor, with one generally serving as the primary supplier.

The distribution and value-added services industry should benefit from favorable long-term macro trends that should help stimulate patient traffic and demand for products and services. This includes an aging population, increased health care awareness and the importance of preventive care, an increasing understanding of the connection between good oral health and overall health, improved access to care globally, the proliferation of medical technology and testing, new pharmacology treatments and expanded third-party insurance coverage, partially offset by the effects of unemployment on insurance coverage and technological improvements, including the advancement of software and services, prosthetic solutions and telemedicine. In addition, the non-acute market continues to benefit from the shift of procedures and diagnostic testing from acute care settings to alternate-care sites, particularly physicians' offices and ambulatory surgery centers.

Customer consolidation will likely lead to multiple locations under common management and the movement of more procedures from the hospital setting to the physician or alternate care setting, as the health care industry is increasingly focused on efficiency and cost containment. This trend has benefited distributors capable of providing a broad array of products and services at low prices. It also has accelerated the growth of Health Maintenance Organizations ("HMOs"), management service organizations, group practices, other managed care accounts and collective buying groups such as Dental Service Organizations ("DSOs") and Group Purchasing Organizations ("GPOs"), which, in addition to their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing specialized management information support. We believe that the trend towards cost containment has the potential to favorably affect demand for technology solutions, including software, which can enhance the efficiency and facilitation of practice management.

## **Competition**

The distribution and manufacture of health care supplies and equipment is highly competitive. Many of the health care products we sell are available to our customers from a number of suppliers. In addition, our competitors could obtain exclusive rights from manufacturers to market particular products. Manufacturers also could seek to sell directly to end-users and thereby eliminate or reduce our role and that of other distributors. In certain parts of the dental end market, such as those related to dental specialty products, and medical end market manufacturers already sell directly to end customers.

In North America, we compete with other distributors, as well as several manufacturers, of dental and medical products, primarily on the basis of price, breadth of product line, e-commerce capabilities, customer service and value-added products and services. In the dental distribution market, our primary competitors in the U.S. are the Patterson Dental division of Patterson Companies, Inc. and Benco Dental Supply Company. In addition, we compete against a number of other distributors that operate on a national, regional and local level. Our primary competitors in the U.S. medical distribution market, which accounts for the large majority of our global medical sales, are McKesson Corporation and Medline Industries, Inc., which are national distributors. We also compete with a number of regional and local medical distributors, as well as a number of manufacturers that sell directly to physicians and patients in their homes.

Outside of the U.S., we believe we are the only global distributor of supplies and equipment to dental practices, and our competitors are primarily local and regional companies. We compete on the basis of price and customer service against several large competitors, including Cadence Group, Proclinic Group, DD Group, Nuent Group, Lifco AB, Planmeca Group, Dental Union, and Dental Bauer, as well as a large number of other dental and medical product distributors and manufacturers.

Within Global Specialty Products, our primary global competitors include Straumann, Envista, Zimvie, and Dentsply Sirona for dental implants. These companies, along with Geistlich Pharma AG and Botiss Biomaterials GmbH, also compete with us in the biomaterials for dental tissue regeneration market.

Within Global Technology, we compete against numerous dental software providers, including the Eaglesoft division of Patterson Companies, Inc., Carestream Dental LLC, Centaur Software Development Co Pty Ltd. (d.b.a. dental4windows, dental4web), Open Dental Software, Inc., PlanetDDS LLC, Good Methods Global Inc. (d.b.a. CareStack), Curve Dental, LLC., the NextGen division of Quality Systems, Inc., eClinicalWorks and Epic Systems Corporation. In other software end markets, including revenue cycle management, patient relationship management and patient demand generation, we compete with companies such as Vyne Medical, Dental Intelligence, and Weave Communications, Inc. Many of these competitors connect to our software platforms through our API program.

## **Manufacturing and Raw Materials**

We manufacture certain of our specialty products (dental implants, endodontics, and orthopedics) at our 17 company manufacturing sites. We also outsource certain manufactured products to third parties. We purchase our raw materials from distributors or mills. Although no single supplier is material, raw materials may be sourced from a single supplier or a limited number of suppliers for reasons of quality assurance, regulatory requirements, cost, and availability.

We believe that we have a readily available supply of raw materials and components sourced from various suppliers for our major product lines with some redundancy to ensure product availability. In recent periods, we have experienced increased costs due to labor cost increases, source of supply, and tariffs, which may have had a negative impact on our profit margins. In most cases, through negotiations, consolidation of suppliers, and insourcing, we have been able to reduce the impact.

## Competitive Strengths

We have 94 years of experience in distributing products to health care practitioners resulting in strong awareness of the Henry Schein® brand. Our competitive strengths include:

*A focus on understanding and meeting our customers' unique needs.* Leveraging our deep expertise in the end markets we serve, we are committed to providing customized value-driven products and solutions to our customers that reflect the technology-driven services best suited for their practice needs. We are committed to continuing to enhance these offerings through organic investment in our portfolio and our teams, as well as through the acquisition of new products and services that may help us better serve our customers.

*Direct sales and marketing expertise.* Our sales and marketing efforts are designed to establish and solidify customer relationships through coordinated and tailored engagement strategies that connect customers where and how they prefer. We deliver value by emphasizing our broad product lines, including exclusive distribution agreements, competitive prices and ease of order placement, particularly through our e-commerce platforms. The key elements of our direct sales and marketing efforts are:

- *Field sales consultants.* Our field sales consultants, including equipment and specialty sales specialists, covering major North American, European and other international markets. These consultants complement our direct marketing and telesales efforts and enable us to better market, service and support the sale of more sophisticated products and equipment.
- *Omni-channel marketing.* We market to existing and prospective office-based health care providers through a combination of owned, earned and paid digital channels, tradeshows, as well as through catalogs, flyers, direct mail and other promotional materials. Our strategies include an emphasis on educational content through webinars and content marketing initiatives. We continue to leverage our marketing technology and data insights to improve our targeting capability and the relevance of messaging and offers.
- *Telesales.* We support our direct marketing effort with inbound and outbound telesales representatives, who facilitate order processing, generate new sales through direct and frequent contact with customers and stay abreast of market developments and the hundreds of new products, services and technologies introduced each year to educate practice personnel. Through automation and skilled agents, we have strengthened our support model, enhancing the customer experience.
- *Electronic commerce solutions.* We provide our customers and sales teams with innovative and competitive e-commerce solutions. We continue to invest in our e-commerce platforms so customers can find the products they need and to enable an engaging purchase experience, supported by excellent customer service. Additionally, we have built enhanced account management tools that meet the needs of customers of all sizes. Our global e-commerce platform, henryschein.com, focuses on accelerating the adoption of digital commerce technologies across our Company, driving the transformation of our business strategy and operations using digital technology, and enabling the growth of digital sales revenue.
- *Social media.* Our operating entities and employees engage our customers and supplier partners through various social media platforms, which are an important element of our communications and marketing efforts. We continue to expand our social media presence to raise awareness about issues, engage customers beyond a sale and deliver services and solutions to specialized audiences.

*Cost-effective purchasing.* We believe that cost-effective purchasing is a key element to maintaining and enhancing our position as a competitively priced provider of health care products. We continuously evaluate our purchase requirements and suppliers' offerings and prices in order to obtain products at the lowest possible cost. In 2025, our top 10 Global Distribution and Value-Added Services suppliers and our single largest supplier accounted for approximately 25% and 4%, respectively, of our aggregate purchases.

*Efficient distribution.* We distribute our products from our 38 strategically located distribution centers. We strive to maintain optimal inventory levels in order to satisfy customer demand for prompt delivery and complete order

fulfillment. These inventory levels are managed on a daily basis with the aid of our management information systems. Once an order is entered, it is electronically transmitted to the distribution center nearest the customer's location for order fulfillment.

*Supply chain solutions.* We have implemented a fulfillment system, supported by customized inventory management systems for individual practices, large group practices, and integrated delivery networks.

*Commitment to superior customer service.* We maintain a strong commitment to providing superior customer service. We frequently monitor our customer service through customer surveys, focus groups and statistical reports. Our customer service policy primarily focuses on:

- Exceptional order fulfillment. We ship an average of approximately 150,000 cartons daily.
- Comprehensive ordering process. Customers may place orders 24 hours a day, 7 days a week via e-commerce solutions, telephone, e-mail and mail.

*Broad product and service offerings at competitive prices.* We offer a broad range of products, including the Henry Schein corporate brand, and services to our customers at competitive prices, in the following categories:

### **Global Distribution and Value-Added Services**

- *Consumable merchandise and equipment.* We distribute consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, dental specialty products, diagnostic tests, infection-control products and vitamins. We stock a comprehensive selection of more than 300,000 products and Henry Schein corporate brand cost-effective, high-quality consumable merchandise and specialty products.
- *Home health business.* We distribute homecare medical products, including incontinence, urology, ostomy, enteral nutrition, advanced wound, and diabetes supplies, as well as continuous glucose monitoring devices. These products are delivered directly to patients in their homes, providing convenience and accessibility while supporting patient care and adherence to treatment plans.
- *Value-added products and services.* We offer a broad range of value-added solutions, including continuing education programs for practitioners, consulting services, and practice services. Our suite of technology-driven tools and expert advisory services helps health care professionals enhance practice efficiency and improve patient outcomes.
- *Repair services.* We have 127 equipment sales and service centers worldwide that provide a variety of repair, installation and technical services for our health care customers. Our equipment service technicians understand the importance of having tools and equipment running smoothly to operate offices without interruption. Our manufacturer-trained technicians cover major markets and deliver personalized and local services, providing installation and repair services for dental handpieces, dental and medical small equipment, table-top sterilizers and large dental equipment.
- *Financial services.* We offer our customers solutions in operating their practices more efficiently by providing access to a number of financial services and products provided by third party suppliers (including non-recourse financing for equipment, technology and software products, non-recourse practice financing for leasehold improvements, business debt consolidation and commercial real estate, non-recourse patient financing and credit card processing) at rates that we believe are generally lower than what our customers would be able to secure independently. We also provide staffing services, dental practice valuation and brokerage services.

## **Global Specialty Products**

- *Dental implants and digital solutions.* We develop, manufacture, market and distribute a broad portfolio of patented and evidence-based dental implants, prosthetic components, instruments and digital workflow solutions for implant-based tooth restorations. With research and development and manufacturing facilities in the United States, Switzerland, Germany, Brazil and France, we serve customers with various global and regional implant brands across a wide range of price segments. Supported by our specialized sales force, we market our products and solutions in approximately 90 countries, directly to dental practices and surgical specialists via our sales subsidiaries and network of international third-party and Henry Schein distribution partners.
- *Biomaterials.* We market and distribute a broad portfolio of biomaterials for dental tissue regeneration. The product portfolio primarily consists of a broad range of privately branded allograft, xenograft, and synthetic biomaterials. Our dedicated biomaterial specialists support our direct implant sales force and Henry Schein oral surgery-focused distribution channels.
- *Orthodontics.* We develop, manufacture, and distribute a comprehensive range of orthodontic products, including brackets, braces, aligners, and accessories. In collaboration with leading clinicians, our research and development teams drive innovation to enhance patient care. With manufacturing facilities in the United States, Mexico, and France, we serve dental practices in over 70 countries through our specialized sales force, international partners, and the Henry Schein distribution network.
- *Endodontics.* We develop, manufacture, market and distribute a complete portfolio of endodontic products across multiple brands catering to both endodontic specialists and general practitioners. This includes stainless steel and NiTi shaping files, irrigation solutions, endodontic power equipment, sealers, and root repair materials. Leveraging our research and development and manufacturing facilities in the United States, Switzerland, and Brazil we focus on delivering meaningful innovation to help advance endodontic care, provide advanced training and education through a network of training centers and digital services, and serve our customers through multiple brands and multiple channels addressing all segments of the market. By investing in dedicated endo-specific competencies and resources to support our different sales channels, we are successfully marketing our products and brands in over 90 countries.
- *Orthopedics.* We develop, manufacture and distribute innovative implants and instruments that are designed to treat injuries, diseases and disorders of the limbs, joints and related tissues in the upper and lower extremities. We also provide surgical accessories, including blades, burs, drills, a variety of pins and wires to support orthopedic surgical procedures, and a portfolio of specialized instruments designed to simplify implant removal and preserve patient bone-stock during revision arthroplasty procedures. We employ an extensive global network of independent sales agencies and direct sales specialists, and we partner closely with IDNs and GPOs. The majority of our revenue is generated in the United States market, with the remaining revenue coming from Canada and countries in Latin America, Europe and Asia Pacific region.
- *Other.* We also source or manufacture other medical and dental health care products and services that are sold to customers, including handpiece and small equipment, rotary, hand instruments, repair services, restoratives and preventives, as well as certain other health care-related consumable merchandise products and services.

## Global Technology

- We sell practice management, business analytics, revenue cycle management, clinical workflow, artificial intelligence, patient engagement and patient demand creation software solutions to our dental customers. Our practice management solutions provide practitioners with electronic medical records, patient treatment history, analytics, billing, accounts receivable analyses and management, appointment calendars, revenue cycle management, clinical workflow, electronic claims processing, network and hardware services, e-commerce and electronic marketing services, e-Prescribe medications and prescription solutions, sourcing third party patient payment plans, and transition services and training and education programs for practitioners. We have technical representatives supporting customers using our practice management solutions and services.

As of December 27, 2025, we had an active user base of approximately 95,000 practices and 324,000 consumers, including users of AxiUm®, Dentally®, Dentrix Ascend®, DentalVision®, Dentrix® Dental Systems, EXACT®, Gesden®, Jarvis Analytics®, Oasis, Officite™, OrisLine®, PBS Endo®, Power Practice® Px and subscriptions for Demandforce®, Sesame, and Lighthouse 360® for dental practices and DentalPlans.com® for dental patients.

## Products and Services

The following table sets forth the percentage of consolidated net sales by principal categories of products and services offered through our Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology reportable segments:

	December 27, 2025	December 28, 2024	December 30, 2023
<b>Global Distribution and Value-Added Services:</b>			
Dental merchandise <sup>(1)</sup>	36.6%	37.3%	38.8%
Dental equipment <sup>(2)</sup>	13.6	13.6	13.5
Value-added services <sup>(3)</sup>	1.8	1.8	1.6
<b>Total Dental</b>	<u>52.0</u>	<u>52.7</u>	<u>53.9</u>
<b>Medical <sup>(4)</sup></b>	<u>32.5</u>	<u>32.2</u>	<u>31.7</u>
<b>Total Global Distribution and Value-Added Services:</b>	84.5	84.9	85.6
<b>Global Specialty Products <sup>(5)</sup></b>	11.7	11.4	10.8
<b>Global Technology <sup>(6)</sup></b>	5.1	5.0	4.9
Eliminations	<u>(1.3)</u>	<u>(1.3)</u>	<u>(1.3)</u>
<b>Total</b>	<u><u>100.0%</u></u>	<u><u>100.0%</u></u>	<u><u>100.0%</u></u>

- (1) Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products and our own corporate brand of consumable merchandise.
- (2) Includes dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, equipment repair services and high-tech and digital restoration equipment.
- (3) Consists of financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services.
- (4) Includes branded and generic pharmaceuticals, home solutions products, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, PPE products, and vitamins.
- (5) Includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other health care-related products and services.
- (6) Consists of the development and distribution of practice management software, e-services and other technology-enabled products for health care providers.

## Business Strategy

Our mission is to provide innovative, integrated health care products and services; and to be trusted advisors and consultants to our customers - enabling them to deliver the best quality patient care and enhance their practice management efficiency and profitability. Our BOLD+1 Strategic Plan consists of the following:

- **Build (“B”)** Complementary software, specialty, and services businesses for high growth
- **Operationalize (“O”)** One Distribution to deliver exceptional customer experience, increased efficiency, and growth
- **Leverage (“L”)** One Schein to broaden and deepen relationships with our customers
- **Drive (“D”)** Digital transformation for our customers and for Henry Schein
- **+1** Create value for our stakeholders

To accomplish this, we apply our competitive strengths in executing the following strategies:

- *Increase penetration of our existing customer base.* We have over one million customers worldwide and we intend to increase sales to our existing customer base and enhance or secure our position as their primary supplier. We believe our offering of a broad range of products, services and support, including software solutions that can help drive improved workflow efficiency and patient communications for practices, coupled with our full-service value proposition, helps us to retain and grow our customer base.
- *Increase the number of customers we serve.* This strategy includes increasing the productivity of our field sales consultants and telesales team, as well as using our customer database to focus our marketing efforts in all of our operating segments. In the dental business, we provide products and services to independent practices, mid-market groups, and large DSOs as well as community health centers and government sites of care. Leveraging our broad array of assets and capabilities, we offer solutions to address these new markets. In the medical business, we have expanded to serve customers located in settings outside of the traditional office, such as urgent care clinics, retail, occupational health and home health settings. As health care settings shift, we remain committed to serving these practitioners and providing them with the products and services they need.
- *Leverage our value-added products and services.* We continue to increase cross-selling efforts for key product lines utilizing a consultative selling process. We have significant cross-selling opportunities between our dental software users and our dental customers, and opportunities to expand our vaccine, injectables and other pharmaceuticals sales to health care practitioners, as well as cross-selling Electronic Health Record (“EHR”) systems and software when we sell our core products. Our strategy extends to providing health systems, integrated delivery networks and other large group and multi-site health care organizations, including physician clinics, these same value-added products and services. As physicians and health systems closely align, we have increased access to opportunities for cross-marketing and selling our product and service portfolios.
- *Pursue strategic acquisitions and joint ventures.* Our acquisition strategy is focused on investments in companies, including high growth high margin businesses aligned with our BOLD+1 strategy, that add new customers and sales teams, increase our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we have already invested in businesses), and finally, those that enable us to access new products and technologies.

## Markets Served

Demographic trends indicate that our markets are growing, as an aging U.S. population is increasingly using health care services. According to the U.S. Census Bureau’s International Database, between 2025 and 2035, the population of people aged 45 and older is expected to grow by approximately 10%. Between 2025 and 2045, this age group is expected to grow by approximately 17%. This compares with expected total U.S. population growth rates of approximately 4% between 2025 and 2035 and approximately 6% between 2025 and 2045.

In the dental industry, expenditures in oral health care are predicted to rise as the 45-and-older segment of the population increases. There is increasing demand for new technologies that allow dentists to increase productivity, and this is being driven in the U.S. by lower insurance reimbursement rates. At the same time, there is an expected increase in dental insurance coverage.

In the medical market, there continues to be a migration of procedures from acute-care settings to physicians' offices and home health settings, a trend that we believe provides additional opportunities for us. There also is the continuing use of vaccines, injectables and other pharmaceuticals in alternate-care settings. We believe we have established a leading position as a vaccine supplier to the office-based physician practitioner.

We support our dental and medical professionals through the many SKUs that we offer, as well as through important value-added services, including practice management software, electronic claims processing, financial services and continuing education, all designed to help maximize a practitioner's efficiency.

Additionally, we seek to expand our dental full-service model and medical offerings in countries where opportunities exist. We do this through both direct sales and by partnering with local distribution and manufacturing companies.

For information on revenues and long-lived assets by geographic area, see Note 4 – Segment and Geographic Data of “Notes to Consolidated Financial Statements.”

### **Seasonality and Other Factors Affecting Our Business and Quarterly Results**

Our business is subject to seasonal and other quarterly fluctuations. Sales and profitability generally have been higher in the third and fourth quarters due to the timing of sales of seasonal products (including influenza vaccine), purchasing patterns of office-based health care practitioners for certain products (including equipment and software) and year-end promotions. Sales and profitability may also be impacted by the timing of certain annual and biennial dental tradeshow where equipment promotions are offered. In addition, some dental practices delay equipment purchases in the U.S. until year-end due to tax incentives. We expect our historical seasonality of sales to continue in the foreseeable future.

### **Governmental Regulations**

We strive to be compliant in all material respects with the applicable laws, regulations and guidance described below, and believe we have effective compliance programs and other controls in place to ensure substantial compliance. However, compliance is not guaranteed either now or in the future, as certain laws, regulations and guidance may be subject to varying and evolving interpretations that could affect our ability to comply, as well as future changes, additions and enforcement approaches, including political changes. When we discover situations of non-compliance we seek to remedy them and bring the affected area back into compliance.

Changes to applicable laws, regulations and guidance described below, as well as related administrative or judicial interpretations, may require us to update or revise our operations, services, marketing practices and compliance programs and controls, and may impose additional and unforeseen costs on us, pose new or previously immaterial risks to us, or may otherwise have a material adverse effect on our business.

#### *Government*

Certain of our businesses involve the distribution, manufacturing, importation, exportation, marketing, sale and promotion of pharmaceuticals and/or medical devices, and in this regard, we are subject to extensive local, state, federal and foreign governmental laws and regulations, including as applicable to our wholesale distribution of pharmaceuticals and medical devices, manufacturing activities, and as part of our specialty home medical supplies businesses that distribute and sell medical equipment and supplies directly to patients. Federal, state and certain foreign governments have also increased enforcement activity in the health care sector, particularly in areas of fraud and abuse, anti-bribery and anti-corruption, controlled substances handling, medical device regulations and data privacy and security standards.

Certain of our businesses involve pharmaceuticals and/or medical devices, including orthopaedic, in vitro diagnostic devices, software regulated as a medical device, and sales of medical equipment and supplies directly to patients, that are paid for by third parties and/or patients and must operate in compliance with a variety of burdensome and complex coding, billing and record-keeping requirements in order to substantiate claims for payment under federal, state and commercial/private health care reimbursement programs.

Government and private insurance programs fund a large portion of the total cost of medical care, and there have been efforts to limit such private and government insurance programs, including efforts, thus far unsuccessful, to seek repeal of the entire United States Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each enacted in March 2010 (as amended, the “ACA”).

Certain of our businesses are subject to various additional federal, state, local and foreign laws and regulations, including with respect to the sale, transportation, importation, storage, handling and disposal of hazardous or potentially hazardous substances; “forever chemicals” such as per- and polyfluoroalkyl substances; warnings related to potential cancer or reproductive harm linked to chemicals; amalgam bans; pricing disclosures; supply chain transparency around human trafficking and labor practices; and safe working conditions. In addition, activities to control medical costs, including laws and regulations lowering reimbursement rates for pharmaceuticals, medical devices, medical supplies and/or medical treatments or services, are ongoing. Laws and regulations are subject to change and their evolving implementation may impact our operations and financial performance.

Certain of our businesses also maintain contracts with governmental agencies and are subject to certain regulatory requirements specific to government contractors.

Our businesses are generally subject to numerous laws and regulations that could impact our financial performance, and failure to comply with such laws or regulations could have a material adverse effect on our business. A few noteworthy items that have come into effect recently are noted below:

- Regulation (EU) 2023/1182 of June 14, 2023, entered into force on January 1, 2025. This regulation lays down specific rules relating to medicinal products for human use intended to be placed on the market in Northern Ireland in accordance with Article 6 of Directive 2001/83/EC.
- Directive No. 2025/794 of April 14, 2025, known as the “Stop-the-Clock” Directive, amended Directives (EU) 2022/2464 (CSRD) by introducing a uniform two-year postponement of the sustainability reporting requirements for financial years beginning on or after January 1, 2025 and on or after January 1, 2026. It also extends the deadline for transposing Directive (EU) 2024/1760 (CSDDD) by one year (i.e. July 26, 2027) and the date of application of the transposed provisions depending on the type of companies subject to it (July 26, 2028, or July 26, 2029, as applicable).
- Regulation (EU) 2025/327 of February 11, 2025 on the European Health Data Space and amending Directive 2011/24/EU and Regulation (EU) 2024/2847 establishes the European Health Data Space (EHDS) by providing for common rules, standards and infrastructures and a governance framework, with a view to facilitating access to electronic health data for the purpose of primary use and secondary use of this data. This could potentially affect Henry Schein or its customers.
- The U.S. has adopted new and increased tariffs on imports from countries, and such tariffs remain subject to frequently evolving exemptions and modifications, as well as to court challenges, including a recent invalidation in the Supreme Court of many of the tariffs. Some countries have imposed retaliatory tariffs and other restrictions on imports from the U.S. These developments, and anticipated future developments, have created a volatile environment for global trade, and new trade policies with individual countries. It is unclear whether, or the extent to which, the current tariffs on trade with numerous countries will remain in place, or change, the exceptions that may apply, and their timing.
- In the United States, the One Big Beautiful Bill Act (“OBBBA”), signed into law on July 4, 2025, includes a number of provisions that are expected to result in reductions in the number of Medicaid enrollees, as well as reductions in federal funding to state Medicaid programs, resulting in potentially adverse impacts

on utilization of services and coverage of products. The OBBBA also includes changes to corporate tax rates, limitations on certain deductions and modifications to international tax provisions.

### *Operating, Security and Licensure Standards*

Certain of our businesses are subject to local, state and federal governmental laws and regulations relating to the manufacturing and/or distribution of pharmaceuticals and medical devices and supplies. Among the United States federal laws applicable to us are the Controlled Substances Act, the Federal Food, Drug, and Cosmetic Act, as amended (“FDC Act”), Section 361 of the Public Health Service Act and Section 401 of the Consolidated Appropriations Act of the Social Security Act, as well as laws regulating the billing of and reimbursement from government programs, such as Medicare and Medicaid, and from commercial payers. We are also subject to comparable foreign regulations.

The FDC Act, the Controlled Substances Act, their implementing regulations, and similar foreign laws generally regulate the introduction, manufacture, advertising, marketing and promotion, sampling, pricing and reimbursement, labeling, packaging, storage, handling, returning or recalling, reporting, and distribution of, and record keeping for, pharmaceuticals and medical devices shipped in interstate commerce or internationally, and states may similarly regulate such activities within the state. Furthermore, Section 361 of the Public Health Service Act, which provides authority to prevent the introduction, transmission or spread of communicable diseases, serves as the legal basis for the United States Food and Drug Administration’s (“FDA”) regulation of human cells, tissues and cellular and tissue-based products, also known as “HCT/P products.”

The Federal Drug Quality and Security Act of 2013 regulates pharmaceutical supply chain requirements and pre-empts certain state laws. Title II of this measure, known as the Drug Supply Chain Security Act (“DSCSA”), establishes a national electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States that went into effect on November 27, 2023. The law’s track and trace requirements applicable to manufacturers, wholesalers, third-party logistics providers (e.g., trading partners), repackagers and dispensers (e.g., pharmacies) of prescription drugs took effect in January 2015, and, as stated, continues to be implemented. The DSCSA product tracing requirements replace the former FDA drug pedigree requirements and pre-empt certain state requirements that are inconsistent with, more stringent than, or in addition to, the DSCSA requirements.

Those DSCSA requirements that were scheduled to change on November 27, 2023, and include requiring trading partners to provide, receive and maintain documentation about products and ownership only “electronically” (and not via paper), were subject to a one-year “stabilization period” announced by the FDA through two guidance documents in late August 2023. The FDA permitted the stabilization period to accommodate an additional year, until November 27, 2024, to allow trading partners to implement, troubleshoot and mature their electronic (versus paper), interoperable systems, during which time the FDA did not intend to take action to enforce the requirements for the interoperable, electronic, package level product tracing. Additionally, the FDA announced that it did not intend to take action to enforce the portion of the FDC Act with respect to drug product that was introduced in a transaction into commerce by the product’s manufacturer or repackager before November 27, 2024, and for subsequent transactions of such product through the product’s expiry. The FDA stated this stabilization period was intended to avoid disruption to the supply chain and ensure continued patient access to drug products as trading partners move towards full implementation of the DSCSA’s enhanced drug security requirements. The FDA again extended the stabilization period in late 2024 as follows: (1) manufacturers and repackagers: May 27, 2025; (2) wholesale distributors: August 27, 2025; (3) dispensers with 26 or more pharmacists and technicians: November 27, 2025; and (4) small dispensers: November 27, 2026. The FDA stated that these continued exemptions apply to any product transacted by eligible trading partners who have initiated their “systems and processes, as described in section 582(g)(1) of the FD&C Act,” including electronic DSCSA data connections with immediate trading partners by November 27, 2024. The additional time extends to trading partners throughout the pharmaceutical distribution supply chain who subsequently engage in a transaction including such product. The FDA also stated that, for the purposes of these exemptions, eligible trading partners are those who have initiated their systems and processes by successfully completing data connections with their immediate trading partners, and those trading partners who initiated processes including documentation of efforts to establish data connections, but were not able to fully complete these processes.

The DSCSA also establishes certain requirements for the licensing and operation of prescription drug wholesalers and third-party logistics providers (“3PLs”) and includes the eventual creation of national wholesaler and 3PL licenses in cases where states do not license such entities. The DSCSA requires that wholesalers and 3PLs distribute drugs in accordance with certain standards regarding the recordkeeping, storage and handling of prescription drugs. The DSCSA requires wholesalers and 3PLs to report state licensure to the FDA on an annual basis, including the name and address of each facility, and contact information. According to FDA guidance, states are pre-empted from imposing any licensing requirements that are inconsistent with, less stringent than, directly related to, or covered by the standards established by federal law in this area. Current state licensing requirements concerning wholesalers will remain in effect until the FDA issues new regulations as directed by the DSCSA. The FDA issued a proposed rule establishing wholesaler and 3PL national standards for licensing and other requirements in February 2022, but that rule has not yet been finalized. In addition, with respect to our specialty home medical supplies business, we are subject to certain state licensure laws (including state pharmacy laws), and also certain accreditation standards, including to qualify for reimbursement from Medicare, Medicaid, and other third-party payers.

The Food and Drug Administration Amendments Act of 2007 and the Food and Drug Administration Safety and Innovation Act of 2012 amended the FDC Act to require the FDA to promulgate regulations to implement a unique device identification (“UDI”) system for medical devices. The UDI rule phased in the implementation of the UDI regulations, generally beginning with the highest-risk devices (i.e., Class III medical devices) and ending with the lowest-risk devices. The UDI regulations require “labelers” to include unique device identifiers (“UDIs”), with a content and format prescribed by the FDA and issued under a system operated by an FDA-accredited issuing agency, on the labels and packages of medical devices (including, but not limited to, certain software that qualifies as a medical device under FDA rules), and to directly mark certain devices with UDIs. The UDI regulations also require labelers to submit certain information concerning UDI-labeled devices to the FDA, much of which information is publicly available on an FDA database, the Global Unique Device Identification Database (GUDID). The UDI regulations and subsequent FDA guidance regarding the UDI requirements provide for certain exceptions, alternatives and time extensions. For example, the UDI regulations include a general exception for Class I devices exempt from the Quality System Regulation (other than record-keeping requirements and complaint files). Regulated labelers include entities such as device manufacturers, repackagers, reproducers and relabelers that cause a device’s label to be applied or modified, with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label and include certain of our businesses. The FDA also released a final rule in February 2024 to amend, effective February 2026, certain device current good manufacturing practice requirements in 21 CFR Part 820 (Quality System Regulation) to align more closely with the international consensus standard (ISO 13485) specific for device quality management systems requirements (QMSR) used by other countries.

As a distributor of controlled substances and List 1 and 2 chemicals, we are required, under the Controlled Substances Act, to obtain and renew annually registrations for our facilities from the United States Drug Enforcement Administration (“DEA”) permitting us to handle controlled substances. We are also subject to other statutory and regulatory requirements relating to the storage, sale, marketing, handling, reporting, record-keeping and distribution of such drugs and List 1 and 2 chemicals, in accordance with the Controlled Substances Act and its implementing regulations, and these requirements have been subject to heightened enforcement activity in recent times. We are subject to inspection by the DEA.

Certain of our businesses are also required to register for permits and/or licenses with, and comply with operating and security standards of, the DEA, the FDA, the United States Department of Health and Human Services (“HHS”), state radiation control agencies, and various state boards of pharmacy, state health departments and/or comparable state agencies as well as comparable foreign agencies, and certain accrediting bodies, depending on the type of operations and location of product distribution, manufacturing or sale. These businesses include those that distribute, manufacture, relabel, and/or repackage prescription pharmaceuticals and/or medical devices and/or HCT/P products, or own pharmacy operations, or install, maintain or repair equipment, including X-ray machines.

In addition, Section 301 of the National Organ Transplant Act, and a number of comparable state laws, impose civil and/or criminal penalties for the transfer of human organs, as defined in the regulations, for valuable consideration, while generally permitting payments for the reasonable costs incurred in their procurement, processing, storage and

distribution. We are also subject to foreign government regulation of such products. The DEA, the FDA and state regulatory authorities have broad inspection and enforcement powers, including the ability to suspend or limit the distribution of products by our distribution centers, seize or order the recall of products and impose significant criminal, civil and administrative sanctions for violations of these laws and regulations. Foreign regulations subject us to similar foreign enforcement powers.

### *EU Regulation of Medicinal and Dental Products*

European Union (“EU”) member states regulate their own health care systems, as does EU law. The latter regulates certain matters, most notably medicinal products and medical devices. Medicinal products are defined, broadly, as substances or combinations of substances having certain functionalities and may not include medical devices. EU “regulations” apply in all member states, whereas “directives” are implemented by the individual laws of member states.

On medicines for humans, we are regulated under Directive No. 2001/83/EC of 6 November 2001, as amended by Directive 2003/63/EC of 25 June 2003, EU Regulation (EC) No. 726/2004 of 31 March 2004 and others. These rules provide for the authorization of products, and regulate their manufacture, importation, marketing and distribution. These rules implement requirements which may be implemented without warning, as well as a national pharmacovigilance system under which marketing authorizations may be withdrawn, and includes potential sanctions for breaches of the rules, and on other bases such as harmfulness or lack of efficacy. As mentioned above, Directive No. 2001/83/EC was recently amended by Regulation (EU) 2023/1182 of 14 June 2023. This regulation lays down specific rules relating to medicinal products for human use intended to be placed on the market in Northern Ireland in accordance with Article 6 of Directive 2001/83/EC.

EU Regulation No. 1223/2009 of 30 November 2009 *on cosmetic products* requires that cosmetic products (which includes dental products) be safe for human health when used under normal or reasonably foreseeable conditions of use and comply with certain obligations which apply to manufacturers, importers and distributors. It includes market surveillance, and non-compliance may result in the recall or withdrawal of products, along with other sanctions.

In the EU, the EU Medical Device Regulation No. 2017/745 of 5 April 2017 (“EU MDR”) covers a wide scope of our activities, from dental material and medical devices to X-ray machines, and certain software. It was meant to become applicable three years after publication (i.e., May 26, 2020). However, on April 23, 2020, to allow European Economic Area (“EEA”) national authorities, notified bodies, manufacturers and other actors to focus fully on urgent priorities related to the COVID-19 pandemic, the European Council and Parliament adopted Regulation 2020/561, postponing the date of application of the EU MDR by one year (to May 26, 2021).

The EU MDR significantly modifies and intensifies the regulatory compliance requirements for the medical device industry as a whole. Among other things, the EU MDR:

- strengthens the rules on placing devices on the market and reinforces surveillance once they are available;
- establishes explicit provisions on manufacturers’ responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;
- improves the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;
- sets up a central database to provide patients, health care professionals and the public with comprehensive information on products available in the EU;
- strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market; and
- identifies importers and distributors and medical device products through registration in the EUDAMED database, which comprises several modules that are not yet fully functional. In order not to hinder the mandatory use of EUDAMED by the functional delay of a single module, Regulation No. 2024/1860 of 13 June 2024 has therefore amended Article 34 of the EU MDR to organize a gradual commissioning of the various modules of EUDAMED, once they have been independently audited and declared operational by means of a Commission notice published in the Official Journal of the European Union. In this case, the obligations and requirements

relating to the concerned electronic modules of EUDAMED will apply six months after the date of publication of the notice. These changes came into force on July 9, 2024. Due to Commission Decision No. 2025/2371 of 26 November 2025, as from May 28, 2026, the first four EUDAMED modules will be mandatory to use; and

- as amended by the above-mentioned Regulation No. 2024/1860, contains specific provisions in the event of interruption or discontinuation of supply of a device.

In particular, the EU MDR imposes strict requirements for the confirmation that a product meets the regulatory requirements, including regarding a product's clinical evaluation and a company's quality systems, and for the distribution, marketing and sale of medical devices, including post-market surveillance.

Regulation 2023/607 of the European Parliament and of the Council of March 15, 2023 *amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices* has, notably, extended the EU MDR transitional periods applicable to certain medical devices that have been assessed and/or certified under the Directive No. 93/42/EEC of 1993 *concerning medical devices* ("EU Medical Device Directive"). Subject to certain conditions, medical devices that (i) obtained a certificate under the EU Medical Device Directive from May 25, 2017, (ii) which was still valid on May 26, 2021, and (iii) has not been subsequently withdrawn may, for the moment, continue to be placed on the market or put into service until December 31, 2027 for higher risk devices or December 31, 2028 for medium and lower risk devices. Nevertheless, EU MDR requirements regarding the distribution, marketing and sale including quality systems and post-market surveillance have to be observed by manufacturers, importers and distributors as of the application date (i.e., since May 26, 2021).

Other EU regulations that may apply under appropriate circumstances include EU Regulation No. 1907/2006 of 18 December 2006 *concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals*, which requires importers to register substances or mixtures that they import in the EU beyond certain quantities, and the EU Regulation No. 1272/2008 of 16 December 2008 *on classification, labelling and packaging of substances and mixtures* (recently amended by Regulation No. 2024/2865 of October 23, 2024, whose provisions come into force on different dates), which sets various obligations with respect to the labelling and packaging of concerned substances and mixtures.

Furthermore, compliance with legal requirements has required and may in the future require us to delay product release, sale or distribution, or institute voluntary recalls of, or other corrective action with respect to products we sell, each of which could result in regulatory and enforcement actions, financial losses and potential reputational harm. Our customers are also subject to significant federal, state, local and foreign governmental regulations, which may affect our interactions with customers, including the design and functionality of our products.

#### *Antitrust and Consumer Protection*

The federal government of the United States, most U.S. states and many foreign countries have antitrust laws that prohibit certain types of conduct deemed to be anti-competitive, as well as consumer protection laws that seek to protect consumers from improper business practices. At the U.S. federal level, the Federal Trade Commission oversees enforcement of these types of laws, and states have similar government agencies. Violations of antitrust or consumer protection laws may result in various sanctions, including criminal and civil penalties. Private plaintiffs may also bring civil lawsuits against us in the United States for alleged antitrust law violations, including claims for treble damages. EU law also regulates competition and provides for detailed rules protecting consumers.

#### *Health Care Fraud*

Certain of our businesses are subject to federal and state (and similar foreign) health care fraud and abuse, referral and reimbursement laws and regulations with respect to their operations. Some of these laws, referred to as "false claims laws," prohibit the submission or causing the submission of false or fraudulent claims for reimbursement to federal, state and other health care payers and programs. Other laws, referred to as "anti-kickback laws," prohibit soliciting, offering, receiving or paying remuneration in order to induce the referral of a patient or ordering, purchasing, leasing or arranging for, or recommending, ordering, purchasing or leasing of, items or services that are paid for by federal, state and other health care payers and programs. Certain additional state and federal laws, such

as the federal Physician Self-Referral Law, commonly known as the “Stark Law,” prohibit physicians and other health care professionals from referring a patient to an entity with which the physician (or family member) has a financial relationship, for the furnishing of certain designated health services (for example, durable medical equipment and medical supplies), unless an exception applies. Violations of the federal Anti-Kickback Statute or the Stark Law may be enforced as violations of the federal False Claims Act.

The fraud and abuse laws and regulations have been subject to heightened enforcement activity over the past few years, and significant enforcement activity has been the result of “relators” who serve as whistleblowers by filing complaints in the name of the United States (and if applicable, particular states) under applicable false claims laws, and who may receive up to 30% of total government recoveries. Penalties under fraud and abuse laws may be severe, including treble damages and substantial civil penalties under the federal False Claims Act, as well as potential loss of licenses and the ability to participate in federal and state health care programs, criminal penalties, or imposition of a corporate integrity agreement or corporate compliance monitoring which could have a material adverse effect on our business. Also, these measures may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations or incur substantial defense and settlement expenses. Even unsuccessful challenges by regulatory authorities or private relators could result in reputational harm and the incurring of substantial costs. Most states have adopted similar state false claims laws, and these state laws have their own penalties, which may be in addition to federal False Claims Act penalties, as well as other fraud and abuse laws.

With respect to measures of this type, the United States government and industry trade associations (among others) have expressed concerns about financial relationships among suppliers, manufacturers and distributors on the one hand and physicians, dentists and other health care professionals on the other. As a result, we regularly review and revise our marketing practices as necessary to facilitate compliance.

We also are subject to certain United States and foreign laws and regulations concerning the conduct of our foreign operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, German anti-corruption laws and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records, which have been the focus of increasing enforcement activity globally in recent years.

While we believe that we are substantially compliant with applicable fraud and abuse laws and regulations, and have adequate compliance programs and controls in place to ensure substantial compliance, we cannot predict whether changes in applicable law, or interpretation of laws, or changes in our services or marketing practices in response to changes in applicable law or interpretation of laws, or failure to comply with applicable law, could have a material adverse effect on our business.

#### *Affordable Care Act (ACA) and Other Insurance Reform*

The ACA increased federal oversight of private health insurance plans and included a number of provisions designed to reduce Medicare expenditures and the cost of health care generally, to reduce fraud and abuse, and to provide access to increased health coverage. The ACA also materially expanded the number of individuals in the United States with health insurance. The ACA remains subject to ongoing legal and political challenges that contribute to create uncertainty, and any outcomes of those challenges could have a significant impact on the U.S. health care industry.

The federal Physician Payments Sunshine Act or Open Payments Program (the “Sunshine Act”) imposes annual reporting and disclosure requirements for drug and device manufacturers and distributors with regard to payments or other transfers of value made to certain covered recipients (including physicians, dentists, teaching hospitals, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives), and for such manufacturers and distributors and for group purchasing organizations, with regard to certain ownership interests held by covered recipients in the reporting entity. CMS publishes information from these reports on a publicly available website, including amounts transferred and physician, dentist, teaching hospital, and non-physician practitioner identities. The Sunshine Act pre-empts similar state reporting laws, although we or our subsidiaries may be required to report under certain state transparency laws that address circumstances not covered by the Sunshine Act, and some of these state laws, as well as the federal law, can be

unclear. We are also subject to foreign regulations requiring reporting or disclosures to provide transparency on certain interactions between manufacturers, suppliers, distributors and their customers. This includes certain member states in the EU and other countries such as Brazil (Minas Gerais state), Saudi Arabia and Israel.

In the United States, federal and state government actions to seek to increase health-related price transparency may also affect our business. For example, CMS requires hospitals to publish online a list of their standard charges for all items and services, including discounted cash prices and payer-specific and de-identified negotiated charges, in a publicly accessible online file, and payers to disclose in-network negotiated rates, including with device suppliers and manufacturers, and historical out-of-network allowed amounts for all covered items and services, including prescription drugs. Hospitals are also required to publish a consumer-friendly list of standard charges for certain “shoppable” services (i.e., services that can be scheduled by a patient in advance) and associated ancillary services or, alternatively, maintain an online price estimator tool. These requirements went into effect in three stages from 2022 to 2024. CMS may impose civil monetary penalties for noncompliance with these price transparency requirements. In addition to a variety of transparency measures being enacted at the state level, the federal No Surprises Act (“NSA”) imposes additional price transparency requirements. The NSA is intended to reduce the number of “out-of-network” patients. This will result in fewer out-of-network payments to physicians and other providers, which may cause financial stress to those providers who are dependent on higher out-of-network fees.

The Medicare Access and CHIP Reauthorization Act of 2015 (“MACRA”), enacted on April 16, 2015, established the Quality Payment Program, which modifies certain Medicare Part B payments to “eligible clinicians,” including physicians, dentists and other practitioners. Under MACRA, certain eligible clinicians are required to participate in Medicare through the Merit-Based Incentive Payment System (“MIPS”) or Advanced Alternative Payment Models, through which Medicare Part B is adjusted up or down based on reported data related to quality, promoting interoperability, cost and improvement activities. MIPS eligible clinicians must report performance year data by March 31 of the following calendar year. Payment adjustments, based on submitted data, are applied to Medicare Part B claims during the performance year following data submission. MACRA provides substantial financial incentives for physicians to participate in risk contracts, and to increase physician information technology and reporting obligations. MACRA continues to evolve and its implications depend on future regulatory activity and physician activity in the marketplace. New state-level payment and delivery system reform programs, including those modeled after such federal programs, are also increasingly being rolled out through Medicaid administrators, as well as through the private sector, which may further alter the marketplace and impact our business.

Recently, in addition to other government efforts to control health care costs, there has been increased scrutiny on drug pricing and concurrent efforts to control or reduce drug costs by Congress, the President, executive branch agencies and various states. At the state level, several states have adopted laws that require drug manufacturers (including relabelers and repackagers) to provide advance notice of certain price increases and to report information relating to those price increases, while others have taken legislative or administrative action to establish prescription drug affordability boards or multi-payer purchasing pools to reduce the cost of prescription drugs. At the federal level, section 1927 of the Social Security Act sets forth Average Sales Price (ASP) reporting requirements for manufacturers (including repackagers and relabelers) and requires that manufacturers provide CMS with pricing information for their Part B-covered drugs no later than 30 days after the close of the previous quarter. Also at the federal level, several related bills have been introduced and regulations proposed which, if enacted or finalized, respectively, would impact drug pricing and related costs. Under the Medicare Drug Price Negotiation Program, CMS continues to negotiate prices for certain drugs with participating manufacturers. Also, at the federal level, the Inflation Reduction Act of 2022, among other things, requires drug manufacturers (including repackagers and relabelers) that raise certain of their drug prices faster than the rate of inflation to pay rebates to Medicare, and over time will authorize the federal government to negotiate directly with drug manufacturers to lower the prices of certain brand-name drugs covered by Medicare. These various evolving efforts create uncertainty and may adversely affect our business.

As a result of political, economic and regulatory influences, the health care distribution industry in the United States is under intense scrutiny and subject to fundamental changes. We cannot predict what further reform proposals, if any, will be adopted, when they may be adopted, or what impact they may have on us.

### *EU Directive on the pricing and reimbursement of medicinal products*

EU law provides for the regulation of the pricing of medicinal products which are implemented by EU member states (Directive No. 89/105/EC of 21 December 1988 *relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems*). Member states may, subject notably to transparency conditions and to the statement of reasons based upon objective and verifiable criteria, regulate the price charged (or its increases) for authorized medicines and their level of reimbursement, or they may freeze prices, place controls on the profitability of persons responsible for placing medicinal products on the market, and include or exclude the medicine on the list of products covered by national health insurance systems.

EU law does not expressly include provisions like those of the Sunshine Act in the United States, but a number of EU member states (such as France in 2011, Denmark in 2014, and Italy in 2022) have enacted laws to increase the transparency of relationships in the health care sector. The scope of these laws varies from one member state to another and may, for example, include the relations between health care industry players and physicians or their associations, students preparing for medical professions or their associations, teachers, health establishments or publishers of prescription and dispensing assistance software.

### *Regulated Software; Electronic Health Records; Privacy*

The FDA has become increasingly active in addressing the regulation of computer software and digital health products intended for use in health care settings, including, for example, most recently, with respect to artificial intelligence and machine learning-enabled medical devices, and the cybersecurity of medical devices. Certain of our businesses involve the development and sale of software and related products, including to support physician and dental practice management, and it is possible that the FDA or foreign government authorities could determine that one or more of our products is a medical device, which could subject us or one or more of our businesses to substantial additional requirements with respect to these products.

In addition, our businesses that involve physician and dental practice management products, our specialty home medical supplies business, and our self-insured health plans include electronic information technology systems that store and process personal health, clinical, financial and other sensitive information of individuals. These information technology systems may be vulnerable to breakdown, wrongful intrusions, data breaches and malicious attack, which could require us to expend significant resources to eliminate these problems and address related security concerns and could involve claims against us by private parties and/or governmental agencies. For example, we are directly or indirectly subject to numerous and evolving federal, state, local and foreign laws and regulations that protect the privacy and security of personal information, such as the federal Health Insurance Portability and Accountability Act of 1996, as amended, and implementing regulations (“HIPAA”) under which parts of our business are covered entities or business associates, the Controlling the Assault of Non-Solicited Pornography and Marketing Act (“CAN-SPAM”), the Telephone Consumer Protection Act of 1991 (“TCPA”), Section 5 of the Federal Trade Commission Act (“FTC Act”), the California Privacy Act (“CCPA”), various other state comprehensive and health data-specific privacy laws that have or will soon come into effect, and several privacy bills have been proposed both at the federal and state level that may result in additional legal requirements that impact our business. Laws and regulations relating to privacy and data protection are continually evolving and subject to potentially differing interpretations, including those relating to artificial intelligence, the proliferation of which may result in additional regulation. These requirements may not be harmonized, may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another or may conflict with other rules or our practices. In addition to state-specific data breach notification laws (which exist in all U.S. states and territories), cybersecurity laws such as the federal Cyber Incident Reporting for Critical Infrastructure Act of 2022, proposed Federal Acquisition Regulations, and amendments to SEC reporting requirements require us to provide notifications about material cybersecurity incidents in limited timeframes and before investigations are complete. Our businesses’ failure to comply with these laws and regulations could expose us to breach of contract claims, substantial fines, penalties and other liabilities and expenses, government investigations, litigation, costs for remediation and harm to our reputation. Also, evolving laws and regulations in this area could restrict the ability of our customers to obtain, use or disseminate patient information, or could require us to incur significant additional

costs to re-design our products to reflect these legal requirements, which could have a material adverse effect on our operations.

Also, the European Parliament and the Council of the EU adopted the pan-European General Data Protection Regulation (“GDPR”), that has been effective since May 25, 2018, which increased privacy rights for individuals (“Data Subjects”), including individuals who are our customers, suppliers and employees. The GDPR extended the scope of responsibilities for data controllers and data processors, and generally imposes increased requirements and potential penalties on companies, such as us, that are either established in the EU and process personal data of Data Subjects (regardless the Data Subject location), or that are not established in the EU but that offer goods or services to Data Subjects in the EU or monitor their behavior in the EU. Noncompliance can result in penalties of up to the greater of EUR 20 million, or 4% of global company revenues (sanction that may be public), and Data Subjects may seek damages. Member states may individually impose additional requirements and penalties regarding certain limited matters (for which the GDPR left some room of flexibility), such as employee personal data. With respect to the personal data it protects, the GDPR requires, among other things, controller accountability, consents from Data Subjects or another acceptable legal basis to process the personal data, notification within 72 hours of a personal data breach where required, data integrity and security, and fairness and transparency regarding the storage, use or other processing of the personal data. The GDPR also provides rights to Data Subjects relating notably to information, access, rectification, erasure of the personal data and the right to object to the processing. Despite the UK’s exit from the EU, the UK still also has laws equivalent to the GDPR/EU data protection laws (UK GDPR) and has implemented further data protection related legislation. Data protection authorities located in different EU Member States and in the UK may interpret GDPR/UK GDPR differently, or requirements of national laws may vary between the EU Member States and the UK, or guidance on GDPR/UK GDPR and compliance practices may be often updated or otherwise revised. Any of these events will increase the complexity and costs of processing personal data in the UK or European Economic Area or concerning individuals located in the UK or European Economic Area.

On August 20, 2021, China promulgated the PRC Personal Information Protection Law (“PIPL”), which took effect on November 1, 2021. The PIPL imposes specific rules for processing personal information and it also specifies that the law shall also apply to personal information activities carried out outside China but for the purpose of providing products or services to PRC citizens. Any non-compliance with these laws and regulations may subject us to fines, orders to rectify or terminate any actions that are deemed illegal by regulatory authorities, other penalties, as well as reputational damage or legal proceedings against us, which may affect our business, financial condition or results of operations. The PIPL carries maximum penalties of CNY50 million or 5% of the annual revenue of entities that process personal data. Data protection laws in other countries outside of the United States are also quickly evolving, with many countries having updated, or are in the process of updating, their laws to bring them more in line with the model created by GDPR.

In the United States, the CCPA, which increases the privacy protections afforded California residents, became effective January 1, 2020. The CCPA establishes a privacy framework for covered businesses such as ours by, among other things, creating an expanded definition of personal information, establishing new data privacy rights for California residents and creating a new and potentially severe statutory damages framework for violations of the CCPA, as well as potentially severe statutory damages and a private right of action against businesses that suffer a data security breach due to their violation of a duty to implement reasonable security procedures and practices. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. In addition, in November 2020, California voters adopted the CPRA, which became effective January 1, 2023 and enhances and strengthens regulatory requirements and individual protections that currently exist under the CCPA. Other states have enacted or are considering enacting similar privacy laws, which may subject us to additional requirements and restrictions that could have an impact on our business. As of January 1, 2026, broad state laws relating to privacy, data protection, and information security are in effect in 20 states, further complicating our privacy compliance obligations through the introduction of increasingly disparate requirements across the various U.S. jurisdictions in which we operate. Additionally, Washington state and Nevada have enacted specific health data privacy laws, and other states are considering similar legislation. Additional states are expected to pass their own versions of data privacy laws in the future. Congress is considering legislation that may preempt some or all of such U.S. state privacy laws, but which may also provide a more expansive private right of action for privacy claims than exists under current state laws.

The evolving complexity of privacy and data security legislation in the United States and other jurisdictions globally may complicate our compliance efforts and further increase our risk of regulatory enforcement, penalties, and litigation. While we believe we have substantially compliant programs and controls in place to comply with the U.S. state and federal privacy laws and applicable international privacy laws such as GDPR and PIPL, our compliance with data privacy and cybersecurity laws is likely to impose additional costs on us, and we cannot predict whether the interpretations of the requirements, or changes in our practices in response to new requirements or interpretations of the requirements, could have a material adverse effect on our business.

Our products and services utilize new technologies, such as AI. The regulatory landscape for AI is changing rapidly, with both domestic and international activity. While there is currently no comprehensive federal legislation in the U.S. concerning the use, development or deployment of AI, regulators pursue AI-related enforcement actions under existing federal consumer protection laws and have issued related guidance. Further, state privacy, consumer protection and AI-specific laws are proliferating and may be applicable to our business. Other countries are also applying their data and consumer protection laws to AI, particularly generative AI, and are considering and implementing specific legal frameworks with respect to AI. Regulation (EU) 2024/1689 on harmonized rules on artificial intelligence (the EU AI Act), for example, establishes a comprehensive regulatory framework for AI that became law in August 2024 with implementation phased through into 2027. As with the GDPR, it has extra-territorial effect. Any failure or perceived failure by us to comply with such requirements could have an adverse impact on our business. Anticipated further evolution of regulations and legislation on this topic may substantially increase the penalties to which we could be subject in the event of any non-compliance. Compliance with these laws is challenging, constantly evolving, and time consuming and federal regulators, state attorneys general and plaintiff's attorneys have been and will likely continue to be active in this space. We may incur substantial expense in complying with legal obligations to be imposed by new regulations and we may be required to make significant changes to our solutions and expanding business operations, all of which may materially adversely affect our operations.

We also sell products and services that health care providers, such as physicians and dentists, use to store and manage patient medical or dental records. These customers, and we, are subject to laws, regulations and industry standards, such as HIPAA and the Payment Card Industry (PCI) Data Security Standards, which require the protection of the privacy and security of those records, and our products may also be used as part of these customers' comprehensive data security programs, including in connection with their efforts to comply with applicable privacy and security laws. Perceived or actual security vulnerabilities in our products or services, or the perceived or actual failure by us or our customers who use our products or services to comply with applicable legal or contractual data privacy and security requirements, may not only cause us significant reputational harm, but may also lead to claims against us by our customers and/or governmental agencies and involve substantial fines, penalties and other liabilities and expenses and costs for remediation.

Various federal initiatives involve the adoption and use by health care providers of certain EHR systems and processes. The initiatives include, among others, programs that incentivize physicians and dentists, through MIPS, to use EHR technology in accordance with certain evolving requirements, including regarding quality, promoting interoperability, cost and improvement activities. Qualification for the MIPS incentive payments requires the use of EHRs that are certified as having certain capabilities designated in evolving standards adopted by CMS and the Office of the National Coordinator for Health Information Technology of HHS ("ONC"). Certain of our businesses involve the manufacture and sale of such certified EHR systems and other products linked to government supported incentive programs. In order to maintain certification of our EHR products, we must satisfy these changing governmental standards. If any of our EHR systems do not meet these standards, yet have been relied upon by health care providers to receive federal incentive payments, we may be exposed to risk, such as under federal health care fraud and abuse laws, including the False Claims Act. Additionally, effective September 1, 2023, the Office of the Inspector General ("OIG") for HHS issued a final rule implementing civil money penalties for information blocking as established by the Cures Act. OIG incorporated regulations published by ONC as the basis for enforcing information blocking penalties. Each information blocking violation carries up to a \$1 million penalty.

Moreover, in order to satisfy our customers, and comply with evolving legal requirements, our products may need to incorporate increasingly complex functionality, such as with respect to reporting and information blocking. Although we believe we are positioned to accomplish this, the effort may involve increased costs, and our failure to

implement product modifications, or otherwise satisfy applicable standards, could have a material adverse effect on our business.

Other health information standards, such as regulations under HIPAA, establish standards regarding electronic health data transmissions and transaction code set rules for specific electronic transactions, such as transactions involving claims submissions to third party payers. Failure to abide by these and other electronic health data transmission standards could expose us to breach of contract claims, substantial fines, penalties, and other liabilities and expenses, costs for remediation and harm to our reputation.

Additionally, as electronic medical devices are increasingly connected to each other and to other technology, the ability of these connected systems to safely and effectively exchange and use exchanged information becomes increasingly important. As a medical device manufacturer, we must manage risks including those associated with an electronic interface that is incorporated into a medical device.

There may be additional legislative or regulatory initiatives in the future impacting health care.

### *E-Commerce*

Electronic commerce solutions have become an integral part of traditional health care supply and distribution relationships. Our distribution business is characterized by rapid technological developments and intense competition. The continuing advancement of online commerce requires us to cost-effectively adapt to changing technologies, to enhance existing services and to develop and introduce a variety of new services to address the changing demands of consumers and our customers on a timely basis, particularly in response to competitive offerings.

Through our proprietary, technologically-based suite of products, we offer customers a variety of competitive alternatives. We believe that our tradition of reliable service, our name recognition and large customer base built on solid customer relationships, position us well to participate in this significant aspect of the distribution business. We continually explore ways and means to improve and expand our online presence and capabilities, including in our online commerce offerings and our use of various social media outlets.

### *International Transactions*

United States and foreign import and export laws and regulations require us to abide by certain standards relating to the importation and exportation of products. We also are subject to certain laws and regulations concerning the conduct of our foreign operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, German anti-corruption laws and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records, as well as other types of foreign requirements similar to those imposed in the United States.

While we believe that we are substantially compliant with the foregoing laws and regulations promulgated thereunder and possess all material permits and licenses required for the conduct of our business, there can be no assurance that laws and regulations that impact our business or laws and regulations as they apply to our customers' practices will not have a material adverse effect on our business.

See "Item 1A. Risk Factors." for a discussion of additional burdens, risks and regulatory developments that may affect our results of operations and financial condition.

### **Proprietary Rights**

We hold trademarks relating to the "Henry Schein<sup>®</sup>" name and logo, as well as certain other trademarks. Additionally, certain of our manufacturing businesses hold patents on certain of our products. We believe that we have taken necessary steps to protect our proprietary rights, but no assurance can be given that we will be able to successfully enforce or protect our rights in the event that they are infringed upon by a third party.

## Employees and Human Capital

At Henry Schein, we have long recognized that as a purpose-driven company, our commitment to creating shared value drives positive societal and environmental impact while supporting long-term business success. Building trusted relationships with the key stakeholders who make up our Mosaic of Success - Team Schein Members (TSMs), customers, suppliers, stockholders, and society, helps drive our Company's sustained growth, amplifies our collective strengths, and brings to life our vision of making the world healthier, together. Overseen by the Nominating and Governance Committee of our Board of Directors ("Board") with the Compensation Committee also playing a role in environmental, social, and governance matters related to human capital engagement and executive compensation, some key 2025 highlights related to human capital matters include:

- Continuing to compensate employees based on role, experience, and performance, consistent with fair pay practices and competitive outcomes across the workforce;
- Expanding our learning journey by educating TSMs on multiple components of our culture and values, creating an understanding of how to sustain a meaningful, inclusive, and learning oriented culture; and
- Continuing to drive a connected and caring community for our TSMs by fostering an environment where they can feel a sense of inclusion, belonging, and purpose.

At Henry Schein, our employees continue to be one of our greatest assets. We employ more than 25,000 people, with approximately 48% of our workforce based in the United States and approximately 52% based outside of the United States. Approximately 14% of our employees are subject to collective bargaining agreements. We believe that our relations with our employees are excellent.

TSMs are the cornerstone of our Company. We provide a connected and caring community that invests in the career journey of our TSMs and encourages their contribution to our mission of making the world healthier. Our TSM experience strategy is centered around our Team Schein Values under the pillars of Community, Caring, and Career. We know our business success is built on the engagement and commitment of our team, which is dedicated to meeting the needs of their fellow TSMs, our customers, supplier partners, stockholders, and society.

We recognize the changes in how and where we work, and that a continued connection to our long-standing values is important for our team members as we evolve our culture. Throughout 2025, we continued listening to our team through our continuous listening program, including The Pulse Global Culture Survey, quarterly Pulse surveys, and TSM roundtables, to garner feedback from our TSMs on their employee experience. We believe that a great employee experience also drives a great customer experience. We want all our TSMs to pursue their ambitions, deliver within our value-driven culture, and enjoy a rewarding career enabled by great people leaders.

Our recent listening efforts show that our Team Schein Values and TSM community remain our top strengths, and that overall TSM engagement is driven by a small set of people-centric factors, led by how supported, well, and connected TSMs feel, with communication and culture acting as amplifiers of trust and inclusion. Day-to-day experience varies across teams, particularly during periods of change, shaping how workload, pace, and priorities are experienced. The greatest opportunity lies in strengthening consistency and clarity around direction and expectations, so teams feel better supported as we continue to evolve. The feedback from our listening efforts is shared with our Executive Management Committee and Board, both of whom are committed to addressing identified opportunities. Additionally, in 2025 we conducted our second Corporate Citizenship Barometer to quantify stakeholder perceptions of the Company's environmental and social priorities, commitments, and impacts. As part of this commitment, some highlights from 2025 included:

- ***Community:*** *Provide opportunities for TSMs to have fun while contributing to an inclusive team that respects and supports one another.*
  - Continued our focus on creating an inclusive environment where TSMs feel a sense of belonging; notably, in 2025 for the fourth time, our top strength identified in The Pulse Global Culture Survey was our Company's inclusive culture. To deepen our commitment to inclusion across the Company, Global Directors and Vice Presidents and U.S. Managers are responsible for attending educational training focused on developing our culture. We continue to expand our learning journey, educating TSMs on key topics that help us develop a culture of inclusion and understanding.

- Completed our second year of Henry Schein Games, a global virtual platform that drives community and engagement and offers field-day type in-person events at various global locations that brought TSMs together through friendly competition by earning points for their team by engaging in cultural-related activities and posting photos.
- Expanded the number of Connection Days throughout the globe at Henry Schein facilities, which were designed to boost team morale by bringing TSMs together to participate in team building activities at least once per quarter.
- Continued focus on our Employee Resource Groups (“ERGs”), a vehicle for all TSMs to share, connect, learn, and develop both personally and professionally. Each of our ERGs has a sponsor from our Executive Management Committee and our Board. Our Chief Executive Officer (“CEO”) engages directly in many of our ERG programs.
- Launched Functional Resource Groups (“FRGs”), a vehicle for TSMs to learn, collaborate, and problem-solve – bridging gaps and uniting global TSMs within similar functions across departments, regions, and work models.
- Launched MySchein Reels and Community Explorer –pages on our internal intranet that drive awareness of various connection opportunities throughout the Company.
- Piloted an enhanced workplace technology tool that offers functionality for collaboration by allowing teams to see when others are working in an office, seamless booking of spaces both at Henry Schein facilities and on-demand spaces, and a Company events calendar.
- Certified an additional 100 TSMs through our Culture Ambassador Program, which educates TSMs on our culture and certifies TSMs as mentors to new hires during their first 90 days to ensure new TSMs understand how we live our values day to day, and how they can engage in the Team Schein Culture.
- ***Caring:*** *Build a world we want to live in by supporting each other and the communities in which we live and work.*
  - Continued to offer a variety of opportunities to volunteer to drive purpose and engage in local communities in which TSMs live and work, such as through Carry the Load, the We Care Global Challenge, Back to School, and Holiday Cheer.
  - Continued to strengthen our strategic partnerships with industry associations, customers, and suppliers that support access to quality health care through various key programs and initiatives (e.g., S.M.I.L.E. Healthcare Pathway Program, Gives Kids A Smile, Cares Package Program, Global Student Outreach Program, and Prepare to Care).
  - In 2025, we shipped nearly 2,500 Henry Schein CARES packages to over 200 grant recipients. These packages contained donated products enabling health care heroes across the globe to support screening, restorative, and educational events.
  - Developed the Stan’s Service Award program to honor Stanley M. Bergman’s legacy that aims to celebrate TSMs who embody the philosophy of “doing well by doing good.” This program awards a limited number of cash grants to non-profit organizations globally where TSMs volunteer their time.
  - Expanded our global and highly rated Steps for Suicide Prevention campaign, which brings TSMs together to walk for a cause and provide education, partnering with the American Foundation for Suicide Prevention, Suicide Awareness and Remembrance (for Veterans), and other local organizations.
  - We also understand the importance of driving a culture of wellness for our own team members through our Mental Wellness Committee, which is supported by our CEO, Executive Management Committee, and Board. In 2025, we launched an “Intrinsic Motivation” campaign to help TSMs understand what drives them at work and how they can get more involved in initiatives that align to that motivator to help TSMs find work that is more meaningful, energizing, and fulfilling.
- ***Career:*** *Provide opportunities for TSMs to develop personally and professionally with an emphasis on embodying our values to achieve our collective goals with excellence and integrity.*
  - Launched The HELIX Network, a leadership development program that cultivates high-performing TSMs to represent Henry Schein with external partners.
  - Implemented globally the Core Leadership Capabilities (CLCs) for all TSMs that highlights the leadership capabilities that all TSMs are expected to demonstrate for career success. The CLCs are a common language and foundational step to developing and refining the tools, processes, and programs

which support the evolution of a TSM's career, including enhancing skills and career development, leading to enhanced career pathing and internal mobility.

- Launched Career Explorer, a centralized hub for TSMs to access the tools and resources needed to support their career journey. The hub provides access to the Career & Leadership Opportunities page which markets internal roles and assignments across the company to support internal movement; directs TSMs to the Global Talent & Development page for support in the talent, performance, learning, and assessment space; highlights career stories from fellow TSMs for inspiration; and details our Core Leadership Capabilities, which provide transparency of the leadership capabilities that all TSMs are expected to demonstrate for career success.
- Continued investment in our employees by providing both formal and informal learning opportunities focused on growing and enhancing knowledge, skills, and abilities through a broad suite of professional development training programs for current and future roles. In 2025, we continued to add new workshops that enabled TSMs to build the skills they need for today and for the future.
- Continued expansion of our Leadership Development programs, inclusive of our formal mentorship and coaching programs.
- Continued roll-out of talent planning efforts designed to ensure a strong leadership pipeline across the organization by strategically identifying and developing talent through targeted development opportunities and intentional succession plans. Information derived from talent planning efforts informs curriculum design and content to help focus on the right capabilities and help ensure alignment of career development efforts with the future needs of the organization. Our Board is provided with periodic updates regarding our talent and succession planning efforts and participates in professional development activities with our TSMs.
- Enhanced company-wide recognitions, including our Teddy Philson Team Schein Award, which was redesigned in 2023 to provide more visibility and meaningful recognition to TSMs who exemplify our Team Schein Values, as well as other programs including service awards which highlight TSMs who exemplify our Team Schein Values. In 2025, we recognized 16 award winners around the world at our Global Directors and Vice Presidents Management Meeting.

### **Available Information**

We make available free of charge through our website, [www.henryschein.com](http://www.henryschein.com), our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, statements of beneficial ownership of securities on Forms 3, 4 and 5 and amendments to these reports and statements filed or furnished pursuant to Section 13(a) and Section 16 of the Securities Exchange Act of 1934 as soon as reasonably practicable after such materials are electronically filed with, or furnished to, the United States Securities and Exchange Commission, or SEC. Our principal executive offices are located at 135 Duryea Road, Melville, New York 11747, and our telephone number is (631) 843-5500. Unless the context specifically requires otherwise, the terms the "Company," "Henry Schein," "we," "us" and "our" mean Henry Schein, Inc., a Delaware corporation, and its consolidated subsidiaries.

## Information about our Executive Officers

The following table sets forth certain information regarding our executive officers as of February 24, 2026:

Name	Age	Position
Stanley M. Bergman	76	Chairman, Chief Executive Officer, Director
Andrea Albertini	55	Chief Executive Officer, Global Distribution and Technology
Michael S. Ettinger	64	Executive Vice President and Chief Operating Officer
Mark E. Mlotek	70	Executive Vice President, Chief Strategic Officer
Tom Popeck	56	Chief Executive Officer, Henry Schein Products
Christine Sheehy	58	Senior Vice President, Chief Human Resources Officer
Ronald N. South	64	Senior Vice President, Chief Financial Officer

**Stanley M. Bergman** has been our Chairman and Chief Executive Officer since 1989 and a director since 1982. Mr. Bergman held the position of President from 1989 to 2005. Mr. Bergman held the position of Executive Vice President from 1985 to 1989 and Vice President of Finance and Administration from 1980 to 1985. Mr. Bergman is a South African Chartered Accountant and a Certified Public Accountant. Mr. Bergman will retire as Chief Executive Officer on March 1, 2026, following which Mr. Bergman will remain as Chairman of the Board.

**Andrea Albertini** has been Chief Executive Officer, Global Distribution Group and Technology Group since January 2025. In this role, Mr. Albertini is responsible for our Global Distribution and Value-Added Services segment and our Global Technology segment. Mr. Albertini joined us in 2013 and has held several positions within the organization including Chief Executive Officer, International Distribution Group, President, International Distribution Group, President of our EMEA Dental Distribution Group, and Vice-President of International Dental Equipment. Prior to joining Henry Schein, Mr. Albertini held leadership positions at Cefla Dental Group and Castellini.

**Michael S. Ettinger** has been our Executive Vice President and Chief Operating Officer since 2022. Prior to his current position, Mr. Ettinger served as Senior Vice President, Corporate & Legal Affairs, Chief of Staff and Secretary from 2015 to 2022, Senior Vice President, Corporate & Legal Affairs and Secretary from 2013 to 2015, Corporate Senior Vice President, General Counsel & Secretary from 2006 to 2013, Vice President, General Counsel and Secretary from 2000 to 2006, Vice President and Associate General Counsel from 1998 to 2000 and Associate General Counsel from 1994 to 1998. Before joining us, Mr. Ettinger served as a senior associate with Bower & Gardner and as a member of the Tax Department at Arthur Andersen.

**Mark E. Mlotek** has been our Executive Vice President and Chief Strategic Officer since 2012. Mr. Mlotek was a director from 1995 to May 2025. Prior to his current role, Mr. Mlotek was Senior Vice President and subsequently Executive Vice President of the Corporate Business Development Group between 2000 and 2012. Prior to that, Mr. Mlotek was Vice President, General Counsel and Secretary from 1994 to 1999 and became a director in 1995. Prior to joining us, Mr. Mlotek was a partner in the law firm of Proskauer Rose LLP, counsel to us, specializing in mergers and acquisitions, corporate reorganizations and tax law from 1989 to 1994.

**Tom Popeck** has been our Chief Executive Officer, Henry Schein Products Group since January 2025. In this role, Mr. Popeck is responsible for our Global Specialty Products segment. Since joining us in 2019, Mr. Popeck has held several key positions including Chief Executive Officer, Healthcare Specialties Group, and President of our Healthcare Specialties Group. Prior to joining Henry Schein, Mr. Popeck held various sales leadership and general management executive positions at Stryker.

**Christine Sheehy** has been our Senior Vice President, Chief Human Resources Officer since November 2024. Ms. Sheehy joined us in 2019 and has held several key positions with increasing responsibility, including Vice President of the Human Resources Business Partner function for our North America Distribution Group, Healthcare Specialties Group, several Global Oral Reconstruction businesses, and our Corporate Functions. Prior to joining Henry Schein, Ms. Sheehy held various leadership positions at Standard Chartered Bank and Banco Real.

**Ronald N. South** has been our Senior Vice President and Chief Financial Officer (and principal financial officer and principal accounting officer) since 2022. Prior to holding his current position, Mr. South was our Vice President Corporate Finance since 2008, and Chief Accounting Officer from 2013 until 2022. Prior to joining us in 2008 as our Vice President, Corporate Finance, Mr. South held leadership roles at Bristol-Myers Squibb and PepsiCo, and held several roles of increasing responsibility with PricewaterhouseCoopers LLP, where he advised clients located in the United States, Europe, and Latin America. Mr. South is a Certified Public Accountant.

### Other Executive Management

The following table sets forth certain information regarding other Executive Management as of February 24, 2026:

Name	Age	Position
R. Steven Boggan	61	Chief Executive Officer, Global Oral Reconstruction Group, Americas
David Kochman	46	Senior Vice President, Chief Corporate Affairs Officer
James Mullins	61	Senior Vice President, Global Supply Chain
Kelly Murphy	45	Senior Vice President and General Counsel
Christopher Pendergast	63	Senior Vice President and Chief Technology Officer

**R. Steven Boggan** has been our Chief Executive Officer, Global Oral Reconstruction Group since July 2025. As CEO of our Global Oral Reconstruction Group, which is part of our Global Specialty Products segment, Mr. Boggan leads commercial operations in the Americas, global marketing, and R&D. Mr. Boggan joined Henry Schein, as the President and CEO of BioHorizons, which we acquired in 2014. Mr. Boggan joined BioHorizons in 1995 and was promoted to President and CEO in 2000. Prior to BioHorizons, Mr. Boggan was employed at Dow Corning Wright and Wright Medical Technology from 1989 until 1995.

**David Kochman** has been our Senior Vice President, Chief Corporate Affairs Officer since January 2025. Mr. Kochman joined us in 2015 and has held roles of increasing responsibility, including Vice President, Chief Corporate Affairs Officer, and Vice President, Corporate Affairs & Deputy Chief of Staff, Office of the CEO. Prior to joining Henry Schein, Mr. Kochman served as General Counsel and Corporate Development Officer for a privately held company and was previously a Partner at the law firm Reed Smith LLP.

**James Mullins** has been our Senior Vice President of Global Supply Chain since 2018. Mr. Mullins joined us in 1988 and has held a number of key positions with increasing responsibility, including Global Chief Customer Service Officer.

**Kelly Murphy** has been our Senior Vice President and General Counsel since 2021. In 2025, in addition to her global legal responsibilities, her role expanded to include leadership of our Regulatory and Compliance functions. Since joining us in 2011, Ms. Murphy has held several key positions of increasing responsibility within the legal function, most recently serving as Deputy General Counsel.

**Christopher Pendergast** has been our Senior Vice President and Chief Technology Officer since 2018. Prior to joining us, Mr. Pendergast was employed by VSP Global from 2008 to 2018, most recently as the Chief Technology Officer and Chief Information Officer. Prior to VSP Global, Mr. Pendergast served in roles of increasing responsibility at Natural Organics, Inc., from 2006 to 2008, IdeaSphere Inc./Twinlab Corporation from 2000 to 2006, IBM Corporation from 1987 to 1994 and 1998 to 2000 and Rohm and Haas from 1994 to 1998.

## **ITEM 1A. Risk Factors**

Our business operations could be affected by factors that are not presently known to us or that we currently consider not to be material to our operations, so you should not consider the risks disclosed in this section to necessarily represent a complete statement of all risks and uncertainties. The Company believes that the following risks could have a material adverse impact on our business, reputation, operating results, financial condition and/or the trading price of our common stock. The order in which these factors appear does not necessarily reflect their relative importance or priority.

### **COMPANY RISKS**

***We are dependent upon third parties for the manufacture/supply of a significant volume of our products and where we manufacture products, we are dependent upon third parties for raw materials/purchased components.***

We obtain a significant volume of the products we distribute from third parties, with whom we generally do not have long-term contracts. While there is typically more than one source of supply, some key suppliers, in the aggregate, supply a significant portion of the products we sell. In 2025, our top 10 Global Distribution and Value-Added Services suppliers and our single largest supplier accounted for approximately 24% and 4%, respectively, of our aggregate purchases. Additionally, where we are the manufacturer of products for our speciality business (e.g., dental implants, endodontics, and orthopedics), we are dependent upon third parties for raw materials and purchased components. Although no single supplier is material, because of our dependence upon such suppliers, our operations are subject to the suppliers' ability and willingness to supply products in the quantities that we require, and the risks include delays caused by interruption in production based on conditions outside of our control, including a supplier's failure to comply with applicable government requirements (which may result in product recalls, product detentions, and/or cessation of sales) or an interruption in the suppliers' manufacturing capabilities. In the event of any such interruption in supply, we would need to timely identify and obtain acceptable replacement sources. There is no guarantee that we would be able to obtain such alternative sources of supply on a timely basis, if at all, and an extended interruption in supply, particularly of a high-sales volume and/or high-margin product, could result in a significant disruption in our sales and operations, as well as damage to our relationships with customers and our reputation.

***We may be unsuccessful in achieving our strategic growth objectives.***

Our 2025 – 2027 BOLD+1 Strategic Plan is defined under “Business, Business Strategy” above. In particular, we are focused on continuing to grow our Henry Schein specialty brands and technology and value-added services solutions both organically and inorganically, and to drive greater efficiencies. If we are unable to effectively implement our strategic plan, we may not achieve our desired return on our investments through our growth strategies.

***Our business could be affected by the Strategic Partnership Agreement with KKR.***

On January 29, 2025, we announced a strategic investment by funds affiliated with KKR & Co. Inc. (“KKR”), a leading global investment firm, and a Strategic Partnership Agreement (the “Partnership Agreement”) with KKR. Under the Partnership Agreement, two independent directors, Max Lin and William K. “Dan” Daniel, joined our Board of Directors. On May 16, 2025, we issued 3,285,151 shares of common stock to funds affiliated with KKR for an investment of \$250 million, at approximately \$76.10 per share. Pursuant to the Partnership Agreement, KKR also has the ability to purchase additional shares via open market purchases up to a total equity stake of 14.9% of the outstanding shares of common stock of the Company. On November 4, 2025, the Company and KKR entered into an amendment to the Partnership Agreement that increased the beneficial ownership limit from 14.9% to 19.9% of the outstanding shares of the Company's common stock that KKR is permitted to acquire during the standstill period. The standstill provisions, including the increased ownership limit, continue in effect for a period of six months following the later of the expiration of the term of the Partnership Agreement and the date on which no KKR director appointed pursuant to the Partnership Agreement is serving on the Company's Board of Directors. On December 7, 2025, pursuant to the Partnership Agreement, KKR notified the Company of its election to exercise the Extension Election (as defined in the Partnership Agreement) whereby the Company's Board of

Directors will renominate KKR's designees, Max Lin and William K. "Dan" Daniel, to stand for election at the Company's 2026 annual meeting of stockholders for a term expiring at the Company's 2027 annual meeting of stockholders. The Partnership Agreement may have unintended consequences, such as uncertainty about our management, operations, or future strategic direction, which could result in the loss of future business opportunities or negatively impact our ability to attract and retain qualified talent. KKR also invests in many different types of businesses, and has or may continue to invest in customers, suppliers, joint venture partners, or other entities that have relationships with the Company, or in competitors of such entities, which may create unintended conflicts resulting in a loss of business.

***Our future growth (especially for our Global Technology and Global Specialty Products segments) is dependent upon our ability to develop or acquire and maintain and protect new products and services and utilize new technologies that achieve market acceptance with acceptable margins.***

Our future success depends on our ability to timely develop (or obtain the right to sell) competitive and innovative (particularly for our Global Technology and Global Specialty Products segments) products and services and utilize new technologies, such as artificial intelligence ("AI") (among other emerging technologies) and to market them and/or utilize them quickly and cost-effectively. Our ability to anticipate customer needs and emerging trends and develop or acquire new products, services and technologies at competitive prices requires significant resources, including employees with the requisite skills, experience and expertise, particularly in our Global Technology segment, including dental practice management, patient engagement and demand creation software solutions. The failure to successfully address these challenges could materially disrupt our sales and operations.

We have increased and expect to continue to increase our use of AI technologies in various contexts to improve customer and patient experiences and drive efficiencies in certain areas of our business, including, without limitation, making AI features available within our practice management systems, which, among other things, helps dentists and clinical staff detect caries. While these innovations can present benefits to the Company, they also create risks and challenges. The use of AI in healthcare offerings poses certain clinical risks resulting from potential misdiagnosis or misinformation provided from AI applications, diminishing critical judgment, or loss of interpersonal care from clinicians. These deficiencies could undermine the decisions, predictions, or analysis AI applications produce, as well as their adoption, subjecting us to competitive harm, legal liability (including under new proposed legislation regulating AI in jurisdictions such as the EU or new applications of existing data protection, privacy, intellectual property, and other laws), regulatory actions, and reputational harm. In addition, some AI scenarios, such as using AI applications to generate patient data (including, without limitation, using AI to capture and summarize patient interactions, and voice-activated perio charting), present ethical, privacy, or other social issues, risking reputational harm and/or reduced market demand or acceptance of AI solutions. The safeguards we have designed to promote the ethical implementation of AI may not be sufficient to protect us against negative outcomes. All of these risks are amplified by the critical nature of healthcare decisions and the sensitivity of health-related information, and the occurrence of any of the above could have a material adverse effect on our business, financial condition or operating results. Additionally, if investments in emerging technologies are less successful at attracting and retaining customers than similar investments by our competitors, or if we are otherwise unsuccessful at realizing the benefits of these technological investments generally, this could have a material adverse effect on our business, financial condition, or operating results. Additionally, widely accessible generative AI that rapidly surpasses our organizational ability to understand associated risks and opportunities (including employees' failure to comply with principles, policies and processes governing AI usage) could endanger our intellectual property, lead to misuse or loss of data and cause reputational harm and other fines, penalties or losses.

***Risks inherent in acquisitions, dispositions and joint ventures could offset the anticipated benefits.***

One of our business strategies has been to expand in part through acquisitions and joint ventures and we expect to continue to make acquisitions and enter into joint ventures in the future. There is risk that one or more may not succeed. We cannot be sure, for example, that we will achieve the benefits of revenue growth that we expect from these transactions or that we will avoid unforeseen additional costs, taxes, or expenses. Our ability to successfully implement our acquisition and joint venture strategy depends upon, among other things, the following:

- the availability of suitable acquisition or joint venture candidates at acceptable prices;

- our ability to consummate such transactions, which could potentially be prohibited due to U.S. or foreign antitrust regulations;
- the liquidity of our investments and the availability of financing on acceptable terms;
- our ability to retain customers or product lines of the acquired businesses or joint ventures;
- our ability to retain, recruit and incentivize the management of the companies we acquire; and
- our ability to successfully integrate these companies' operations, systems, services, products and personnel with our culture, management policies, legal, regulatory and compliance policies, information technology and cybersecurity systems and policies, internal procedures, working capital management, financial, operational and internal controls and strategies.

Furthermore, some of our acquisitions and future acquisitions may give rise to an obligation to make contingent payments or to satisfy certain repurchase obligations, which payments could have material adverse impacts on our financial results individually or in the aggregate. Additionally, when we decide to sell assets or a business, we may encounter difficulty in finding buyers or timely executing alternative exit strategies on acceptable terms, which could delay the accomplishment of our strategic objectives. Dispositions may also involve continued financial involvement in a divested business, such as through transition service agreements, indemnities or other current or contingent financial obligations.

***Certain provisions in our governing documents and other documents to which we are a party may discourage third parties from seeking to acquire us that might otherwise result in our stockholders receiving a premium over the market price of their shares.***

The provisions of our certificate of incorporation and by-laws may make it more difficult for a third-party to acquire us, may discourage acquisition bids and may impact the price that certain investors might be willing to pay in the future for shares of our common stock. These provisions, among other things require (i) the affirmative vote of the holders of at least 60% of the shares of common stock entitled to vote to approve a merger, consolidation, or a sale, lease, transfer or exchange of all or substantially all of our assets; and (ii) the affirmative vote of the holders of at least 66 2/3% of our common stock entitled to vote to (a) remove a director; and (b) to amend or repeal our by-laws, with certain limited exceptions. In addition, certain of our employee incentive plans provide for accelerated vesting of equity awards upon termination without cause within two years following a change in control, or grant the plan committee discretion to accelerate awards upon a change of control. Further, certain agreements between us and our executive officers provide for increased severance payments and certain benefits if those executive officers are terminated without cause by us or if they terminate for good reason, in each case within two years following a change in control or within ninety days prior to the effective date of the change in control or after the first public announcement of the pendency of the change in control.

***Adverse changes in supplier rebates or other purchasing incentives could negatively affect our business.***

The terms on which we purchase or sell products from many suppliers may entitle us to receive a rebate or other purchasing incentive based on the attainment of certain growth goals. Suppliers may reduce or eliminate rebates or incentives offered under their programs, or increase the growth goals or other conditions we must meet to earn rebates or incentives to levels that we cannot achieve. Increased competition either from generic or equivalent branded products could result in us failing to earn rebates or incentives that are conditioned upon achievement of growth goals. Additionally, factors outside of our control, such as customer preferences, consolidation of suppliers or supply issues, can have a material impact on our ability to achieve the growth goals established by our suppliers, which may reduce the amount of rebates or incentives we receive.

***Sales of corporate brand products and products that we manufacture entail additional risks, including the risk that such sales could materially adversely affect our relationships with suppliers.***

We offer certain corporate brand products that are available exclusively from us. The sale of such corporate brand products and the sale of products that we manufacture subject us to potential product liability risks, mandatory or voluntary product recalls, potential supply chain and distribution chain disruptions and potential intellectual property infringement risks, among other risks. In addition, an increase in the sales of our corporate brand products and our own manufactured products may negatively affect our sales of products owned by our suppliers which,

consequently, could adversely impact certain of our supplier relationships. Our ability to locate qualified, economically stable suppliers who satisfy our requirements, and to acquire sufficient products in a timely and effective manner, are critical to ensuring, among other things, that customer confidence is not diminished. In addition, we are exposed to the risk that our competitors or our large customers may introduce their own private label, generic, or low-cost products that compete with our products at lower price points. Such products could capture significant market share or decrease market prices overall, eroding our sales and margins. Any failure to develop sourcing relationships with a broad and deep supplier base could have a material adverse effect on our business, financial condition or operating results.

***Our business could be affected by activist investors.***

We actively engage in discussions with our stockholders. In other cases, stockholders can engage in certain divisive activist tactics, which can take many forms (including potential proxy contests). Some stockholder activism has resulted in, and could in the future result in, substantial costs, such as professional fees, and the diversion of management's and our Board of Directors' attention and resources from our business and strategic plans. Additionally, it could cause uncertainty about our management, operations or future strategic direction, which could result in the loss of future business opportunities or negatively impact our ability to attract and retain qualified talent. Activists or other stockholders holding a large portion of our outstanding shares could also exert influence on actions requiring a stockholder vote, including the election of directors and the approval of certain extraordinary business transactions. These risks could cause volatility in the trading price of our common stock based on factors other than the fundamentals of our business.

## **INDUSTRY RISKS**

***Security risks generally associated with our information systems and our technology products and services have in the recent past adversely affected our business and results of operations, and could in the future materially adversely affect our business and our results of operations if such products, services, or systems (or third-party systems we rely on) are interrupted, damaged by unforeseen events, are subject to cyberattacks or fail for any extended period of time.***

We rely on information systems ("IS") in our business to obtain, rapidly process, analyze, manage and store customer, product, supplier and employee data to, among other things:

- maintain and manage worldwide systems to facilitate the purchase and distribution of thousands of inventory items from numerous distribution centers;
- receive, process and ship orders on a timely basis;
- manage the accurate billing and collections for our customers;
- process payments to suppliers;
- provide products and services that maintain certain of our customers' electronic medical or dental records (including protected health information of their patients); and
- maintain and manage global human resources, compensation and payroll systems.

There could be an adverse impact on our business, financial condition or operating results if we do not maintain an adequate information and technology infrastructure (e.g., hardware, networks, software, people and processes) to effectively protect and support the current and future information requirements of the business. In addition to health information in our customers' electronic medical and dental records, certain of our IS store other sensitive personal and financial information, such as health care and other information related to our employees and individuals we service, as well as other sensitive information such as credit card information from our third-party business partners, that is confidential, and in many cases subject to privacy laws.

Our IS are susceptible to, among other things, natural disasters, power losses, telecommunication failures, cybersecurity threats and other criminal activity. Information security risks have significantly increased in recent years in part because of an overall increase in cyber incidents, their increased sophistication and the involvement of organized crime, hackers, terrorists and foreign state agents. The health care industry has been targeted by threat actors seeking to undermine companies' cybersecurity defensive measures. Moreover, cyberattacks have become more difficult to detect and respond to. They increasingly exploit AI and machine learning techniques, such as

generative AI-phishing, deepfake impersonations, automated vulnerability discovery, adaptive malware and large-scale credential-stuffing campaigns. New subsidiaries that we acquire and non-integrated subsidiaries have been, and may continue to be, targets to cyberattacks as we update their defensive measures to meet our standards. We have processes in place intended to ensure that our security measures keep pace with new and emerging risks. We regularly review, monitor and implement multiple layers of security through technology, processes and our people. We utilize security technologies designed to protect and maintain the integrity of our IS and data, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems and those of our third-party service providers have been, and may in the future be, vulnerable to privacy and security incidents, cybersecurity attacks and data breaches, acts of vandalism or theft, computer viruses and other malicious code, misplaced or lost data, programming and/or human errors, attacks or other acts undermining IS of third party business partners including our customers, or other similar events that could impact the security, reliability and availability of our systems. In addition, hardware, software or applications developed internally or procured from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security. As a practical matter, so long as we depend on IS to operate our business, and our business partners do the same, there can be no guaranty that such measures will successfully stop any one particular cybersecurity incident given the constantly evolving nature of the threat. We have incurred, continue to incur, and may in the future incur substantial costs as we update our cybersecurity defense systems and our general computer controls to meet evolving challenges, and legislative or regulatory action related to cybersecurity which may increase our costs to develop or implement new technology products and services.

A cyberattack that bypasses or compromises our, or our vendors', IS cybersecurity and/or general information technology ("IT") controls (including third-party systems we rely on) causing an IS security breach may lead, and has in the past led, to a disruption of our, or our vendors', IS business systems (including third-party systems we rely on), interruption of operations (including, without limitation, receiving, verifying and processing customer orders, customer service, accounts payable, warehouse management and shipping and systems tied to internal controls over financial reporting), the loss or alteration of business, financial and other protected information, a negative impact on our financial performance, and to an adverse impact on our financial accounting and reporting controls. A cyberattack that bypasses or compromises our IS cybersecurity and/or general computer controls or those of third parties with whom we engage may also lead to claims against us by affected parties and/or governmental agencies, and involve fines and penalties, as well as substantial defense and settlement expenses. Any of these impacts may alone, or collectively, have a material impact on our business. A successful cyberattack has, and may again in the future, disrupt our business operations, adversely impact our financial accounting and reporting of results of operations, divert the attention of management, and adversely impact our results of operations.

In addition, we develop products and provide services to our customers that are technology-based, and a cyberattack that bypasses the IS supporting our products or services causing a security breach and/or perceived security vulnerabilities in our products or services could also cause significant loss of business and reputational harm, and actual or perceived vulnerabilities may lead to claims against us by our customers and/or governmental agencies. In addition, certain of our practice management products and services purchased by health care providers, such as physicians and dentists, are used to store and manage patient medical or dental records, and when cloud-based approaches are used, we may be responsible for hosting those records. These customers, and in some cases, we are subject to laws and regulations which require that they protect the privacy and security of those records, and our products may be used as part of these customers' comprehensive data security programs, including in connection with their efforts to comply with applicable privacy and security laws.

In addition to immaterial and unrelated incidents at certain of our subsidiaries, in October 2023 Henry Schein experienced a cybersecurity incident that primarily affected the operations of our North American and European dental and medical distribution businesses. Henry Schein One, our practice management software, revenue cycle management and patient relationship management solutions business was not affected, and our manufacturing businesses were mostly unaffected. Nevertheless, the October 2023 cybersecurity incident disrupted key business operations, adversely impacted our financial results for the fourth quarter and full year 2023, diverted attention of management, and caused the Company to incur significant remediation costs. The incident had residual impact on our financial results in 2024. We have spent, and plan to expend in the future, additional resources to continue to

protect against, or to address problems caused by, business interruptions and data security breaches. We also may be perceived as a more vulnerable target of the cyber hackers as a result of the October 2023 incident.

***The health care products distribution industry is highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating, and we may not be able to compete successfully.***

We compete with numerous companies, including several major manufacturers and distributors. Some of our competitors have greater financial and other resources than we do, which could allow them to compete more successfully. Most of our products are available from several sources and our customers tend to have relationships with several distributors. Competitors could obtain exclusive rights to market particular products, which we would then be unable to market. Manufacturers also could increase their efforts to sell directly to end-users and thereby eliminate or reduce our role in distribution. Industry consolidation among health care product distributors and manufacturers, price competition, product unavailability, whether due to our inability to gain access to products or to interruptions in manufacturing supply, or the emergence of new competitors, also could increase competition. Consolidation has also increased among manufacturers of health care products, which could have a material adverse effect on our margins and product availability. We could be subject to charges and financial losses in the event we fail to satisfy minimum purchase commitments contained in some of our contracts. Additionally, traditional health care supply and distribution relationships are being challenged by online commerce solutions. The continued advancement of online commerce by third parties and online price transparency requires us to cost-effectively adapt to changing technologies, to enhance existing services and to differentiate our business (including with additional value-added services) to address changing demands of consumers and our customers. The emergence of such competition and our inability to anticipate and effectively respond to changes on a timely basis could have a material adverse effect on our business, financial condition or operating results.

***The health care industry is experiencing changes due to political, economic and regulatory influences that could materially adversely affect our business.***

The health care industry is highly regulated and subject to changing political, economic and regulatory influences. Uncertainty surrounding possible changes to the health care environment, including changes to regulatory enforcement priorities, may directly or indirectly adversely affect us. In recent years, the health care industry has been undergoing significant changes driven by various efforts to reduce costs, including, among other factors: trends toward managed care; collective purchasing arrangements and consolidation among office-based health care practitioners; and changes in reimbursements to customers, including increased attention to value-based payment arrangements, as well as enforcement activities (and related monetary recoveries) by governmental officials. Both our profitability and that of our customers may be materially adversely affected by laws and regulations reducing reimbursement rates for pharmaceuticals, medical supplies and devices, and/or medical treatments or services, changes to the methodology by which reimbursement levels are determined, or regulating pricing, contracting and discounting practices with respect to medical products and services. It is possible that the adoption of the One Big Beautiful Bill Act could impact eligibility for participation in Medicare and Medicaid programs, resulting in a change in utilization of the health care system. In addition, a number of states are considering and enacting laws or regulations to expand their oversight of health care transactions, which may impact the financial stability and strategic opportunities of certain of our customers. If we are unable to react effectively to these and other changes in the health care industry, our business could be materially adversely affected. The ACA greatly expanded health insurance coverage in the United States and has been the target of legal and political challenges since its adoption. Any outcome of these challenges that changes the ACA could have a significant impact on the U.S. health care industry and the ability or willingness of individuals to engage with it.

***Expansion of GPOs, DSOs, MSOs or provider networks and the multi-tiered costing structure may place us at a competitive disadvantage.***

The health care products industry is subject to a multi-tiered costing structure, which can vary by manufacturer and/or product. Under this structure, certain institutions can obtain more favorable prices for health care products than we are able to obtain. The multi-tiered costing structure continues to expand as many large integrated health care providers and others with significant purchasing power, such as GPOs, DSOs and MSOs, demand more favorable pricing terms. Additionally, the formation of provider networks, GPOs, DSOs and MSOs may shift

purchasing decisions to entities or persons with whom we do not have a historical relationship and may threaten our ability to compete effectively, which could in turn negatively impact our financial results. In addition, such organizations may establish direct relationships with manufacturers, thereby either eliminating or reducing the services historically provided by distributors. Although we are seeking to obtain similar terms from manufacturers to access lower prices demanded by GPO, DSO and MSO contracts or other contracts, and to develop relationships with existing and emerging provider networks, GPOs, DSOs and MSOs, we cannot guarantee that such terms will be obtained or contracts executed.

***Increases in shipping costs or service issues with our third-party shippers could harm our business.***

Our ability to meet our customers' expedited delivery expectations is an integral component of our business strategy for which our customers rely. Shipping is a significant expense in the operation of our business. We ship almost all of our orders through third-party delivery services, and typically bear the cost of shipment. Accordingly, any significant increase in shipping rates could have a material adverse effect on our business, financial condition or operating results. While we have recently experienced increases in shipping costs, we do not expect these additional expenses to be material to our results now, however they could become material in a future fiscal period. Similarly, strikes or other service interruptions by those shippers, including at transportation centers or shipping ports, could cause our operating expenses to rise and materially adversely affect our ability to deliver products on a timely basis.

## **MACRO-ECONOMIC AND POLITICAL RISKS**

***Uncertain global and domestic macro-economic and political conditions could materially adversely affect our results of operations and financial condition.***

Uncertain global and domestic macro-economic and political conditions that affect the economy and the economic outlook of the United States, Europe, Asia and other parts of the world could have a material adverse effect on our business, financial condition or operating results. These uncertainties, include, among other things, those listed under "Management's Discussion and Analysis of Financial Condition and Results of Operations, Cautionary Note Regarding Forward-Looking Statements."

Additionally, changes in government, government debt and/or budget crises may lead to reductions in government spending in certain countries, which could reduce overall health care spending and/or lead to higher income or corporate taxes, which could depress spending overall. Recessionary or inflationary conditions and depressed levels of consumer and commercial spending may also cause customers to reduce, modify, delay, or cancel plans to purchase our products and may cause suppliers to reduce their output or change their terms of sale. We have experienced inflationary pressures, including higher freight costs and interest expense, and pressures resulting from the strengthening of the dollar, which have and continue to impact our results of operations. We generally sell products to customers with payment terms. If customers' cash flow or operating and financial performance deteriorate, or if they are unable to make scheduled payments or obtain credit, they may not be able to, or may delay, payment to us. Likewise, for similar reasons suppliers may restrict credit or impose different payment terms.

## **REGULATORY AND LITIGATION RISKS**

***Failure to comply with existing and future regulatory requirements could materially adversely affect our business.***

We strive to be compliant with the applicable laws, regulations and guidance described below in all material respects, and believe we have effective compliance programs and other controls in place to ensure substantial compliance. However, compliance is not guaranteed either now or in the future as certain laws, regulations and guidance may be subject to varying and evolving interpretations that could affect our ability to comply, as well as future changes, additions and enforcement approaches, including in light of political changes. Changes with respect to the applicable laws, regulations and guidance described below may require us to update or revise our operations, services, marketing practices, and compliance programs and controls, and may impose additional and unforeseen costs on us, pose new or previously immaterial risks to us, or may otherwise have a material adverse

effect on our business. There can be no assurance that current and future government regulations will not adversely affect our business, and we cannot predict new regulatory priorities, the form, content or timing of regulatory actions, and their impact on the health care industry and on our business and operations.

Global efforts to contain health care costs continue to exert pressure on product pricing. In the United States, there has been increased scrutiny on drug pricing and concurrent efforts to control or reduce drug costs by Congress, the President, executive branch agencies and various states. We may be required to report drug pricing data under federal laws and regulations. Several U.S. states have adopted laws, that may apply to some of our operations, that require drug manufacturers, including re-packagers or re-labelers, to provide advance notice of certain price increases and to report information relating to price increases, while others have established prescription drug affordability boards or multi-payer purchasing pools to reduce the cost of prescription drugs. At the federal level, for example, the Inflation Reduction Act of 2022, among other things, requires drug manufacturers that raise certain of their drug prices faster than the rate of inflation to pay rebates to Medicare, and over time will authorize the federal government to negotiate directly with drug manufacturers to lower the prices of certain brand-name drugs covered by Medicare. These various evolving efforts create uncertainty and may adversely affect our business.

Under the Sunshine Act, we are required to collect and report detailed information regarding certain financial relationships we have with covered recipients (*e.g.*, physicians, dentists, teaching hospitals, other health care practitioners) as well as physician ownership or investment interest. We may be required to report information under state transparency laws that address circumstances not covered by the Sunshine Act. We are also subject to similar foreign transparency laws. While we believe we have substantially compliant programs and controls in place satisfying the above laws and requirements, such compliance imposes additional costs on us and the requirements are sometimes unclear.

Our business is subject to additional requirements under various local, state, federal and foreign laws and regulations applicable to the sale and distribution of, and third-party payment for, pharmaceuticals and medical devices and HCT/P products. Among the federal laws with which we must comply are the Controlled Substances Act, the Food, Drug & Cosmetic Act, the Federal Drug Quality and Security Act, including the Drug Supply Chain Security Act, and Section 361 of the Public Health Services Act. Among other things, such laws and the regulations promulgated thereunder:

- regulate the introduction, manufacture, advertising, marketing, promotion, sampling, pricing, reimbursement, labeling, packaging, storage, handling, returning, recalling, reporting, distribution of, disposal, and recordkeeping for drugs, HCT/P products and medical devices, including unique device identifiers;
- subject us to inspection by the FDA, OSHA, and DEA and similar state authorities;
- regulate the storage, transportation and disposal of hazardous materials;
- require us to advertise and promote our drugs and devices in accordance with FDA regulations;
- require us to report average sales price (ASP) to CMS for drugs or biologicals payable under Medicare Part B with or without a Medicaid drug rebate agreement;
- require registration with the FDA and the DEA and various state agencies;
- require us to design and operate a system to identify and report suspicious orders of controlled substances to the DEA and certain states;
- require us to manage returns of products that have been recalled and subject us to inspection of our recall procedures and activities;
- impose on us reporting requirements if a pharmaceutical, HCT/P product or medical device causes an adverse event, serious illness, injury or death;
- require manufacturers, wholesalers, re-packagers and dispensers of prescription drugs to identify and trace certain prescription drugs as they are distributed;
- require the licensing of prescription drug wholesalers and third-party logistics providers; and
- mandate compliance with standards for the recordkeeping, storage, handling and documentation of transactions involving prescription drugs and devices and associated reporting requirements.

The FDA regulates certain computer software and digital health products intended for use in health care settings, including, for example, AI and machine learning-enabled medical devices and the cybersecurity of medical devices. Certain of our businesses involve the development and sale of software and related products to support physician

and dental practice management, and it is possible that the FDA or foreign government authorities could determine that one or more of our products is subject to regulation as a medical device, which could subject our businesses to substantial additional requirements, costs, potential enforcement actions or liabilities for noncompliance with respect to these products. For example, some of our imaging software is regulated as a medical device which subjects our businesses to substantial additional requirements, costs and potential enforcement actions or liabilities for noncompliance with respect to these products.

Applicable federal, state, local and foreign laws and regulations also may require us to meet various standards relating to, among other things, licensure, registration, program eligibility, procurement, third-party reimbursement, sales and marketing practices, product integrity and supply tracking to product manufacturers, product labeling, personnel, privacy and security of health or other personal information, installation, maintenance and repair of equipment and the importation and exportation of products. The FDA, DEA, OCR, and state privacy regulators, as well as CMS (including with respect to complex Medicare reimbursement requirements applicable to our specialty home medical supplies business) and state Medicaid agencies, have recently increased their regulatory and enforcement activities and, in particular, the DEA has heightened enforcement activities due to the opioid crisis in the United States.

The failure to comply with any of these laws or regulations, or new interpretations of them, or the imposition of any additional laws and regulations, could materially adversely affect our business. The costs to us associated with complying with the various applicable statutes and regulations, as they now exist and as they may be modified, could be material. Allegations by a governmental body that we have not complied with these laws could have a material adverse effect on our businesses. While we believe that we are substantially compliant with applicable laws and regulations, and have adequate compliance programs and controls in place to ensure substantial compliance, if it is determined that we have not complied with these laws, we are potentially subject to warning letters, substantial civil and criminal penalties, mandatory recall of product, seizure of product and injunction, consent decrees and suspension or limitation of payments to us, product sale and distribution. If we enter into settlement agreements to resolve allegations of non-compliance, we could be required to make settlement payments or be subject to civil and criminal penalties, including fines and the loss of licenses. Non-compliance with government requirements could also adversely affect our ability to participate in important federal and state government health care programs, such as Medicare and Medicaid, and damage our reputation.

***The EU Medical Device Regulation (“MDR”) may adversely affect our business.***

The EU MDR significantly modified the regulatory compliance requirements for the medical device industry as a whole. Among other things, as mentioned above, the EU MDR:

- strengthens the rules on placing devices on the market and reinforces surveillance thereafter;
- establishes explicit provisions on manufacturers’ responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;
- improves the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;
- sets up a central database (EUDAMED) to provide patients, health care professionals and the public with comprehensive information on devices, importers, and distributors registered in the EU;
- strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market; and
- contains specific provisions in the event of interruption or discontinuation of supply of a device.

The EU MDR imposes strict requirements for the confirmation that a product meets the regulatory requirements, including regarding a product’s clinical evaluation and a company’s quality systems, and for the distribution, marketing and sale of medical devices, including post-market surveillance. Pursuant to Regulation 2023/607 and subject to certain conditions, medical devices that (i) obtained a certificate under the EU Medical Device Directive from May 25, 2017, (ii) which was still valid on May 26, 2021, and (iii) has not been subsequently withdrawn may continue to be placed on the market or put into service until December 31, 2027 for higher risk devices or December 31, 2028 for medium and lower risk devices. The modifications created by the EU MDR may have an impact on the way we design and manufacture products and the way we conduct our business in the EEA.

***If we fail to comply with laws and regulations relating to health care fraud or other laws and regulations, we could suffer penalties or be required to make significant changes to our operations, which could materially adversely affect our business.***

Certain of our businesses are subject to federal and state (and similar foreign) health care fraud and abuse, referral and reimbursement laws and regulations with respect to their operations. Some of these laws, referred to as “false claims laws,” prohibit the submission or causing the submission of false or fraudulent claims for reimbursement to federal, state and other health care payers and programs. Other laws, referred to as “anti-kickback laws,” prohibit soliciting, offering, receiving or paying remuneration in order to induce or reward the referral of a patient or ordering, purchasing, leasing or arranging for, or recommending ordering, purchasing or leasing of, items or services that are paid for by federal, state and other health care payers and programs. Certain additional state and federal laws, such as the federal Physician Self-Referral Law (“Stark Law”), prohibit physicians and other health care professionals from referring a patient to an entity with which the physician (or family member) has a financial relationship, for the furnishing of certain designated health services (for example, durable medical equipment and medical supplies), unless an exception applies.

The fraud and abuse laws and regulations have been subject to heightened enforcement activity over the past few years, often as the result of “relators” who serve as whistleblowers by filing complaints in the name of the United States (and if applicable, particular states) under applicable false claims laws, and who may receive up to 30% of total government recoveries. Penalties under fraud and abuse laws may be severe, including treble damages and substantial civil penalties under the federal False Claims Act, as well as potential loss of licenses and the ability to participate in federal and state health care programs, criminal penalties, or imposition of a corporate compliance monitor, which could have a material adverse effect on our business. Also, these measures may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations or incur substantial defense and settlement expenses. Even unsuccessful challenges by regulatory authorities or relators could result in reputational harm and the incurring of substantial costs. Most states have adopted similar state false claims acts, and these state laws have their own penalties which may be in addition to federal False Claims Act penalties, and other fraud and abuse laws.

The U.S. government and industry trade associations (among others) have expressed concerns about financial relationships between suppliers or manufacturers on the one hand and physicians, dentists and other health care providers, on the other. As a result, we regularly review and revise our marketing practices as necessary to facilitate compliance.

Our aspirations, goals and disclosures related to environmental, social and governance matters and the focus on regulators and private litigants among other things on related claims made by companies and funds expose us to numerous risks, including reputational, financial, legal and other risks, that could have an adverse impact on us. California has adopted stringent new climate disclosure requirements, as has the EU.

We are subject to Directive (EU) 2022/2464 on corporate sustainability reporting (“CSRD”) which became effective on January 5, 2023. CSRD requires in-scope companies to report sustainability-related information that is material from both a financial risk or opportunity and an environmental or social impact perspective, and the assessment of materiality is inherently subjective. Furthermore, Directive No. 2025/794 of 14 April 2025, the “Omnibus” Directive, amended Directive 2022/2464 by introducing a two-year postponement of the sustainability reporting requirements for financial years beginning on or after 1<sup>st</sup> January 2025 and on or after 1<sup>st</sup> January 2026. This “Omnibus” legislative package amending the CSRD alters the scope, thresholds, timing and contents of reporting obligations, which may increase our costs. CSRD is being transposed into national law across EU Member States, and further legislative or implementation changes may also increase our costs.

We also are subject to certain United States and foreign laws and regulations concerning the conduct of our foreign operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, German anti-corruption laws and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records. Our businesses are generally subject to numerous other laws and regulations that could impact our financial results, including, without limitation, securities, antitrust, consumer protection and marketing laws and regulations.

In the EU, Directive No. 2019/1937 of October 23, 2019, *on the protection of persons who report breaches of Union law*, organizes the legal protection of whistleblowers. This Directive covers whistleblowers reporting breaches of EU laws and regulations and protects a wide range of people, including former employees. All private companies with 50 or more employees are required to create effective internal reporting channels. All EU Member States have now implemented the Directive.

In the EU, both active and passive corruption in the private sector are criminalized. The EU Council Framework Decision 2003/568/JHA of 22 July 2003 *on combating corruption in the private sector* establishes more detailed rules on the liability of legal persons and deterrent sanctions. However, the liability of legal persons is regulated at a national level.

Failure to comply with fraud and abuse laws and regulations, and other laws and regulations, could result in significant civil and criminal penalties and costs, including the loss of licenses and the ability to participate in federal and state health care programs, and could have a material adverse effect on our business. We may determine to enter into settlements, make payments, agree to consent decrees or enter into other arrangements to resolve such matters. Intentional or unintentional failure to comply with settlement agreements or consent decrees could materially adversely affect our business.

While we believe that we are substantially compliant with applicable laws and regulations, and believe we have adequate compliance programs and controls in place to ensure substantial compliance, we cannot predict whether changes in applicable law, or interpretation of laws, or changes in our services or marketing practices in response to changes in applicable law or interpretation of laws, could have a material adverse effect on our business.

***If we fail to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions, we could be required to make significant changes to our products, or incur substantial fines, penalties, or other liabilities.***

Our businesses that involve physician and dental practice management products, equipment and our specialty home medical supplies businesses, and our self-funded employee benefits programs include information technology (IT) systems that store and process personal health, clinical, financial, and other sensitive information of individuals. These IT systems may be vulnerable to breakdown, wrongful intrusions, data breaches and malicious attack, which could require us to expend significant resources to eliminate these problems and address related security concerns, and could involve claims against us by private parties and/or governmental agencies.

We are directly or indirectly subject to numerous and evolving federal, state, local and foreign laws and regulations that protect the privacy and security of personal information (including health data), such as HIPAA, CAN-SPAM, TCPA, Section 5 of the FTC Act, the CCPA/CPRA and various other privacy laws that have or will soon come into effect. Laws and regulations relating to privacy and data protection are continually evolving and subject to potentially differing interpretations, including those relating to AI. These requirements may not be harmonized, may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another or may conflict with other rules or our practices. In addition to state-specific data breach notification laws (which exist in all U.S. states and territories), cybersecurity laws such as the federal Cyber Incident Reporting for Critical Infrastructure Act of 2022, proposed Federal Acquisition Regulations and amendments to SEC reporting requirements may require us to provide notifications about cybersecurity incidents in limited timeframes and before investigations are complete. Our businesses' failure to comply with these laws and regulations could expose us to breach of contract claims, substantial fines, penalties and other liabilities and expenses, costs for remediation and harm to our reputation. Evolving laws and regulations in this area could restrict the ability of our customers to obtain, use or disseminate patient information, or could require us to incur significant additional costs to re-design our products to reflect these legal requirements, which could have a material adverse effect on our operations.

In addition, the European Parliament and the Council of the EU adopted the GDPR that has been effective since May 25, 2018, which increased privacy rights for Data Subjects in the European Economic Area (EEA), including individuals who are our customers, suppliers and employees. The GDPR extended the scope of responsibilities for data controllers and data processors, and generally imposes increased requirements and potential penalties on companies, such as us, that are either established in the EU and process personal data of Data Subjects (regardless

the Data Subject location), or that are not established in the EU but that offer goods or services to Data Subjects in the EU or monitor their behavior in the EU. Noncompliance can result in penalties of up to the greater of EUR 20 million, or 4% of global company revenues (sanction that may be public), and Data Subjects may seek damages. Member states may individually impose additional requirements and penalties regarding certain limited matters (for which the GDPR left some room of flexibility), such as employee personal data. With respect to the personal data it protects, the GDPR requires, among other things, controller accountability, consents from Data Subjects or another acceptable legal basis to process the personal data, notification within 72 hours of a personal data breach where required, data integrity and security, and fairness and transparency regarding the storage, use or other processing of the personal data. The GDPR also provides rights to Data Subjects relating notably to information, access, rectification, erasure of the personal data and the right to object to the processing. Despite Brexit, the UK also has data protection laws equivalent to the GDPR and has implemented further data protection related legislation. Switzerland enacted FADP. Data protection authorities located in different EU Member States may interpret GDPR differently, or requirements of national laws may vary between the EU Member States, UK and Switzerland, or guidance on GDPR and related laws and compliance practices may be often updated or otherwise revised. Any of these events will increase the complexity and costs of processing personal data in the European Economic Area, UK or Switzerland or concerning individuals located in these jurisdictions.

Effective November 1, 2021, China's PIPL imposes specific rules for processing personal information and specifies that the law shall also apply to personal information activities carried out outside China but for the purpose of providing products or services to PRC citizens. Any non-compliance with these laws and regulations may subject us to fines, orders to rectify or terminate any actions that are deemed illegal by regulatory authorities, other penalties, reputational damage, or legal proceedings against us, which may affect our business, financial condition or results of operations. The PIPL carries maximum penalties of CNY50 million or 5% of the annual revenue of entities that process personal data. Data protection laws in other countries, such as Brazil, are also quickly evolving, with many countries having updated, or are in the process of updating, their laws to bring them more in line with the model created by GDPR.

In the United States, the CCPA, effective January 1, 2020, establishes a privacy framework for covered businesses such as ours by, among other things, creating an expanded definition of personal information, establishing new data privacy rights for California residents and creating a new and potentially severe statutory damages framework for violations of the CCPA, as well as potentially severe statutory damages and a private right of action against businesses that suffer a data security breach due to their violation of a duty to implement reasonable security procedures and practices. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. In addition, California voters adopted the CPRA (effective January 1, 2023) which enhances and strengthens regulatory requirements and individual protections that currently exist under the CCPA. Effective as of January 1, 2026, the CCPA/CPRA regulatory framework includes expanded requirements. Other states have enacted or are considering enacting similar privacy laws, which may subject us to additional requirements and restrictions that could have an impact on our business. As of January 1, 2026, comprehensive privacy laws are now in effect in 20 states, further complicating our privacy compliance obligations through the introduction of increasingly disparate requirements across the various U.S. jurisdictions in which we operate. Additionally, certain states have enacted specific health data privacy laws and other states are considering similar legislation. Congress is considering legislation that may preempt some or all of such U.S. state privacy laws, but which may also provide a more expansive private right of action for privacy claims than exists under current state laws.

The evolving complexity of privacy and data security legislation in the U.S. and other jurisdictions globally may complicate our compliance efforts and further increase our risk of regulatory enforcement, penalties and litigation. While we believe we have substantially compliant programs and controls in place to comply with privacy laws domestically and internationally, our compliance with data privacy and cybersecurity laws is likely to impose additional costs on us, and we cannot predict whether the interpretations of the requirements, or changes in our practices in response to new requirements/interpretations, could have a material adverse effect on our business.

Our products and services utilize new technologies, such as AI. The regulatory landscape for AI is changing rapidly, with both domestic and international activity. While there is currently no comprehensive federal legislation in the U.S. concerning the use, development or deployment of AI, regulators pursue AI-related enforcement actions under existing federal consumer protection laws and have issued related guidance. Further, state privacy, consumer

protection and AI-specific laws are proliferating and may be applicable to our business. Other countries are also applying their data and consumer protection laws to AI, particularly generative AI, and are considering and implementing specific legal frameworks with respect to AI. Regulation (EU) 2024/1689 on harmonized rules on artificial intelligence (the EU AI Act), for example, establishes a comprehensive regulatory framework for AI that became law in August 2024 with implementation phased through into 2027. As with the GDPR, it has extra-territorial effect. Any failure or perceived failure by us to comply with such requirements could have an adverse impact on our business. Anticipated further evolution of regulations and legislation on this topic may substantially increase the penalties to which we could be subject in the event of any non-compliance. Compliance with these laws is challenging, constantly evolving and time consuming and federal regulators, state attorneys general and plaintiff's attorneys have been and will likely continue to be active in this space. We may incur substantial expense in complying with legal obligations to be imposed by new regulations and we may be required to make significant changes to our solutions and expanding business operations, all of which may adversely affect our operations.

We also sell products and services that health care providers, such as physicians and dentists, use to store and manage patient medical or dental records. These customers and we are subject to laws, regulations and industry standards, such as HIPAA and the Payment Card Industry (PCI) Data Security Standards, which require the protection of the privacy and security of those records. Our products or services may be used as part of these customers' comprehensive data security programs, including in connection with their efforts to comply with applicable data privacy and security laws and contractual requirements. Perceived or actual security vulnerabilities in our products or services, or the perceived or actual failure by us or our customers who use our products or services to comply with applicable legal or contractual data privacy and security requirements, may not only cause us significant reputational harm, but may also lead to claims against us by our customers and/or governmental agencies and involve substantial fines, penalties and other liabilities and expenses and costs for remediation. Additionally, under the GDPR (and equivalent laws) and U.S. state privacy laws, health data belong to the category of "sensitive data" and benefit from specific protection. Processing of such data is generally prohibited, except for specific exceptions.

Certain of our businesses involve the manufacture and sale of electronic health record (EHR) systems and other products linked to government supported incentive programs, where the EHR systems must be certified as having certain capabilities designated in evolving standards, such as those adopted by CMS and ONC. In order to maintain certification of our EHR products, we must satisfy the changing governmental standards. If any other EHR systems do not meet these standards, yet have been relied upon by health care providers to receive federal incentive payments, we may be exposed to risk, such as under federal health care fraud and abuse laws, including the False Claims Act. Additionally, effective September 1, 2023, the HHS-OIG issued a final rule implementing civil money penalties for information blocking as established by the Cures Act. OIG incorporated regulations published by ONC as the basis for enforcing information blocking penalties. Each information blocking violation carries a \$1 million penalty. While we believe we are substantially in compliance with such certifications and with applicable fraud and abuse laws and regulations and that we have adequate compliance programs and controls in place to ensure substantial compliance, we cannot predict whether changes in applicable law, or interpretation of laws, or resulting changes in our compliance programs and controls, could have a material adverse effect on our business.

Moreover, in order to satisfy our customers and comply with evolving legal requirements, our products may need to incorporate increasingly complex functionality, such as reporting and information blocking. Although we believe we are positioned to accomplish this, the effort may involve increased costs, and our failure to implement product modifications, or otherwise satisfy applicable standards, could have a material adverse effect on our business.

Additionally, as electronic medical devices are increasingly connected to each other and to other technology, the ability of these connected systems to safely and effectively exchange and use exchanged information becomes increasingly important. As a medical device manufacturer, we must manage risks including those associated with an electronic interface that is incorporated into a medical device.

***Tax legislation could materially adversely affect our financial results and tax liabilities.***

We are subject to the tax laws and regulations of the United States federal, state and local governments, as well as foreign jurisdictions. From time to time, various legislative initiatives may be proposed that could materially

adversely affect our tax positions. There can be no assurance that our effective tax rate will not be materially adversely affected by legislation resulting from these initiatives. In addition, tax laws and regulations are extremely complex and subject to varying interpretations. Although we believe that our historical tax positions are sound and consistent with applicable laws, regulations and existing precedent, there can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge.

***We face inherent risk of exposure to product liability, intellectual property infringement and other claims in the event that the use of the products we sell results in injury.***

Our business involves a risk of product liability, intellectual property infringement and other claims in the ordinary course of business, and from time to time we are named as a defendant in cases as a result of our distribution of products. Additionally, we own and own interests in companies that manufacture certain dental and medical products. As a result, we could be subject to the potential risk of product liability, intellectual property infringement or other claims relating to the manufacture and distribution of products by those entities. In addition, as our corporate brand business continues to grow, purchasers of such products may increasingly seek recourse directly from us, rather than the ultimate product manufacturer, for product-related claims. Another potential risk we face in the distribution of our products is liability resulting from counterfeit or tainted products infiltrating the supply chain. In addition, some of the products that we transport and sell are considered hazardous materials. The improper handling of such materials or accidents involving the transportation of such materials could subject us to liability or at least legal action that could harm our reputation.

***Customs policies or legislative import restrictions could hinder the Company's ability to import goods necessary to our operations on a timely basis and result in government enforcement actions and/or sanctions.***

Government-imposed import policies and legislation regulating the import of goods and prohibiting the use of forced labor or human trafficking could result in delays or the inability to import goods in a timely manner that are necessary to our operations, and such policies or legislation could also result in financial penalties, other sanctions, government enforcement actions and reputational harm. Certain of our suppliers have had their ability to service certain markets restricted or negatively impacted because of allegations of forced labor in their supply chain. While the Company has policies against and seeks to avoid the import of goods that are manufactured in whole or in part by forced labor or through human trafficking, as a result of legislative and governmental policy initiatives, we may be subject to increasing potential delays, added costs, supply chain disruption and other restrictions.

## **GENERAL RISKS**

***Our business operations, results of operations, cash flows, financial condition and liquidity may be negatively impacted by the effects of disease outbreaks, epidemics, pandemics, or similar wide-spread public health concerns and other natural or man-made disasters, such as terrorism, civil unrest, fire and extreme weather.***

Our business operations, results of operations, cash flows, financial condition and liquidity may be negatively impacted by the effects of disease outbreaks, epidemics, pandemics, similar wide-spread public health concerns and other natural or man-made disasters, such as terrorism, civil unrest, fire and extreme weather (“disasters”). For example, as a global health care solutions company, the COVID-19 pandemic and the governmental responses to it had a material adverse effect on our business, financial condition, operating results and cash flows. The impacts and potential impacts from the COVID-19 pandemic included, and could include as a result of other disasters, adverse impacts such as significant volatility in supply, demand and selling prices, interrupted operations of industries that use or manufacture the products we distribute for personal protective equipment (PPE), test kits and related products, reduction in peoples’ ability and willingness to be in public, impact of adapted business practices, volatility in the financial markets, and unavailability or impairment of our manufacturing, distribution, or other facilities, or firmwide systems such as our IS.

***Our global operations are subject to inherent risks that could materially adversely affect our business.***

Our global operations are subject to risks that could materially adversely affect our business, including, among other things:

- difficulties and costs relating to staffing and managing foreign operations;
- difficulties and delays inherent in sourcing products, establishing channels of distribution and contract manufacturing in foreign markets;
- fluctuations in the value of foreign currencies;
- uncertainties relating to trade agreements and international trade relationships;
- longer payment cycles and difficulty of collecting receivables in foreign jurisdictions;
- repatriation of cash from our foreign operations to the United States;
- regulatory requirements, including, without limitation, anti-bribery, anti-corruption and laws pertaining to the accuracy of our internal books and records;
- litigation risks;
- unexpected difficulties in importing or exporting our products and import/export tariffs, quotas, sanctions or penalties;
- limitations on our ability under local laws to protect our intellectual property;
- unexpected regulatory, legal, economic and political changes in foreign markets;
- changes in tax regulations that influence purchases of capital equipment;
- civil disturbances, geopolitical turmoil, including terrorism, war or political or military coups; and
- risks associated with climate change, including physical risks such as impacts from extreme weather events and other potential physical consequences, regulatory and technological requirements, market developments, stakeholder expectations and reputational risk.

***Our future success is substantially dependent upon our senior management, and our revenues and profitability depend on our relationships with capable personnel, as well as customers, suppliers and manufacturers of the products that we distribute.***

On July 15, 2025, the Company announced that Mr. Bergman will retire as the Company's CEO on December 31, 2025 (which date was extended to March 1, 2026), and that Mr. Bergman will continue to serve as Chairman of the Board of Directors of the Company following his retirement. On January 12, 2026, the Company announced the appointment of Frederick M. Lowery as its next CEO, effective March 2, 2026, at which time he will join the Company's Board of Directors.

Our future success is substantially dependent upon the efforts and abilities of members of our senior management. Competition for senior management is intense, burnout and turn-over rates are increasing workplace concerns, transitions among senior level officers can present challenges as well as opportunities, and we may not be successful in attracting and retaining key personnel, or transitioning to new personnel following departures. Additionally, our future revenues and profitability depend on our ability to maintain satisfactory relationships with qualified personnel, as well as customers, suppliers and manufacturers. If we fail to maintain our existing relationships with such persons or fail to acquire relationships with such key persons in the future, our business may be materially adversely affected.

***Disruptions in the financial markets may materially adversely affect the availability and cost of credit to us.***

Our ability to make scheduled payments or refinance our obligations with respect to indebtedness will depend on our operating and financial performance, which in turn is subject to prevailing economic conditions and financial, business and other factors beyond our control. Disruptions in the financial markets may materially adversely affect the availability and cost of credit to us.

#### **Item 1B. Unresolved Staff Comments**

We have no unresolved comments from the staff of the SEC that were issued 180 days or more preceding the end of our 2025 fiscal year.

## Item 1C. Cybersecurity

We rely on information systems in our business to obtain, rapidly process, analyze, manage and store customer, product, supplier and employee data to, among other things: maintain and manage multiple information systems worldwide to facilitate the purchase and distribution of thousands of inventory items from numerous distribution centers; receive, process and ship orders on a timely basis; manage the accurate billing and collections for thousands of customers; process payments to suppliers and vendors; provide products and services that maintain certain of our customers' electronic medical or dental records (including protected health information of their patients) and maintain and manage global human resources, compensation and payroll systems. For these purposes, we define "information systems" in a manner consistent with the definition contained in the rules adopted by the SEC to mean "electronic information resources, owned or used by the registrant, including physical or virtual infrastructure controlled by such information resources, or components thereof, organized for the collection, processing, maintenance, use, sharing, dissemination, or disposition of the registrant's information to maintain or support the registrant's operations."

### Cybersecurity Risk Management and Strategy

We have developed and implemented a cybersecurity risk mitigation strategy intended to protect our information systems. Our cybersecurity risk mitigation strategy is designed so that the Company's cybersecurity program is aligned with generally accepted cybersecurity standards and frameworks, in particular the NIST Cybersecurity Framework, or "NIST CSF," and our Company is externally audited, or certified, with ISO27001 partial scope.

We maintain an Office of Cybersecurity ("OCS"), led by our Chief Information Security Officer ("CISO"), which oversees the operations of our cyber risk mitigation strategy. The OCS is a cross-functional, enterprise-wide management team, which continuously evaluates our global cybersecurity program's effectiveness and is focused on maintaining and protecting our information systems. In overseeing the operations of our cyber risk mitigation strategy, the OCS partners with our Global Technology Solutions team, which is led by our Chief Technology Officer ("CTO") and is comprised of over one hundred professionals that support our information systems and operations. Our cyber risk mitigation strategy includes monitoring for and addressing risks that materialize within the Company's information systems, as well as at our third-party vendors, suppliers and other third-party business partners.

Our CISO reports to our CTO. Our CTO, who also serves as Senior Vice President, has more than 30 years of experience leading large-scale global IT organizations and received a Bachelor of Business Administration in Business Computer Information Systems and a Master of Business Administration from Hofstra University. See also Item 1. Business, Other Executive Management. Our Vice President, Global CISO, who also serves as Vice President and Head of the Office of Cyber Security, has over 30 years of experience leading global cybersecurity and technology programs in large and complex corporations, and holds a Certified Information Systems Security Professional and a Certified Information Systems Auditor certification. He also received a BS, Information Technology and Security from Baker College. The cybersecurity risk mitigation strategy is also overseen by senior managers who are members of our Executive Steering Committee, comprised of the Company's most senior technology, legal and internal auditing officers. Our CEO is regularly briefed on issues, incidents, and developments, and our Board oversees our risk mitigation strategy principally through its Audit Committee and Regulatory, Compliance and Cybersecurity Committee, as described in more detail below.

Our cybersecurity risk management program includes, among other elements:

- risk assessments designed to help identify material cybersecurity risks to our information systems;
- a security team principally responsible for managing our (i) cybersecurity risk assessment processes, and (ii) defining cybersecurity control standards;
- the use of expert external service providers to assess, test or otherwise assist with aspects of our cybersecurity controls, and to respond to specific cybersecurity threats;
- the review and assessment of past cybersecurity incidents with a view to learning from those events to further strengthen our cyber risk mitigation strategy;

- a written cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and
- a Global Information Security Policy, together with more detailed information security policies, procedures, standards, and guidelines.

In addition, all employees with systems access are required to participate in mandatory annual cybersecurity and anti-phishing courses, along with compliance programs. Our employees who perform financial gatekeeper roles also receive additional mandatory annual data security training specific to spoofing, phishing and similar data security threats. Per written Company policies, employees are also required to safeguard confidential information.

Our cybersecurity risk strategy is integrated into our overall enterprise risk management program, and our cybersecurity team is supported by and connected with the enterprise risk management team.

### Cyber Incidents

In addition to immaterial and unrelated incidents at certain of our subsidiaries, in October 2023 Henry Schein experienced a cyber incident that primarily affected the operations of our North American and European dental and medical distribution businesses. Henry Schein One, our practice management software, revenue cycle management and patient relationship management solutions business was not affected, and our manufacturing businesses were mostly unaffected. The October 2023 cyber incident disrupted key business operations, adversely impacted our financial results for the fourth quarter and full year 2023, diverted attention of management, and caused the Company to incur significant remediation costs. The incident had residual impact on our financial results in 2024.

### Cybersecurity Governance

Our Board has a Regulatory, Compliance and Cybersecurity Committee that focuses on cybersecurity oversight, together with other board committees, principally the Audit Committee. The purpose of the Regulatory, Compliance and Cybersecurity Committee is to assist the Board by providing guidance to, and oversight of, the Company's senior management responsible for assessing and managing Company-wide regulatory, corporate compliance and cybersecurity risk management programs. The primary responsibilities of the Regulatory, Compliance and Cybersecurity Committee are to (i) discuss cybersecurity strategic decisions, issues, challenges and opportunities relating thereto, (ii) provide expertise to guide assessment and monitoring of Company-wide regulatory, corporate compliance and cybersecurity risk management budgeting, spending and capital investment, (iii) monitor progress and status of the Company's regulatory, corporate compliance and cybersecurity risk management programs, (iv) review and evaluate major regulatory, corporate compliance and cybersecurity risk management initiatives to identify emerging and future opportunities for synergy or to leverage regulatory, corporate compliance and cybersecurity risk management investments more effectively and cost efficiently, (v) report to the Audit Committee on regulatory, corporate compliance and cybersecurity risk management matters reviewed by the Regulatory, Compliance and Cybersecurity Committee that may impact the Company's financial reporting and (vi) be generally available to, and communicate with, the Company's senior management, and to inform the Board in the areas described above.

Our CISO and CTO, along with other key executives who are part of our Executive Steering Committee, review strategy, policy, program effectiveness, standards, enforcement and cybersecurity issue management with the Board's Regulatory, Compliance and Cybersecurity Committee on at least a quarterly basis and with the Audit Committee on at least a bi-annual basis. Our CTO meets with Board members outside of the formal meetings on a regular basis as well as in connection with specific cybersecurity issues or threats.

**ITEM 2. Properties**

Within our Global Distribution and Value-Added Services and Global Specialty Products segments (for properties with more than 100,000 square feet) we lease and/or own approximately 5.0 million square feet of properties, consisting of distribution, office, showroom, manufacturing and sales space, in significant locations including United States, Germany, France, Canada, and Brazil. We also have meaningful market presence in several other European countries, and the Asia-Pacific region. Lease expirations range from 2026 to 2048.

We believe that our properties are in good condition, are well maintained and are suitable and adequate to carry on our business. We have additional operating capacity at certain distribution center facilities.

**ITEM 3. Legal Proceedings**

For a discussion of Legal Proceedings, see Note 17 – Commitments and Contingencies of the Notes to the Consolidated Financial Statements included under Item 8.

**ITEM 4. Mine Safety Disclosures**

Not applicable.

## PART II

### ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our common stock is traded on the Nasdaq Global Select Market tier of the Nasdaq Stock Market, or Nasdaq, under the symbol HSIC.

On February 17, 2026, there were approximately 251 holders of record of our common stock and the last reported sales price was \$77.21. A substantially greater number of holders of our common stock are “street name” or beneficial holders, whose shares are held by banks, brokers and other financial institutions.

#### Purchases of Equity Securities by the Issuer

Our share repurchase program, announced on March 3, 2003, originally allowed us to repurchase up to two million shares pre-stock splits (eight million shares post-stock splits) of our common stock, which represented approximately 2.3% of the shares outstanding at the commencement of the program. Subsequent additional increases since 2003 that have aggregated to an additional \$6.7 billion, authorized by our Board, to the repurchase program provide for a total of \$6.8 billion (including \$500 million authorized on January 27, 2025 and an additional \$750 million authorized on September 8, 2025) of shares of our common stock to be repurchased under this program, with \$780 million currently available for future share repurchases.

On May 19, 2025, we executed an accelerated share repurchase program to repurchase a total of \$250 million of our outstanding common stock based on volume-weighted average prices. In May 2025 we received 3,122,832 shares at an estimated fair value of \$224 million. In July 2025, we received an additional 368,651 shares at an estimated fair value of \$26 million, representing the final amount of shares to be received under this accelerated share repurchase program.

As of December 27, 2025, we had repurchased approximately \$6.0 billion of common stock (107,876,628) shares under these initiatives, with \$780 million available for future common stock share repurchases.

The following table summarizes repurchases of our common stock under our stock repurchase program during the fiscal quarter ended December 27, 2025:

<u>Fiscal Month</u>	<u>Total Number of Shares Purchased (1)</u>	<u>Average Price Paid Per Share</u>	<u>Total Number of Shares Purchased as Part of Our Publicly Announced Program</u>	<u>Maximum Number of Shares that May Yet Be Purchased Under Our Program (2)</u>
9/28/2025 through 11/1/2025	1,020,000	\$ 64.28	1,020,000	14,467,711
11/2/2025 through 11/29/2025	488,067	70.55	488,067	11,799,992
11/30/2025 through 12/27/2025	1,304,805	76.64	1,304,805	10,244,654
	<u>2,812,872</u>		<u>2,812,872</u>	

(1) All repurchases were executed in the open market under our existing publicly announced authorized program.

(2) The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the closing price of our common stock at that time. This table excludes shares withheld from employees to satisfy minimum tax withholding requirements for equity-based transactions.


#### Dividend Policy

We have not declared any cash or stock dividends on our common stock during fiscal years 2025 or 2024. We currently do not anticipate declaring any cash or stock dividends on our common stock in the foreseeable future. We intend to retain earnings to finance the expansion of our business and for general corporate purposes, including our share repurchase program. Any declaration of dividends will be at the discretion of our Board and will depend upon the earnings, financial condition, capital requirements, level of indebtedness, contractual restrictions with respect to payment of dividends and other factors.

## Stock Performance Graph

The graph below compares the cumulative total stockholder return on \$100 invested, assuming the reinvestment of all dividends, on December 26, 2020, the last trading day before the beginning of our 2021 fiscal year, through the end of our 2025 fiscal year with the cumulative total return on \$100 invested for the same period in the Dow Jones U.S. Health Care Index and the Nasdaq Stock Market Composite Index.

### COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURN



### ASSUMES \$100 INVESTED ON DECEMBER 26, 2020 ASSUMES DIVIDENDS REINVESTED

	December 26, 2020	December 25, 2021	December 31, 2022	December 30, 2023	December 28, 2024	December 27, 2025
Henry Schein, Inc.	\$ 100.00	\$ 113.81	\$ 121.30	\$ 114.96	\$ 106.92	\$ 115.57
Dow Jones U.S. Health Care Index	100.00	124.30	119.60	121.86	126.18	144.40
NASDAQ Stock Market Composite Index	100.00	123.04	82.97	120.01	158.80	191.20

## ITEM 6.

[Reserved]

## **ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations**

### **Cautionary Note Regarding Forward-Looking Statements**

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Annual Report on Form 10-K, and in particular the risks discussed under the caption “Risk Factors” in Item 1A of this report and those that may be discussed in other documents we file with the Securities and Exchange Commission (“SEC”).

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: our dependence on third parties for the manufacture and supply of our products and where we manufacture products, our dependence on third parties for raw materials or purchased components; risks relating to the achievement of our strategic growth objectives, including anticipated results of restructuring and value creation initiatives; risks related to the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025; transitions in senior company leadership; our ability to develop or acquire and maintain and protect new products (particularly technology and specialty products) and services and utilize new technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal, regulatory, compliance, financial and human resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; risks related to activist investors; security risks associated with our information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; political, economic and regulatory influences on the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers, and increases in fuel and energy costs; changes in laws and policies governing manufacturing, development and investment in territories and countries where we do business; general global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment (and corresponding increase in under-insured populations), consumer confidence, sovereign debt levels, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies and changes to other economic indicators; failure to comply with existing and future regulatory requirements, including relating to health care; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation, changes in tax rates and availability of certain tax deductions; risks related to product liability, intellectual property and other claims; risks associated with customs policies or legislative import restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters; risks associated with our global operations; the threat or outbreak of war (including, without limitation, geopolitical wars), terrorism or public unrest (including, without limitation, the war in Ukraine, the Israel-Gaza war and other unrest and threats in the Middle East and the possibility of a wider European or global conflict); changes to laws and policies governing foreign trade, tariffs and sanctions or greater restrictions on imports and exports, including changes to international trade agreements and the current imposition of (and the potential for additional) tariffs by the U.S. on numerous countries and retaliatory tariffs; supply chain disruption; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our senior management (including, without

limitation, the transition to a new Chief Executive Officer), employee hiring and retention, increases in labor costs or health care costs, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.

## **Where You Can Find Important Information**

We may disclose important information through one or more of the following channels: SEC filings, public conference calls and webcasts, press releases, the investor relations page of our website ([www.henryschein.com](http://www.henryschein.com)) and the social media channels identified on the About Media Center page of our website.

## **Recent Developments**

### *Chief Executive Officer*

On January 12, 2026, we announced the appointment of Frederick M. Lowery as our new CEO, effective March 2, 2026, at which time Mr. Lowery will join our Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will remain as our CEO through March 1, 2026, at which time Mr. Bergman will retire as CEO, but will remain as Chairman of the Board.

### *Cyber Incident*

As previously reported, in October 2023 Henry Schein experienced a cyber incident that primarily affected the operations of our North American and European dental and medical distribution businesses.

During the years ended December 28, 2024 and December 30, 2023, we had a sales decrease in our dental and medical distribution businesses, which we believe was primarily a result of lower sales to episodic customers following the cyber incident.

With respect to the October 2023 cyber incident, we had a \$60 million insurance policy, following a \$5 million retention. During the years ended December 27, 2025, December 28, 2024 and December 30, 2023, we incurred \$0 million, \$9 million and \$11 million, respectively, of direct expenses related to the cyber incident, mostly consisting of professional fees. During the years ended December 27, 2025 and December 28, 2024, we received insurance proceeds of \$20 million and \$40 million, respectively, representing insurance recovery of losses related to the cyber incident. The expenses and insurance recoveries related to the cyber incident are included in the selling, general and administrative line in our consolidated statements of income.

### *Tariffs and Related Economic Conditions*

The U.S. has adopted new and increased tariffs on imports from countries, which tariffs remain subject to frequently evolving exemptions and modifications, as well as to court challenges, including a recent invalidation in the Supreme Court of many of the tariffs. Some countries have imposed retaliatory tariffs and other restrictions on imports from the U.S. These developments, and anticipated future developments, have created a volatile environment for global trade, and new trade policies with individual countries. It is unclear whether, or the extent to which, the current tariffs on trade with numerous countries will remain in place, or change, the exceptions that may apply, and their timing.

The tariffs did not have a material impact on our results of operations during fiscal year 2025, although sales of U.S. dental equipment were temporarily impacted by market uncertainty related to tariffs in the second half of the

quarter ended June 28, 2025. It is unclear whether, or the extent to which, the current tariffs on trade with numerous countries will remain in place, or change, the exceptions that may apply, and their timing.

### *One Big Beautiful Bill Act*

In the United States, the OBBBA, signed into law on July 4, 2025, includes a number of provisions that are expected to result in reductions in the number of Medicaid enrollees, which will reduce utilization of services and covered products generally. There are also several provisions that will reduce federal funding to state Medicaid programs. The OBBBA, in combination with tariffs, will likely have an adverse impact on utilization, Medicaid payment and cost of production (if foreign components are used).

The OBBBA also includes changes to corporate tax rates, limitations on certain deductions and modifications to international tax provisions.

## **Executive-Level Overview**

Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. We believe we are the world's largest provider of health care products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. We serve more than one million customers worldwide including dental practitioners, laboratories, physician practices and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. We believe that we have a strong brand identity due to our more than 94 years of experience distributing health care products.

We are headquartered in Melville, New York, employ more than 25,000 people (of which approximately 13,000 are based outside of the United States) and have operations or affiliates in 34 countries and territories. Our broad global footprint has evolved over time through our organic growth as well as through contribution from strategic acquisitions.

We have established strategically located distribution centers around the world to enable us to better serve our customers and increase our operating efficiency. This infrastructure, together with broad product and service offerings at competitive prices, and a strong commitment to customer service, enables us to be a single source of supply for our customers' needs.

As a distributor, we market and sell branded products as well as our own corporate brand portfolio of cost-effective, high-quality consumable merchandise products. We also manufacture, source and sell a range of company-owned manufactured products, primarily implants, biomaterial products, endodontics, handpiece and small equipment, hand instrument and repair, restoratives, orthodontics, wound care, orthopedics and dental lab products. We have achieved scale in these global businesses primarily through acquisitions, as manufacturers of these products typically do not utilize a distribution channel to serve customers.

Our reportable segments consist of: (i) Global Distribution and Value-Added Services; (ii) Global Specialty Products; and (iii) Global Technology.

Global Distribution and Value-Added Services includes distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting and other services. This segment also markets and sells under our own corporate brand, a portfolio of cost-effective, high-quality consumable merchandise. Global Specialty Products includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other health care-related products and services. Global Technology includes development and distribution of practice management software, e-services and other products, which are distributed to health care providers.

A key element to grow closer to our customers is our One Schein initiative, which is a unified go-to-market approach that enables practitioners to work synergistically with our supply chain, equipment sales and service and other value-added services, allowing our customers to leverage the combined value that we offer through a single program. Specifically, One Schein provides customers with streamlined access to our comprehensive offering of national brand products, corporate brand products and proprietary specialty products and solutions (including implant, orthodontic and endodontic products). In addition, customers have access to a wide range of services, including software and other value-added services.

### *Industry Overview*

In recent years, the health care industry has increasingly focused on cost containment. This trend has benefited distributors capable of providing a broad array of products and services at low prices. It also has accelerated the growth of DSOs, GPOs, HMOs, group practices, other managed care accounts and collective buying groups, which, in addition to their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing specialized management information support. We believe that the trend towards cost containment has the potential to favorably affect demand for technology solutions, including software, which can enhance the efficiency and facilitation of practice management.

Our operating results in recent years have been significantly affected by strategies and transactions that we undertook to expand our business, domestically and internationally, in part to address significant changes in the health care industry, including consolidation of health care distribution companies, health care reform, trends toward managed care, cuts in Medicare and collective purchasing arrangements.

### *Industry Consolidation*

The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented and diverse. The industry ranges from sole practitioners working out of relatively small offices to group practices or service organizations ranging in size from a few practitioners to a large number of practitioners who have combined or otherwise associated their practices.

Due in part to the inability of office-based health care practitioners to store and manage large quantities of supplies in their offices, the distribution of health care supplies and small equipment to office-based health care practitioners has been characterized by frequent, small quantity orders, and a need for rapid, reliable and substantially complete order fulfillment. The purchasing decisions within an office-based health care practice are typically made by the practitioner or an administrative assistant. Supplies and small equipment are generally purchased from more than one distributor, with one generally serving as the primary supplier.

The trend of consolidation extends to our customer base. Health care practitioners are increasingly seeking to partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician hospital organizations. In many cases, purchasing decisions for consolidated groups are made at a centralized or professional staff level; however, orders are delivered to the practitioners' offices.

Our approach to acquisitions and joint ventures has been to expand our role as a provider of products and services to the health care industry. This trend has resulted in our expansion into service areas that complement our existing operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired businesses.

As industry consolidation continues, we believe that we are positioned to capitalize on this trend, as we believe we have the ability to support increased sales through our existing infrastructure, although there can be no assurances that we will be able to successfully accomplish this. We are focused on building relationships with decision makers who do not reside in the office-based practitioner setting.

As the health care industry continues to change, we continually evaluate possible candidates for joint venture or acquisition and intend to continue to seek opportunities to expand our role as a provider of products and services to the health care industry. There can be no assurance that we will be able to successfully pursue any such opportunity or consummate any such transaction, if pursued. If additional transactions are entered into or consummated, we would incur merger and/or acquisition-related costs, and there can be no assurance that the integration efforts associated with any such transaction would be successful.

### *Aging Population and Other Market Influences*

The health care products distribution industry continues to experience growth due to the aging population, increased health care awareness, the proliferation of medical technology and testing, new pharmacological treatments, and expanded third-party insurance coverage, partially offset by the effects of unemployment on insurance coverage. In addition, the physician market continues to benefit from the shift of procedures and diagnostic testing from acute care settings to alternate-care sites, particularly physicians' offices.

According to the U.S. Census Bureau's International Database, between 2025 and 2035, the 45 and older population is expected to grow by approximately 10%. Between 2025 and 2045, this age group is expected to grow by approximately 17%. This compares with expected total U.S. population growth rates of approximately 4% between 2025 and 2035 and approximately 6% between 2025 and 2045.

According to the U.S. Census Bureau's International Database, in 2025 there are approximately seven million Americans aged 85 years or older, the segment of the population most in need of long-term care and elder-care services. By the year 2050, that number is projected to increase to approximately 17 million. The population aged 65 to 84 years is projected to increase by approximately 15% during the same period.

As a result of these market dynamics, annual expenditures for health care services continue to increase in the United States. We believe that demand for our products and services will grow while continuing to be impacted by current and future operating, economic and industry conditions. The Centers for Medicare and Medicaid Services, or CMS, published "National Health Expenditure Data" indicating that total national health care spending reached approximately \$5.3 trillion in 2024, or 18.0% of the nation's gross domestic product, the benchmark measure for annual production of goods and services in the United States. Health care spending is projected to reach approximately \$8.6 trillion by 2033, or 20.3% of the nation's projected gross domestic product.

We believe similar demographic changes are also occurring in other markets we serve outside the U.S.

### *Government*

Our businesses are generally subject to numerous laws and regulations that could impact our financial performance, and failure to comply with such laws or regulations could have a material adverse effect on our business. See "Item 1. Business – Governmental Regulations" for a discussion of laws, regulations and governmental activity that may affect our results of operations and financial condition.

## Results of Operations

Refer to Item 7: Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2024 Annual Report on Form 10-K for management’s discussion and analysis of financial condition and results of operations for the fiscal year 2024 compared to fiscal year 2023.

The following tables summarize the significant components of our operating results and cash flows for each of the three years ended December 27, 2025, December 28, 2024, and December 30, 2023 (in millions):

	<b>Years Ended</b>		
	<b>December 27, 2025</b>	<b>December 28, 2024</b>	<b>December 30, 2023</b>
<b>Operating results:</b>			
Net sales	\$ 13,184	\$ 12,673	\$ 12,339
Cost of sales	9,079	8,657	8,479
Gross profit	<u>4,105</u>	<u>4,016</u>	<u>3,860</u>
Operating expenses:			
Selling, general and administrative	3,084	3,034	2,956
Depreciation and amortization	263	251	209
Restructuring and related costs	105	110	80
Operating income	<u>\$ 653</u>	<u>\$ 621</u>	<u>\$ 615</u>
Other expense, net	\$ (120)	\$ (108)	\$ (73)
Income taxes	(126)	(128)	(120)
Net income	419	398	436
Net income attributable to Henry Schein, Inc.	398	390	416
<b>Cash flows:</b>			
Net cash provided by operating activities	\$ 712	\$ 848	\$ 500
Net cash used in investing activities	(400)	(430)	(1,135)
Net cash provided by (used in) financing activities	(188)	(510)	701

## Plans of Restructuring and Related Costs

On August 6, 2024, we committed to a restructuring plan (the “2024 Plan”) to integrate our acquisitions, right-size operations and further increase efficiencies. We currently expect this plan to be completed at the end of 2027. During the years ended December 27, 2025 and December 28, 2024, we recorded restructuring and related charges associated with the 2024 Plan of \$105 million and \$73 million, respectively. The restructuring and related costs for these periods primarily related to severance and employee-related costs, accelerated amortization of right-of-use assets and fixed assets, and other exit costs. We expect to record restructuring and related charges associated with the 2024 Plan through the end of 2027; however, an estimate of the amount of these charges for 2026 through 2027 has not yet been determined.

During the year ended December 27, 2025, in connection with the 2024 Plan, we recorded a loss of \$1 million and \$12 million related to the disposal of businesses in the Global Distribution and Value-Added Services and Global Specialty Product segments, respectively, and a net gain related to disposal of a business in the Global Technology segment. These amounts are included in the \$105 million of restructuring and related charges discussed above.

During the year ended December 28, 2024, in connection with the 2024 Plan, we recorded an impairment of goodwill and intangible assets of \$13 million related to the disposal of a portion of a business in the Global Specialty Products segment. This impairment is included in the \$73 million of restructuring and related charges discussed above.

On August 1, 2022, we committed to a restructuring plan (the “2022 Plan”) focused on funding the priorities of the BOLD+1 strategic plan, streamlining operations and other initiatives to increase efficiency. The 2022 Plan was completed as of July 31, 2024. During the years ended December 28, 2024 and December 30, 2023, in connection with our 2022 Plan, we recorded restructuring and related costs of \$37 million and \$80 million, respectively, which primarily related to severance and employee-related costs, accelerated amortization of right-of-use assets and fixed assets, and other exit costs.

During the year ended December 30, 2023, in connection with the 2022 Plan, we recorded an impairment of an intangible asset of \$12 million related to disposal of a U.S. business in the Global Specialty Products segment. This impairment is included in the \$80 million of restructuring and related costs discussed above. The disposal was completed during the first quarter of 2024.

## 2025 Compared to 2024

Note: Percentages for Net Sales; Gross Profit; Operating Expenses; Other Expense, Net; and Income Taxes are based on actual values and may not recalculate due to rounding.

Our reportable segments are determined based on how our Chairman and Chief Executive Officer manages the business, assesses performance and allocates resources. We have three reportable segments: (i) Global Distribution and Value-Added Services; (ii) Global Specialty Products; and (iii) Global Technology.

### Net Sales

Net sales by reportable segment and by major product or service type were as follows:

	2025	% of Total	2024	% of Total	Increase / (Decrease)	
					\$	%
Global Distribution and Value-Added Services						
Global Dental Merchandise <sup>(1)</sup>	\$ 4,831	36.6%	\$ 4,723	37.3%	\$ 108	2.2%
Global Dental Equipment <sup>(2)</sup>	1,799	13.6	1,723	13.6	76	4.4
Global Value-Added Services <sup>(3)</sup>	238	1.8	233	1.8	5	2.2
Global Dental	6,868	52.0	6,679	52.7	189	2.8
Global Medical <sup>(4)</sup>	4,270	32.5	4,081	32.2	189	4.6
Total Global Distribution and Value-Added Services	11,138	84.5	10,760	84.9	378	3.5
Global Specialty Products <sup>(5)</sup>	1,544	11.7	1,446	11.4	98	6.7
Global Technology <sup>(6)</sup>	675	5.1	630	5.0	45	7.1
Eliminations	(173)	(1.3)	(163)	(1.3)	(10)	n/a
Total	\$ 13,184	100.0%	\$ 12,673	100.0%	\$ 511	4.0

- (1) Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products and our own corporate brand of consumable merchandise.
- (2) Includes dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, equipment repair services and high-tech and digital restoration equipment.
- (3) Consists of financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services.
- (4) Includes branded and generic pharmaceuticals, home solutions products, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, PPE products, and vitamins.
- (5) Includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other health care-related products and services.
- (6) Consists of the development and distribution of practice management software, e-services and other technology-enabled products for health care providers.

The components of our sales growth/(decline) were as follows:

	Constant Currency Growth/(Decline)			Foreign Exchange Impact	Total Sales Growth
	Local Internal Growth/(Decline)	Acquisition Growth	Total Constant Currency Growth		
Global Distribution and Value-Added Services					
Global Dental Merchandise	1.4 %	0.2 %	1.6 %	0.6 %	2.2 %
Global Dental Equipment	2.7	0.5	3.2	1.2	4.4
Global Value-Added Services	(2.0)	4.0	2.0	0.2	2.2
Global Dental	1.6	0.4	2.0	0.8	2.8
Global Medical	3.1	1.5	4.6	-	4.6
Total Global Distribution and Value-Added Services	2.2	0.8	3.0	0.5	3.5
Global Specialty Products	3.3	2.4	5.7	1.0	6.7
Global Technology	6.7	-	6.7	0.4	7.1
Total	2.6	0.9	3.5	0.5	4.0

### *Global Sales*

Global net sales for the year ended December 27, 2025 increased 4.0%, attributable to internal growth of 2.6%, acquisition growth of 0.9%, and an increase in foreign exchange of 0.5%. The components of our sales increase are presented in the table above.

### *Global Distribution and Value-Added Services Sales*

Global Distribution and Value-Added Services net sales for the year ended December 27, 2025 increased 3.5%. The components of our sales increase are presented in the table above.

The 1.6% increase in internally generated local currency dental sales was primarily due to sales growth in U.S. dental merchandise and international dental merchandise, as well as growth in traditional dental equipment in the U.S. and growth in traditional and digital dental equipment in international markets.

The 3.1% increase in internally generated local currency medical sales was attributable to growth of our Home Solutions business, dialysis products and pharmaceuticals.

The 2.0% decrease in internally generated local currency value-added services sales was attributable primarily to lower sales in our practice transitions business, partially offset by sales growth from our international businesses.

### *Global Specialty Products*

Global Specialty Products net sales for the year ended December 27, 2025 increased 6.7%. The components of our sales increase are presented in the table above.

The 3.3% increase in internally generated local currency sales was attributable to growth in our implant and biomaterial businesses, and orthopedics, partially offset by a decline in orthodontic sales.

### *Global Technology*

Global Technology net sales for the year ended December 27, 2025 increased 7.1%. The components of sales growth are presented in the table above.

The internally generated local currency increase of 6.7% in Global Technology sales was primarily attributable to the adoption of our core practice management solutions, particularly our cloud-based platforms, as well as an increase in revenue cycle management solutions.

## Gross Profit

Gross profit and gross margin percentages by segment and in total were as follows:

	2025		2024		Increase	
	\$	Gross Margin %	\$	Gross Margin %	\$	%
Global Distribution and Value-Added Services	2,786	25.0%	2,776	25.8%	10	0.4%
Global Specialty Products	847	54.8	802	55.4	45	5.5
Global Technology	457	67.7	424	67.4	33	7.6
Corporate	15	n/a	14	n/a	1	n/a
Total	<u>4,105</u>	31.1	<u>4,016</u>	31.7	<u>89</u>	2.2

As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Gross margin percentages vary between our segments. We realize substantially higher gross margin from products we develop and manufacture within our Global Specialty Products segment compared to products distributed within our Global Distribution and Value-Added Services segment. Within our Global Technology segment, higher gross margins result from us being both the developer and seller of software products and services.

Within our Global Distribution and Value-Added Services segment, gross profit margins may fluctuate between the periods as a result of the changes in product mix and customer mix. With respect to customer mix, sales to our large-group customers are typically completed at lower gross margins as a result of higher sales volumes, while sales to office-based practitioners generally carry higher gross margins due to lower volumes.

The increase in Global Distribution and Value-Added Services gross profit for the year ended December 27, 2025 compared to the prior-year-period is due primarily to increased internally generated sales volume as described above. The decrease in gross margin rates was attributable primarily to the impact of targeted promotional programs and product mix.

The increase in Global Specialty Products gross profit primarily reflects increased internally generated sales volume and gross profit from acquisitions. The decrease in gross margin rates was due to product mix and pricing.

The increase in Global Technology gross profit is the result primarily of higher internally generated sales. The increase in gross margin rates was due to product mix.

## Operating Expenses

Operating expenses (consisting of selling, general and administrative expenses; depreciation and amortization; and restructuring and related costs) by segment were as follows:

	2025	% of Respective Sales	2024	% of Respective Sales	Increase / (Decrease)	
					\$	%
Global Distribution and Value-Added Services	\$ 2,106	18.9%	\$ 2,080	19.3%	\$ 26	1.3%
Global Specialty Products	605	39.2	624	43.2	(19)	(3.1)
Global Technology	277	41.0	272	43.2	5	1.5
Corporate	145	n/a	91	n/a	54	60.8
	3,133	23.8	3,067	24.2	66	2.1
Adjustments <sup>(1)</sup>	319	n/a	328	n/a	(9)	n/a
Total operating expenses	<u>\$ 3,452</u>	26.2	<u>\$ 3,395</u>	26.8	<u>\$ 57</u>	1.7

- (1) Adjustments represent items excluded from segment operating income to enable comparison of financial results between periods. These items may vary independently of business performance. Please see Note 4 – Segment and Geographic Data. These adjustments (current year vs. prior year) consist of (i) acquisition intangible amortization (\$179 million vs. \$184 million), (ii) restructuring and related costs (\$105 million vs. \$110 million), (iii) change in contingent consideration (\$2 million vs. \$45 million), (iv) litigation settlements (\$5 million vs. \$6 million), (v) cyber incident-insurance proceeds, net of third-party advisory expenses (\$20 million net proceeds vs. \$31 million net proceeds), (vi) impairment of intangible assets (\$16 million vs. \$0 million), (vii) impairment of capitalized assets (\$0 million vs. \$12 million), and (viii) costs associated with shareholder advisory matters and select value creation consulting costs (\$36 million vs. \$2 million).

The net increase in operating expenses was attributable to the following:

	Operating Costs (excluding acquisitions)				Total
		Acquisitions	Adjustments		
Global Distribution and Value-Added Services	\$ 3	\$ 23	\$ -	\$ 26	
Global Specialty Products	(23)	4	-	(19)	
Global Technology	5	-	-	5	
Corporate	54	-	-	54	
	39	27	-	66	
Adjustments	-	-	(9)	(9)	
Total operating expenses	<u>\$ 39</u>	<u>\$ 27</u>	<u>\$ (9)</u>	<u>\$ 57</u>	

The components of the net increase in total operating expenses are presented in the table above. The increase in operating costs (excluding acquisitions) during the year ended December 27, 2025 was attributable to an increase in Corporate investments in technology supporting the launch of our Global E-Commerce Platform ([www.henryschein.com](http://www.henryschein.com)), depreciation expense, the impact of certain compensation related costs and timing of certain non-income tax credits during the year ended December 28, 2024, partially offset by cost savings from our restructuring activities, certain changes in estimates and other operating cost efficiencies. In addition, during the year ended December 27, 2025, our operating costs were impacted by recognition of a benefit related to the remeasurement to fair value of previously held equity investments of \$29 million within our Global Specialty Products segment and \$9 million within our Global Distribution and Value-Added Services segment. During the year ended December 28, 2024, our operating costs were impacted by recognition of a remeasurement gain related to the remeasurement to fair value of a previously held equity investments of \$18 million within our Global Distribution and Value-Added Services segment.

### ***Other Expense, Net***

Other expense, net was as follows:

	<b>2025</b>	<b>2024</b>	<b>Variance</b>	
			<b>\$</b>	<b>%</b>
Interest income	\$ 33	\$ 24	\$ 9	37.1%
Interest expense	(150)	(131)	(19)	(14.2)
Other, net	(3)	(1)	(2)	n/a
Other expense, net	<u>\$ (120)</u>	<u>\$ (108)</u>	<u>\$ (12)</u>	10.9

Interest income increased primarily due to increased interest rates. Interest expense increased primarily due to increased borrowings.

### ***Income Taxes***

Our effective tax rate was 23.7% for the year ended December 27, 2025, compared to 24.9% for the prior year period. The difference between our effective and federal statutory tax rates primarily relates to state and foreign income taxes and interest expense, as well as the tax treatment associated with the acquisition of a controlling interest of a previously held non-controlling equity investment.

On July 4, 2025, President Trump signed the reconciliation tax bill, commonly known as the “One Big Beautiful Bill Act” (OBBBA), into law. Corporate provisions in the OBBBA include immediate expensing of domestic research and experimental expenditures, limitations on certain deductions, and modifications to international tax provisions. The changes resulting from the OBBBA did not have a significant impact to the total tax provision.

The Organization of Economic Co-Operation and Development (OECD) issued technical and administrative guidance on Pillar Two rules in December 2021, which provides for a global minimum tax rate on the earnings of large multinational businesses on a country-by-country basis. Effective January 1, 2024, the minimum global tax rate is 15% for various jurisdictions pursuant to the Pillar Two rules. Future tax reform resulting from these developments may result in changes to long-standing tax principles, which may adversely impact our effective tax rate going forward or result in higher cash tax liabilities. As of December 27, 2025, the impact of the Pillar Two rules to our financial statements was immaterial.

## Liquidity and Capital Resources

Our principal capital requirements have included funding of acquisitions, purchases of additional noncontrolling interests, repayments of debt principal, the funding of working capital needs, purchases of fixed assets and repurchases of common stock. Working capital requirements generally result from increased sales, special inventory forward buy-in opportunities and payment terms for receivables and payables. Historically, sales have tended to be stronger during the second half of the year and special inventory forward buy-in opportunities have been most prevalent just before the end of the year, and have caused our working capital requirements to be higher from the end of the third quarter to the end of the first quarter of the following year.

We finance our business primarily through cash generated from our operations, revolving credit facilities and debt placements. Please see Note 14 – Debt for further information. Our ability to generate sufficient cash flows from operations is dependent on the continued demand of our customers for our products and services, and access to products and services from our suppliers.

Our business requires a substantial investment in working capital, which is susceptible to fluctuations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity, special inventory forward buy-in opportunities and our desired level of inventory.

We finance our business to provide adequate funding for at least 12 months. Funding requirements are based on forecasted profitability and working capital needs, which, on occasion, may change. Consequently, we may change our funding structure to reflect any new requirements.

Our acquisition strategy is focused on investments in companies, including high growth high margin businesses aligned with our BOLD+1 strategy, that add new customers and sales teams, increase our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we have already invested in businesses), and finally, those that enable us to access new products and technologies.

We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets, and our available funds under existing credit facilities provide us with sufficient liquidity to meet our currently foreseeable short-term and long-term capital needs.

Net cash provided by operating activities was \$712 million for the year ended December 27, 2025, compared to net cash provided by operating activities of \$848 million for the prior year. The net change of \$136 million was primarily attributable to changes in working capital accounts (primarily accounts receivable, inventory, and accounts payable and accrued expenses), partially offset by an increase in operating income. Our operating cash flows during the year ended December 28, 2024 were positively affected by the residual impacts of the 2023 cyber incident and included a higher-than-normal level of cash collections. Our cash collections normalized during the second half of the year ended December 28, 2024.

Net cash used in investing activities was \$400 million for the year ended December 27, 2025, compared to net cash used in investing activities of \$430 million for the prior year. The net change of \$30 million was primarily attributable to lower acquisition activity.

Net cash used in financing activities was \$188 million for the year ended December 27, 2025, compared to net cash used in financing activities of \$510 million for the prior year. The net change of \$322 million was primarily due to increased net borrowings from debt, proceeds received from the issuance of common stock, and a reduction in acquisitions of noncontrolling interests in subsidiaries, partially offset by increased repurchases of common stock.

The following table summarizes selected measures of liquidity and capital resources:

	<b>December 27, 2025</b>	<b>December 28, 2024</b>
Cash and cash equivalents	\$ 156	\$ 122
Working capital <sup>(1)</sup>	1,236	1,180
Debt:		
Bank credit lines	\$ 764	\$ 650
Current maturities of long-term debt	33	56
Long-term debt	2,310	1,830
Total debt	<u>\$ 3,107</u>	<u>\$ 2,536</u>
Leases:		
Current operating lease liabilities	\$ 78	\$ 75
Non-current operating lease liabilities	251	259

(1) Includes \$491 million and \$241 million of certain accounts receivable which serve as security for U.S. trade accounts receivable securitization at December 27, 2025 and December 28, 2024, respectively.

Our cash and cash equivalents consist of bank balances and investments in money market funds representing overnight investments with a high degree of liquidity.

#### *Accounts receivable days sales outstanding and inventory turns*

Our accounts receivable days sales outstanding from operations decreased to 44.8 days as of December 27, 2025 from 47.3 days as of December 28, 2024, which was primarily attributable to the impact that the cyber incident had on the cash collections during the first half of 2024. During the years ended December 27, 2025 and December 28, 2024, we wrote off approximately \$18 million and \$12 million, respectively, of fully reserved accounts receivable against our trade receivable reserve. Our inventory turns from operations decreased to 4.8 as of December 27, 2025 from 5.0 as of December 28, 2024. Our working capital accounts may be impacted by current and future economic conditions.

#### *Contractual obligations*

The following table summarizes our contractual obligations related to fixed and variable rate long-term debt and finance lease obligations, including interest (assuming a weighted average interest rate of 4.62%), as well as inventory purchase commitments and operating lease obligations as of December 27, 2025:

	<b>Payments due by period</b>				
	<b>&lt; 1 year</b>	<b>2 - 3 years</b>	<b>4 - 5 years</b>	<b>&gt; 5 years</b>	<b>Total</b>
Contractual obligations:					
Long-term debt, including interest	\$ 133	\$ 942	\$ 1,066	\$ 656	\$ 2,797
Inventory purchase commitments	8	1	-	-	9
Operating lease obligations	91	133	84	63	371
Finance lease obligations, including interest	<u>3</u>	<u>3</u>	<u>1</u>	<u>-</u>	<u>7</u>
Total	<u>\$ 235</u>	<u>\$ 1,079</u>	<u>\$ 1,151</u>	<u>\$ 719</u>	<u>\$ 3,184</u>

For information relating to our debt please see Note 14 – Debt.

### *Leases*

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles and certain equipment. Our leases have remaining terms of less than one year to approximately 23 years, some of which may include options to extend the leases for up to 10 years. As of December 27, 2025, our right-of-use assets related to operating leases were \$301 million and our current and non-current operating lease liabilities were \$78 million and \$251 million, respectively. Please see Note 8 – Leases for further information.

### *Stock Repurchases*

On January 27, 2025, our Board authorized the repurchase of up to an additional \$500 million in shares of our common stock.

On May 19, 2025, we executed an accelerated share repurchase program to repurchase a total of \$250 million of our outstanding common stock based on volume-weighted average prices. In May 2025, we received 3,122,832 shares at an estimated fair value of \$224 million. In July 2025, we received an additional 368,651 shares at an estimated fair value of \$26 million, representing the final amount of shares to be received under this accelerated share repurchase program.

On September 8, 2025, our Board authorized the repurchase of up to an additional \$750 million in shares of our common stock.

From March 3, 2003 through December 27, 2025, we repurchased \$6.0 billion, or 107,876,628 shares, under our common stock repurchase programs, with \$780 million available as of December 27, 2025 for future common stock share repurchases.

### *Redeemable Noncontrolling Interests*

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. As of December 27, 2025 and December 28, 2024, our balance for redeemable noncontrolling interests was \$895 million and \$806 million, respectively. Please see Note 20 – Redeemable Noncontrolling Interests for further information.

## Critical Accounting Estimates

Our accounting policies are described in Note 1 – Basis of Presentation and Significant Accounting Policies of the consolidated financial statements. The preparation of consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. We base our estimates on historical data, when available, experience, industry and market trends, and on various other assumptions that are believed to be reasonable under the circumstances, the combined results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. However, by their nature, estimates are subject to various assumptions and uncertainties. Therefore, reported results may differ from estimates and any such differences may be material to our consolidated financial statements.

We believe that the following critical accounting estimates, which have been discussed with the Audit Committee of our Board, affect the significant estimates and judgments used in the preparation of our consolidated financial statements:

### *Inventories and Reserves*

Inventories consist primarily of finished goods, raw materials and work-in-process and are stated at the lower of cost or net realizable value. Cost is determined by the weighted average method for merchandise and actual cost for large equipment, high-technology equipment and drop-shipments. Inventory costs for manufactured products include direct materials, labor, and an allocation of related fixed and variable overhead. The determination of inventory carrying values requires management to make significant estimates and judgments. In assessing the need for inventory reserves and evaluating net realizable value, we consider multiple factors, including inventory condition, on-hand quantities, historical and forecasted sales, product life cycles, and prevailing market and economic conditions.

### *Business Combinations*

The estimated fair value of acquired identifiable intangible assets (i.e., customer relationships and lists, trademarks and trade names, product development and non-compete agreements) is based on critical judgments and assumptions derived from analysis of market conditions, including discount rates, projected revenue growth rates (which are based on historical trends and assessment of financial projections), estimated customer attrition and projected cash flows. These assumptions are forward-looking and could be affected by future economic and market conditions. Please see Note 5 – Business Acquisitions for further discussion of our acquisitions.

### *Goodwill*

Goodwill is subject to impairment assessment at least once annually as of the first day of our fourth quarter, or if an event occurs or circumstances change that would more likely than not reduce a reporting unit's fair value below carrying value. We conduct our goodwill impairment testing at the reporting unit level. We identify our reporting units by assessing whether two or more components are economically similar and therefore should be aggregated. Our reporting units are identified as our operating segments. Goodwill is allocated to such reporting units for the purposes of our impairment assessment. For the year ended December 27, 2025, our reporting structure was:

- (i) Global Distribution and Value-Added Services reportable segment, which included the following operating segments (a) US Distribution Group; (b) Europe, Middle East, and Africa Distribution Group; (c) Americas Non-US Distribution Group; and (d) Asia-Pacific and Australia Distribution Group;
- (ii) Global Specialty Products reportable segment, which included the following operating segments (a) Global Oral Reconstruction Group; and (b) Healthcare Specialty Group; and
- (iii) Global Technology, which is both a reportable segment and an operating segment.

Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities that are considered shared services to the reporting units, and ultimately the determination of the fair value of each reporting unit. The fair value of each reporting unit is calculated by applying the discounted cash flow methodology and confirming with a market approach. There are inherent uncertainties, however, related to fair value models, the inputs and our judgments in applying them to this analysis. The most significant inputs include estimation of detailed future cash flows based on budget expectations, and determination of comparable companies to develop a weighted average cost of capital for each reporting unit.

In performing the annual goodwill impairment assessment, we prepare forward-looking financial projections for each reporting unit based on input from our leadership and approved operating plans. These projections incorporate assumptions related to planned strategic initiatives, the continued integration of recent acquisitions, and prevailing macroeconomic and market conditions. Changes in these assumptions could materially affect the estimated fair values of the reporting units.

Our third-party valuation specialists provide inputs into our determination of the discount rate. The rate is dependent on a number of underlying assumptions, including the risk-free rate, tax rate, equity risk premium, debt to equity ratio and pre-tax cost of debt.

Long-term growth rates are applied to our estimation of future cash flows. The long-term growth rates are tied to growth rates we expect to achieve beyond the years for which we have forecasted operating results. We also consider external benchmarks, and other data points which we believe are applicable to our industry and the composition of our global operations.

We performed our annual quantitative goodwill assessment, and the estimated fair value of each of our reporting units sufficiently exceeded its respective carrying value. As a result, no goodwill impairments were recorded during the years ended December 27, 2025, December 28, 2024, and December 30, 2023.

For the year ended December 28, 2024, in connection with our restructuring initiatives, we recorded an \$11 million impairment of goodwill in the Global Specialty Products segment, relating to the disposal of a portion of a business; such impairment was calculated based on the relative fair value of goodwill.

#### *Definite-Lived Intangible Assets*

Annually or if we identify an impairment indicator, definite-lived intangible assets such as customer relationships and lists, trademarks, trade names, product development and non-compete agreements are reviewed for impairment indicators. If any impairment indicators exist, quantitative testing is performed on the asset.

The quantitative impairment model is a two-step test under which we first calculate the recoverability of the carrying value by comparing the undiscounted projected cash flows associated with the asset or asset group, including its estimated residual value, to the carrying amount. If the cash flows associated with the asset or asset group are less than the carrying value, we perform a fair value assessment of the asset, or asset group. If the carrying amount is found to be greater than the fair value, we record an impairment loss for the excess of book value over the fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate. Although we believe our judgments, estimates and/or assumptions used in estimating cash flows and determining fair value are reasonable, making material changes to such judgments, estimates and/or assumptions could materially affect such impairment analyses and our financial results.

During the year ended December 27, 2025, we recorded \$16 million of impairment charges related to businesses in our Global Distribution and Value-Added Services segment. The impairment charges included \$14 million primarily related to customer lists and relationships attributable to lower than anticipated operating margins in these businesses. The remaining impairment charges of \$2 million related to trade names and non-compete agreements.

During the year ended December 28, 2024, we recorded \$4 million of impairment charges related to businesses in our Global Distribution and Value-Added Services segment. It included \$2 million of a trade name impairment, calculated using the relative fair value, related to a disposal of a business, and \$1 million related to trade name

impairment due to business integration in connection with our restructuring initiatives. The remaining \$1 million impairment charges related to trade names and non-compete agreements.

During the year ended December 30, 2023, we recorded \$19 million of impairment charges related to businesses in our Global Distribution and Value-Added Services segment, consisting of \$7 million primarily related to customer lists and relationships attributable to lower than anticipated operating margins in certain businesses, and a \$12 million charge related to the planned exit of a business in connection with our restructuring initiatives.

The impairment charges for the years ended December 27, 2025, December 28, 2024, and December 30, 2023 were measured as the excess of the carrying values over the estimated fair values of the related intangible assets, determined using discounted estimates of future cash flows and the relief-from-royalty method.

Please see Note 16 – Plans of Restructuring and Related Costs for additional details.

#### *Redeemable Noncontrolling Interests*

Some minority stockholders in certain of our consolidated subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. The redemption amounts have been estimated based on recent transactions and/or implied multiples of earnings and, if such earnings and cash flows are not achieved, the value of the redeemable noncontrolling interests might be impacted. See Note 1 – Basis of Presentation and Significant Accounting Policies and Note 20 – Redeemable Noncontrolling Interests for additional information.

#### *Income Tax*

Determining whether a deferred tax asset will be realized requires significant estimates and judgment to assess whether a valuation allowance is necessary. We consider all available evidence, both positive and negative, including estimated future taxable earnings, ongoing planning strategies, future reversals of existing temporary differences and historical operating results. Additionally, changes to tax laws and statutory tax rates can have an impact on our determination. We evaluate the realizability of our deferred tax assets quarterly.

Accounting Standards Codification Topic 740 prescribes the accounting for uncertainty in income taxes recognized in the financial statements in accordance with provisions contained within its guidance. This topic prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by the taxing authorities. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likelihood of being realized upon ultimate audit settlement. In the normal course of business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessments by these taxing authorities for uncertain tax positions taken in respect of certain tax matters. Please see Note 15 – Income Taxes for further discussion.

#### **Accounting Standards Update**

For a discussion of accounting standards updates that have been adopted or will be adopted in the future, please see Note 1 – Basis of Presentation and Significant Accounting Policies included under Item 8.

## **ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk**

We are exposed to market risks, interest rate risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and each other, and changes to the credit markets. We attempt to minimize these risks primarily by using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our investments, maintaining a strong balance sheet and having multiple sources of capital.

### *Foreign Currency*

The value of certain foreign currencies compared to the U.S. dollar may affect our financial results. Fluctuations in exchange rates may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we consider foreign currency translation to be an accounting exposure, not an economic exposure. A hypothetical 5% change in the average value of the U.S. dollar in 2025 compared to foreign currencies would have changed our 2025 reported Net income attributable to Henry Schein, Inc. by approximately \$6 million.

As of December 27, 2025, our forward foreign currency exchange agreements, which expire through November 3, 2028, had a fair value of \$(20) million as determined by quoted market prices. Included in the forward foreign currency exchange agreements, Henry Schein, Inc. had net investment designated EUR/USD forward contracts with notional values of approximately €300 million and reported fair values of \$(20) million. A 5% increase in the value of the Euro to the USD from December 27, 2025 would decrease the fair value of these forward contracts by \$18 million.

### *Total Return Swaps*

On March 20, 2020, we entered into a total return swap for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan and our deferred compensation plan obligation.

At inception, the notional value of the investments in these plans was \$43 million. At December 27, 2025, the notional value of the investments in these plans was \$117 million. At December 27, 2025, the financing blended rate for this swap was based on the Secured Overnight Financing Rate (“SOFR”) of 3.79% plus 0.75%, for a combined rate of 4.54%. For the years ended December 27, 2025, December 28, 2024, and December 30, 2023 we have recorded a gain within selling, general and administrative expense, of approximately \$11 million, \$8 million and \$10 million, respectively, net of transaction costs, related to this undesignated swap. This swap is expected to be renewed on an annual basis and is expected to result in a neutral impact to our results of operations.

### *Credit Risk Monitoring*

We limit our credit risk with respect to our cash equivalents, short-term investments and derivative instruments by monitoring the credit worthiness of the financial institutions who are the counterparties to such financial instruments. As a risk management policy, we limit the amount of credit exposure by diversifying and utilizing numerous investment grade counterparties.

### *Interest Rate Risk*

As of December 27, 2025, we had variable interest rate exposure for certain of our revolving credit facilities and our U.S. trade accounts receivable securitization.

Our revolving credit facility, which we entered into on July 11, 2023 and expires on July 11, 2028, has a variable interest rate that is based on the SOFR plus a spread based on our leverage ratio at the end of each financial reporting quarter. As of December 27, 2025, there was \$100 million outstanding under this revolving credit facility. During the year ended December 27, 2025, the average outstanding balance was approximately \$203 million. Based upon our average outstanding balances, for each hypothetical increase of 25 basis points, our interest expense thereunder would have increased by \$0.5 million.

Our U.S. trade accounts receivable securitization, which we entered into on April 17, 2013 and expires on December 6, 2027, has a variable interest rate that is based upon the asset-backed commercial paper rate. As of December 27, 2025, the commercial paper rate was 4.06% plus 0.75%, for a combined rate of 4.81%, and the outstanding balance under this securitization facility was \$390 million. During the year ended December 27, 2025, the average outstanding balance was approximately \$363 million. Based upon our average outstanding balances, for each hypothetical increase of 25 basis points, our interest expense thereunder would have increased by \$1 million.

On July 11, 2023, we entered into a three-year \$750 million term loan credit agreement (the “Term Credit Agreement”), which was originally scheduled to mature on July 11, 2026. On June 6, 2025, this agreement was amended and restated to, among other things, (i) extend the maturity date to June 6, 2030, and (ii) modify certain financial definitions and covenants. The interest rate on this term loan is based on the Term SOFR plus a spread based on our leverage ratio at the end of each financial reporting quarter. After renewing the Term Credit Agreement in June of 2025, our hedged portion of the Term Credit Agreement was approximately 90% of the notional total. As of December 27, 2025, the effective fixed rate was 5.69% and the floating rate was 5.01%, resulting in a weighted average rate of 5.62%.

On July 11, 2023, we entered into interest rate swap agreements to hedge the cash flow of our variable rate \$750 million floating debt term loan facility, with three years maturity, effectively changing the floating rate portion of our obligation to a fixed rate. Under the terms of the interest rate swap agreements, we receive variable interest payments based on the one-month Term SOFR rate and pay interest at a fixed rate. As of December 27, 2025, the notional value of the interest rate swap agreements was \$675 million.

**ITEM 8. Financial Statements and Supplementary Data****INDEX TO FINANCIAL STATEMENTS  
HENRY SCHEIN, INC.**

	<b>Page Number</b>
Report of Independent Registered Public Accounting Firm (BDO USA, P.C.; New York, New York; PCAOB ID#243)	70
Consolidated Financial Statements:	
Balance Sheets as of December 27, 2025 and December 28, 2024	72
Statements of Income for the years ended December 27, 2025, December 28, 2024 and December 30, 2023	73
Statements of Comprehensive Income for the years ended December 27, 2025, December 28, 2024 and December 30, 2023	74
Statements of Changes in Stockholders' Equity for the years ended December 27, 2025, December 28, 2024 and December 30, 2023	75
Statements of Cash Flows for the years ended December 27, 2025, December 28, 2024 and December 30, 2023	76
Notes to Consolidated Financial Statements	77
Note 1 – Basis of Presentation and Significant Accounting Policies	77
Note 2 – Cyber Incident	89
Note 3 – Net Sales from Contracts with Customers	89
Note 4 – Segment and Geographic Data	90
Note 5 – Business Acquisitions	93
Note 6 – Inventories, Net	101
Note 7 – Property and Equipment, Net	101
Note 8 – Leases	102
Note 9 – Goodwill and Other Intangibles, Net	104
Note 10 – Investments and Other	106
Note 11 – Fair Value Measurements	107
Note 12 – Concentrations of Risk	110
Note 13 – Derivatives and Hedging Activities	111
Note 14 – Debt	113
Note 15 – Income Taxes	117
Note 16 – Plans of Restructuring and Related Costs	122
Note 17 – Commitments and Contingencies	124
Note 18 – Stock-Based Compensation	125
Note 19 – Employee Benefit Plans	128
Note 20 – Redeemable Noncontrolling Interests	131
Note 21 – Comprehensive Income	131
Note 22 – Earnings Per Share	133
Note 23 – Supplemental Cash Flow Information	134
Note 24 – Related Party Transactions	135
Note 25 – KKR Investment and Accelerated Share Repurchase Program	136

## **Report of Independent Registered Public Accounting Firm**

Shareholders and Board of Directors  
Henry Schein, Inc.  
Melville, New York

### **Opinion on the Consolidated Financial Statements**

We have audited the accompanying consolidated balance sheets of Henry Schein, Inc. (the “Company”) as of December 27, 2025 and December 28, 2024, the related consolidated statements of income and comprehensive income, changes in stockholders’ equity, and cash flows for each of the three years in the period ended December 27, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 27, 2025 and December 28, 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 27, 2025, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 27, 2025, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and our report dated February 24, 2026 expressed an unqualified opinion thereon.

### **Basis for Opinion**

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

### **Critical Audit Matter**

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the Audit Committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

### **Business Acquisition - Valuation of Acquired Intangible Assets**

As described in Notes 1 and 5 of the consolidated financial statements, the Company acquired entities within the

Global Distribution and Value-Added Services, Global Specialty Products and Global Technology segments during the year ended December 27, 2025 for total consideration of \$392 million. The purchase price was allocated to the assets acquired and liabilities assumed based on their respective fair values on the date of acquisition. The Company estimated the fair value of identifiable intangible assets using the relief-from-royalty method and the multi-period excess earnings method which required the Company to make significant estimates and assumptions, including discount rates and projected revenue growth rates.

We identified the revenue growth rates for certain periods and the discount rates used in estimating the fair value of certain trade name and customer relationships as a critical audit matter. The principal considerations for our determination were the subjective judgement required by management in formulating the revenue growth rates and assessing the appropriateness of the discount rates used in developing the fair value of the applicable acquired identifiable intangible assets. Auditing these considerations involved especially subjective and challenging auditor judgement due to the nature and extent of audit effort required to address these matters, including the extent of specialized skill or knowledge needed.

The primary procedures we performed to address this critical audit matter included:

- Evaluating the reasonableness of the revenue growth rates used in estimating the fair value of certain trade name and customer relationships by: (i) reviewing the historical performance of the acquired entity utilizing its audited financial statements, and (ii) assessing the revenue projections against industry metrics for certain periods.
- Utilizing specialists with skill and knowledge in valuation to evaluate the reasonableness of the discount rates used in estimating the fair value of certain trade name and customer relationships by assessing the source information underlying the determination of the discount rates, developing a range of independent estimates for the discount rates, and comparing those to the discount rates selected by the Company.

/s/ BDO USA, P.C.

We have served as the Company's auditor since 1984.

New York, New York  
February 24, 2026

**HENRY SCHEIN, INC.**  
**CONSOLIDATED BALANCE SHEETS**  
(in millions, except share data)

	December 27, 2025	December 28, 2024
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 156	\$ 122
Accounts receivable, net of allowance for credit losses of \$90 and \$78 (1)	1,651	1,482
Inventories, net	2,002	1,810
Prepaid expenses and other	655	569
Total current assets	4,464	3,983
Property and equipment, net	621	531
Operating lease right-of-use assets	301	293
Goodwill	4,213	3,887
Other intangibles, net	1,018	1,023
Investments and other	598	501
Total assets	\$ 11,215	\$ 10,218
<b>LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 1,154	\$ 962
Bank credit lines	764	650
Current maturities of long-term debt	33	56
Operating lease liabilities	78	75
Accrued expenses:		
Payroll and related	340	303
Taxes	179	139
Other	680	618
Total current liabilities	3,228	2,803
Long-term debt (1)	2,310	1,830
Deferred income taxes	146	102
Operating lease liabilities	251	259
Other liabilities	486	387
Total liabilities	6,421	5,381
Redeemable noncontrolling interests	895	806
Commitments and contingencies	-	-
Stockholders' equity:		
Preferred stock, \$0.01 par value, 1,000,000 shares authorized, none outstanding	-	-
Common stock, \$0.01 par value, 480,000,000 shares authorized, 115,771,149 issued and outstanding on December 27, 2025 and 124,155,884 issued and outstanding on December 28, 2024	1	1
Additional paid-in capital	177	-
Retained earnings	3,293	3,771
Accumulated other comprehensive loss	(226)	(379)
Total Henry Schein, Inc. stockholders' equity	3,245	3,393
Noncontrolling interests	654	638
Total stockholders' equity	3,899	4,031
Total liabilities, redeemable noncontrolling interests and stockholders' equity	\$ 11,215	\$ 10,218

(1) Amounts presented include balances held by our consolidated variable interest entity ("VIE"). At December 27, 2025 and December 28, 2024, includes trade accounts receivable of \$491 million and \$241 million, respectively, and long-term debt of \$390 million and \$150 million, respectively. See Note 1 – Basis of Presentation and Significant Accounting Policies for further information.

See accompanying notes.

**HENRY SCHEIN, INC.**  
**CONSOLIDATED STATEMENTS OF INCOME**  
(in millions, except share and per share data)

	Years Ended		
	December 27, 2025	December 28, 2024	December 30, 2023
Net sales	\$ 13,184	\$ 12,673	\$ 12,339
Cost of sales	9,079	8,657	8,479
Gross profit	4,105	4,016	3,860
Operating expenses:			
Selling, general and administrative	3,084	3,034	2,956
Depreciation and amortization	263	251	209
Restructuring and related costs	105	110	80
Operating income	653	621	615
Other income (expense):			
Interest income	33	24	17
Interest expense	(150)	(131)	(87)
Other, net	(3)	(1)	(3)
Income before taxes, equity in earnings of affiliates and noncontrolling interests	533	513	542
Income taxes	(126)	(128)	(120)
Equity in earnings of affiliates, net of tax	12	13	14
Net income	419	398	436
Less: Net income attributable to noncontrolling interests	(21)	(8)	(20)
Net income attributable to Henry Schein, Inc.	\$ 398	\$ 390	\$ 416
<b>Earnings per share attributable to Henry Schein, Inc.:</b>			
Basic	\$ 3.29	\$ 3.07	\$ 3.18
Diluted	\$ 3.27	\$ 3.05	\$ 3.16
Weighted-average common shares outstanding:			
Basic	120,813,977	126,788,997	130,618,990
Diluted	121,717,876	127,779,228	131,748,171

See accompanying notes.

**HENRY SCHEIN, INC.**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
(in millions)

	<u>Years Ended</u>		
	<u>December 27,</u> <u>2025</u>	<u>December 28,</u> <u>2024</u>	<u>December 30,</u> <u>2023</u>
Net income	\$ 419	\$ 398	\$ 436
Other comprehensive income, net of tax:			
Foreign currency translation gain (loss)	207	(207)	53
Unrealized gain (loss) from hedging activities	(24)	13	(18)
Pension adjustment gain (loss)	<u>2</u>	<u>(3)</u>	<u>(3)</u>
Other comprehensive income (loss), net of tax	<u>185</u>	<u>(197)</u>	<u>32</u>
Comprehensive income	604	201	468
Comprehensive income attributable to noncontrolling interests:			
Net income	(21)	(8)	(20)
Foreign currency translation loss (gain)	<u>(32)</u>	<u>24</u>	<u>(5)</u>
Comprehensive loss (income) attributable to noncontrolling interests	<u>(53)</u>	<u>16</u>	<u>(25)</u>
Comprehensive income attributable to Henry Schein, Inc.	<u>\$ 551</u>	<u>\$ 217</u>	<u>\$ 443</u>

See accompanying notes.

**HENRY SCHEIN, INC.**  
**CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY**  
(in millions, except share data)

	Common Stock \$.01 Par Value		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests	Total Stockholders' Equity
	Shares	Amount					
Balance, December 31, 2022	131,792,817	\$ 1	\$ -	\$ 3,678	\$ (233)	\$ 649	\$ 4,095
Net income (excluding \$6 attributable to Redeemable noncontrolling interests)	-	-	-	416	-	14	430
Foreign currency translation gain (excluding gain of \$5 attributable to Redeemable noncontrolling interests)	-	-	-	-	48	-	48
Unrealized loss from hedging activities, including tax benefit of \$7	-	-	-	-	(18)	-	(18)
Pension adjustment loss, including tax benefit of \$0	-	-	-	-	(3)	-	(3)
Distributions to noncontrolling shareholders	-	-	-	-	-	(27)	(27)
Change in fair value of redeemable securities	-	-	11	-	-	-	11
Noncontrolling interests and adjustments related to business acquisitions	-	-	-	-	-	(2)	(2)
Repurchase and retirement of common stock	(3,214,136)	-	(33)	(219)	-	-	(252)
Stock issued upon exercise of stock options	21,068	-	1	-	-	-	1
Stock-based compensation expense	1,065,319	-	39	-	-	-	39
Shares withheld for payroll taxes	(416,605)	-	(34)	-	-	-	(34)
Settlement of stock-based compensation awards	(698)	-	1	-	-	-	1
Transfer of charges in excess of capital	-	-	15	(15)	-	-	-
Balance, December 30, 2023	129,247,765	1	-	3,860	(206)	634	4,289
Net income (excluding loss of \$1 attributable to Redeemable noncontrolling interests)	-	-	-	390	-	9	399
Foreign currency translation loss (excluding loss of \$24 attributable to Redeemable noncontrolling interests)	-	-	-	-	(183)	-	(183)
Unrealized gain from hedging activities, including tax of \$5	-	-	-	-	13	-	13
Pension adjustment loss, including tax benefit of \$2	-	-	-	-	(3)	-	(3)
Distributions to noncontrolling shareholders	-	-	-	-	-	(6)	(6)
Purchase of noncontrolling interests	-	-	(7)	-	-	(1)	(8)
Change in fair value of redeemable securities	-	-	(119)	-	-	-	(119)
Noncontrolling interests and adjustments related to business acquisitions	-	-	(1)	-	-	2	1
Repurchase and retirement of common stock	(5,419,649)	-	(52)	(336)	-	-	(388)
Stock issued upon exercise of stock options	98,755	-	6	-	-	-	6
Stock-based compensation expense	340,722	-	39	-	-	-	39
Shares withheld for payroll taxes	(111,815)	-	(9)	-	-	-	(9)
Settlement of stock-based compensation awards	106	-	-	-	-	-	-
Transfer of charges in excess of capital	-	-	143	(143)	-	-	-
Balance, December 28, 2024	124,155,884	1	-	3,771	(379)	638	4,031
Net income (excluding loss of \$5 attributable to Redeemable noncontrolling interests)	-	-	-	398	-	26	424
Foreign currency translation gain (excluding gain of \$30 attributable to Redeemable noncontrolling interests)	-	-	-	-	175	2	177
Unrealized loss from hedging activities, including tax benefit of \$9	-	-	-	-	(24)	-	(24)
Pension adjustment gain, net of tax of \$3	-	-	-	-	2	-	2
Net distributions to noncontrolling shareholders	-	-	-	-	-	(11)	(11)
Purchase of noncontrolling interests	-	-	(1)	-	-	(1)	(2)
Change in fair value of redeemable securities	-	-	(72)	-	-	-	(72)
Noncontrolling interests and adjustments related to business acquisitions and contingent consideration	-	-	(46)	-	-	-	(46)
Issuance of common stock	3,285,151	-	250	-	-	-	250
Repurchase and retirement of common stock	(12,062,174)	-	(94)	(762)	-	-	(856)
Stock issued upon exercise of stock options	24,172	-	2	-	-	-	2
Stock-based compensation expense	578,536	-	39	-	-	-	39
Shares withheld for payroll taxes	(203,951)	-	(15)	-	-	-	(15)
Settlement of stock-based compensation awards	(6,469)	-	-	-	-	-	-
Transfer of charges in excess of capital	-	-	114	(114)	-	-	-
Balance, December 27, 2025	115,771,149	\$ 1	\$ 177	\$ 3,293	\$ (226)	\$ 654	\$ 3,899

See accompanying notes.

**HENRY SCHEIN, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(in millions)

	Years Ended		
	December 27, 2025	December 28, 2024	December 30, 2023
<b>Cash flows from operating activities:</b>			
Net income	\$ 419	\$ 398	\$ 436
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	311	297	248
Impairment charge on intangible assets	16	-	7
Impairment of capitalized software	-	12	27
Non-cash restructuring and related charges	8	32	27
Stock-based compensation expense	39	39	39
Provision for losses on trade and other accounts receivable	16	14	18
Provision for (benefit from) deferred income taxes	5	(61)	(20)
Equity in earnings of affiliates	(12)	(13)	(14)
Distributions from equity affiliates	11	12	15
Changes in unrecognized tax benefits	4	5	10
Other	(57)	(27)	(3)
Changes in operating assets and liabilities, net of acquisitions:			
Accounts receivable	(124)	315	(327)
Inventories	(95)	(59)	231
Other current assets	(45)	47	(138)
Accounts payable and accrued expenses	216	(163)	(56)
Net cash provided by operating activities	<u>712</u>	<u>848</u>	<u>500</u>
<b>Cash flows from investing activities:</b>			
Purchases of property and equipment	(139)	(148)	(147)
Payments related to equity investments and business acquisitions, net of cash acquired	(199)	(230)	(955)
Proceeds from loan to affiliate	3	4	6
Settlements for net investment hedges	-	-	22
Capitalized software costs	(52)	(39)	(40)
Other	(13)	(17)	(21)
Net cash used in investing activities	<u>(400)</u>	<u>(430)</u>	<u>(1,135)</u>
<b>Cash flows from financing activities:</b>			
Net change in bank credit lines	108	387	153
Proceeds from issuance of long-term debt	489	120	1,368
Principal payments for long-term debt	(44)	(318)	(468)
Debt issuance costs	(2)	-	(3)
Issuance of common stock	250	-	-
Proceeds from issuance of stock upon exercise of stock options	2	6	1
Payments for repurchases and retirement of common stock	(850)	(385)	(250)
Payments for taxes related to shares withheld for employee taxes	(15)	(9)	(34)
Distributions to noncontrolling shareholders	(30)	(54)	(47)
Payments for contingent consideration	(19)	(2)	-
Acquisitions of noncontrolling interests in subsidiaries	(77)	(255)	(19)
Net cash provided by (used in) financing activities	<u>(188)</u>	<u>(510)</u>	<u>701</u>
Effect of exchange rate changes on cash and cash equivalents	(90)	43	(12)
Net change in cash and cash equivalents	34	(49)	54
Cash and cash equivalents, beginning of period	122	171	117
Cash and cash equivalents, end of period	<u>\$ 156</u>	<u>\$ 122</u>	<u>\$ 171</u>

See accompanying notes.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

**Note 1 – Basis of Presentation and Significant Accounting Policies**

*Nature of Operations*

We distribute health care products and value-added services primarily to office-based dental and medical practitioners, across dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and alternate care clinics. We also provide software and technology services to health care practitioners. Our dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as group practices and integrated delivery networks, among other providers across a wide range of specialties.

We have significant operations in the United States, Germany, France, Canada, and Brazil. We also have meaningful market presence in several other European countries and the Asia-Pacific region.

*Basis of Presentation*

Our consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries and VIE. All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates for which we have the ability to influence the operating or financial decisions are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications, individually and in the aggregate, did not have a material impact on our consolidated financial condition, results of operations or cash flows.

The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. We are deemed to be the primary beneficiary of the VIE when we have the power to direct activities that most significantly affect its economic performance and have the obligation to absorb the majority of its losses or the right to receive benefits that could potentially be significant to the VIE. In determining whether we are the primary beneficiary, we consider factors such as ownership interest, debt investments, management representation, authority to control decisions, and contractual and substantive participating rights of each party. For this VIE, related to our U.S. trade accounts receivable securitization as discussed in Note 14 – Debt, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The VIE's creditors have recourse to us for losses on these trade accounts receivable. At December 27, 2025 and December 28, 2024, certain trade accounts receivable that can only be used to settle obligations of this VIE were \$491 million and \$241 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were \$390 million and \$150 million, respectively.

*Fair Value Measurements*

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows:

- Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

- Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3— Inputs that are unobservable for the asset or liability.

See Note 11 – Fair Value Measurements for additional information.

*Use of Estimates*

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for credit losses; fair value of contingent consideration; hedging activity; supplier rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions.

*Fiscal Year*

We report our results of operations and cash flows on a 52 or 53 weeks per fiscal year basis ending on the last Saturday of December. The years ended December 27, 2025, December 28, 2024 and December 30, 2023 consisted of 52 weeks.

*Revenue Recognition*

Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that we expect to receive for those goods or services. To recognize revenue, we:

- identify the contract(s) with a customer;
- identify the performance obligations in the contract;
- determine the transaction price;
- allocate the transaction price to the performance obligations in the contract; and
- recognize revenue when, or as, we satisfy a performance obligation.

We generate revenue from the sale of dental and medical consumable products, equipment, and services such as equipment repair and financial services (Global Distribution and Value-Added Services revenues), company-manufactured specialty products (Global Specialty Products revenue), and software products and related services (Global Technology revenues). Provisions for discounts, rebates to customers, customer returns and other contra revenue adjustments are included in the transaction price at contract inception by estimating the most likely amount based upon historical data and estimates and are provided for in the period in which the related sales are recognized.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

Revenue derived from the sale of consumable products and company-manufactured specialty products is recognized at the point in time when control transfers to the customer, (e.g. when legal title and risks and rewards of ownership transfer to the customer, we have no post-shipment obligations, and we have an enforceable right to payment). Sales of consumable products typically entail high-volume, low-dollar orders shipped using third-party common carriers.

Revenue derived from the sale of equipment is recognized when control transfers to the customer. This occurs when the equipment is delivered. Such sales typically entail scheduled deliveries of large equipment primarily by equipment service technicians. Most equipment requires minimal installation, which is typically completed at the time of delivery.

Our merchandise and equipment products generally carry standard warranty terms provided by the manufacturer; however, in instances where we provide a warranty on company-manufactured products or labor services, the warranty costs are accrued in accordance with Accounting Standards Codification (“ASC”) Topic 460 Guarantees. At December 27, 2025 and December 28, 2024, we had accrued approximately \$8 million and \$8 million, respectively, for warranty costs.

Revenue derived from the sale of software products is recognized when products are delivered to customers or made available electronically. Such software is generally installed by customers and does not require extensive training. Revenue derived from post-contract customer support for software, including annual support and/or training, is generally recognized over time using time elapsed as the input method that best depicts the transfer of control to the customer. Revenue derived from software sold on a Software-as-a-Service basis is recognized ratably over the subscription period as control is transferred to the customer.

Revenue derived from other sources, including freight charges, equipment repairs and financial services, is recognized when the related product revenue is recognized or when the services are provided. We apply the practical expedient to treat shipping and handling activities performed after the customer obtains control as fulfillment activities, rather than a separate performance obligation in the contract.

Sales, value-add and other taxes we collect concurrent with revenue-producing activities are excluded from revenue.

Some of our revenue is derived from bundled arrangements that include multiple distinct performance obligations, which are accounted for separately. When we sell software products together with related services (i.e., training and technical support), we allocate the transaction price to each distinct performance obligation based on the estimated standalone selling price for each performance obligation. Bundled arrangements that include elements that are not considered software consist primarily of equipment and the related installation service. We allocate revenue for such arrangements based on the relative selling prices of the goods or services. If an observable selling price is not available (i.e., because we or others do not sell the goods or services separately), we use one of the following techniques to estimate the standalone selling price: adjusted market approach; cost-plus-margin approach; or the residual method. There is no specific hierarchy for the use of these methods, but the estimated selling price reflects our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a standalone basis taking into consideration the cost structure of our business, technical skill required, customer location and other market conditions.

See Note 3 – Net Sales from Contracts with Customers for additional disclosures of disaggregated net sales and Note 4 – Segment and Geographic Data for disclosures of net sales by segment and geographic data.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

*Sales Returns*

Sales returns are recognized as a reduction of revenue by the amount of expected returns and are recorded as refund liability within accrued expenses-other within our consolidated balance sheets. We estimate the sales return liability based on historical data for specific products, adjusted as necessary for new products. The allowance for returns is presented gross as a refund liability and we record a right of return asset (and a corresponding adjustment to cost of sales) for any products that we expect to be returned and resaleable.

*Cost of Sales*

The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier chargebacks and rebates) and inbound and outbound freight charges.

Costs related to purchasing, receiving, inspections, warehousing, internal inventory transfers and other costs of our distribution network are included in selling, general and administrative expenses along with other operating costs. Total distribution network costs were \$107 million, \$105 million and \$105 million for the years ended December 27, 2025, December 28, 2024 and December 30, 2023, respectively.

*Supplier Rebates*

Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned. The factors we consider in estimating supplier rebate accruals include forecasted inventory purchases, sales, supplier rebate contract terms, which generally provide for increasing rebates based on either increased purchase or sales volumes.

*Direct Shipping and Handling Costs*

Freight and other direct shipping costs are included in cost of sales. Direct handling costs, which represent primarily direct compensation costs of employees who pick, pack and otherwise prepare, if necessary, merchandise for shipment to our customers are reflected in selling, general and administrative expenses. Direct handling costs were \$105 million, \$106 million and \$98 million for the years ended December 27, 2025, December 28, 2024 and December 30, 2023, respectively.

*Advertising and Promotional Costs*

We expense advertising and promotional costs as incurred. Total advertising and promotional expenses were \$46 million, \$43 million and \$47 million for the years ended December 27, 2025, December 28, 2024 and December 30, 2023, respectively.

*Stock-Based Compensation Costs*

We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite service period for certain time-based restricted stock units with cliff vesting and on an accelerated basis for the option awards and certain time-based restricted stock units with graded vesting. For performance-based awards, at each reporting date, we reassess whether achievement of the performance condition is probable and accrue compensation expense when achievement of the performance condition is probable. Our stock-based compensation expense is reflected in selling, general and administrative expenses.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

*Employment Benefit Plans and other Postretirement Benefit Plans*

Some of our employees in our international markets participate in various noncontributory defined benefit plans. We recognize the funded status, measured as the difference between the fair value of plan assets and the projected benefit obligation. Each unfunded plan is recognized as a liability and each funded plan is recognized as either an asset or liability based on its funded status. We measure our plan assets and liabilities at the end of our fiscal year.

Net periodic pension costs and valuations are dependent on assumptions used by third-party actuaries in calculating those amounts. These assumptions include discount rates, expected return on plan assets, rate of future compensation levels, retirement rates, mortality rates, and other factors. We record the service cost component of net pension cost in selling, general and administrative expenses within our consolidated statements of income.

Gains and losses that result from changes in actuarial assumptions or from actual experience that differs from actuarial assumptions are recognized in and then amortized from accumulated other comprehensive income (loss).

*Cash and Cash Equivalents*

We consider all highly liquid short-term investments with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Outstanding checks in excess of funds on deposit of \$25 million and \$33 million, primarily related to payments for inventory, were classified as accounts payable as of December 27, 2025 and December 28, 2024.

*Accounts Receivable and Allowance for Credit Losses*

Accounts receivable are generally recognized when revenues are recognized. In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that we do not expect to collect. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts.

We record allowances for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided at differing rates, based upon the age of the receivable, the collection history associated with the geographic region that the receivable was recorded in, current economic trends and reasonable supportable forecasts. We write off accounts receivable and charge it against its recorded allowance when we deem it uncollectible.

Our net accounts receivable balance was \$1,651 million, \$1,482 million, and \$1,863 million, at December 27, 2025, December 28, 2024 and December 30, 2023, respectively.

The following table presents our allowances for credit losses:

<b>Description</b>	<b>As of</b>		
	<b>December 27, 2025</b>	<b>December 28, 2024</b>	<b>December 30, 2023</b>
Balance at beginning of year	\$ 78	\$ 83	\$ 65
Provision for credit losses	20	14	17
Adjustments to existing allowances for late fees, foreign currency exchange rates, and write-offs	(8)	(19)	1
Balance at end of year	<u>\$ 90</u>	<u>\$ 78</u>	<u>\$ 83</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

*Contract Assets*

Contract assets include amounts related to any conditional right to consideration for work completed but not billed as of the reporting date. Contract assets are transferred to accounts receivable when the right becomes unconditional. The contract assets primarily relate to our bundled arrangements for the sale of equipment and consumables and sales of term software licenses. Current contract assets are included in prepaid expenses and other and the non-current contract assets are included in investments and other within our consolidated balance sheets. Current and non-current contract asset balances as of December 27, 2025 and December 28, 2024 were not material.

*Contract Liabilities*

Contract liabilities are comprised of advance payments and upfront payments for service arrangements provided over time that are accounted for as deferred revenue amounts. Contract liabilities are transferred to revenue once the performance obligation has been satisfied. Current contract liabilities are included in accrued expenses: other and the non-current contract liabilities are included in other liabilities within our consolidated balance sheets.

During the years ended December 27, 2025, December 28, 2024, and December 30, 2023, we recognized substantially all of the current contract liability amounts that were previously deferred at the beginning of each year.

The following table presents our contract liabilities:

<u>Description</u>	As of		
	<u>December 27, 2025</u>	<u>December 28, 2024</u>	<u>December 30, 2023</u>
Current contract liabilities	\$ 81	\$ 81	\$ 89
Non-current contract liabilities	<u>9</u>	<u>8</u>	<u>9</u>
Total contract liabilities	<u>\$ 90</u>	<u>\$ 89</u>	<u>\$ 98</u>

*Inventories and Reserves*

Inventories consist primarily of finished goods, raw materials and work-in-process and are stated at the lower of cost or net realizable value. Cost is determined by the weighted average method for merchandise and actual cost for large equipment, high-technology equipment and drop-shipments. Inventory costs for manufactured products include direct materials, labor, and an allocation of related fixed and variable overhead. The determination of inventory carrying values requires management to make significant estimates and judgments. In assessing the need for inventory reserves and evaluating net realizable value, we consider multiple factors, including inventory condition, on-hand quantities, historical and forecasted sales, product life cycles, and prevailing market and economic conditions.

*Property and Equipment*

Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is computed under the straight-line method using estimated useful lives (See Note 7 – Property and Equipment, Net for estimated useful lives). Amortization of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the remaining lease term.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

*Capitalized Software Development Costs*

Capitalized software costs consist of costs to purchase and develop software for internal use and for sale or use by customers. For software to be used solely to meet internal needs, we capitalize costs incurred during the application development stage and include such costs within property and equipment, net within our consolidated balance sheets. For software to be sold, leased, or marketed to external users, we capitalize software development costs when technological feasibility is reached, and for cloud-based applications used to deliver our services we capitalize costs incurred during the application development stage, and include such costs within investments and other within our consolidated balance sheets.

*Leases*

We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange for consideration. As a lessee, we include operating leases in operating lease right-of-use (“ROU”) assets, operating lease liabilities, and non-current operating lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, current maturities of long-term debt, and long-term debt in our consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized upon commencement of the lease based on the present value of the lease payments over the lease term. As most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate based on the estimated rate of interest for fully collateralized and fully amortizing borrowings over a similar term of the lease payments at commencement date to determine the present value of lease payments. When readily determinable, we use the implicit rate. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Expenses associated with operating leases and finance leases are included in selling, general and administrative and interest expense, respectively within our consolidated statement of income. Short-term leases with a term of 12 months or less are not capitalized.

We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles, which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.

*Business Acquisitions*

We account for business acquisitions under the acquisition method of accounting, under which the net assets of acquired businesses are recorded at their fair value at the acquisition date and our consolidated financial statements include the acquired businesses’ results of operations from that date.

Certain prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration, or we may be entitled to recoup a portion of purchase price cash consideration if certain financial targets or negotiated goals are met. We have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition, using the income approach, including a probability-weighted discounted cash flow method or an option pricing method, where applicable. Any adjustments to these accrual amounts are recorded in selling, general and administrative within our consolidated statements of income.

While we use our best estimates and assumptions to accurately value consideration transferred, assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

result, within 12 months following the date of acquisition, or the measurement period, we may record adjustments to consideration transferred, assets acquired and liabilities assumed with the corresponding offset to goodwill within our consolidated balance sheets. At the end of the measurement period or final determination of the values of such assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recognized in our consolidated statements of operations.

*Goodwill*

Any excess of acquisition consideration over the fair value of identifiable net assets acquired is recorded as goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized, such as future customers and technology, as well as the assembled workforce.

Goodwill is subject to impairment analysis at least once annually as of the first day of our fourth quarter, or if an event occurs or circumstances change that would more likely than not reduce a reporting unit's fair value below carrying value. We conduct our goodwill impairment testing at the reporting unit level. We identify our reporting units by assessing whether two or more components are economically similar and therefore should be aggregated. Our reporting units are identified as our operating segments. Goodwill is allocated to such reporting units for the purposes of our impairment analyses. For the year ended December 27, 2025, our reporting structure was:

- (i) Global Distribution and Value-Added Services reportable segment, which included the following operating segments (a) US Distribution Group; (b) Europe, Middle East, and Africa Distribution Group; (c) Americas Non-US Distribution Group; and (d) Asia-Pacific and Australia Distribution Group;
- (ii) Global Specialty Products reportable segment, which included the following operating segments (a) Global Oral Reconstruction Group; and (b) Healthcare Specialty Group; and
- (iii) Global Technology, which is both a reportable segment and an operating segment.

Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities that are considered shared services to the reporting units, and ultimately the determination of the fair value of each reporting unit. The fair value of each reporting unit is calculated by applying the discounted cash flow methodology and confirming with a market approach. There are inherent uncertainties, however, related to fair value models, the inputs and our judgments in applying them to this analysis. The most significant inputs include estimation of detailed future cash flows based on budget expectations, and determination of comparable companies to develop a weighted average cost of capital for each reporting unit.

In January 2025, we performed a geographical realignment within the Global Distribution and Value-Added Services reportable segment intended to provide increased transparency into the performance of our global distribution businesses and to reflect evolving management oversight and decision-making. As a result of the realignment and the change in reporting units, we reallocated goodwill to each of our new reporting units using a relative fair value approach. The relative fair values of the new reporting units were determined based on a quantitative valuation analysis that considered projected cash flows, market assumptions, and other relevant valuation inputs. Reporting units under the former and new structures of the Global Distribution and Value-Added Services reportable segment were tested for impairment as of January 1, 2025, and it was determined that the fair values of our reporting units more likely than not exceeded their carrying values, resulting in no impairment as of January 1, 2025 under both structures.

In connection with our restructuring initiatives, during the year ended December 28, 2024, we recorded an \$11 million impairment of goodwill in the Global Specialty Products segment, relating to the disposal of a portion of a business; such impairment was calculated based on the relative fair value of goodwill.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

*Intangible Assets*

In connection with our business acquisitions, we recognize assets acquired and liabilities assumed based on fair value estimates as of the date of acquisition. The estimated fair value of identifiable intangible assets (i.e., customer relationships and lists, trademarks and trade names, product development and non-compete agreements) is based on critical judgments and assumptions derived from analysis of market conditions, including discount rates, projected revenue growth rates (which are based on historical trends and assessment of financial projections), estimated customer attrition and projected cash flows. We have calculated the value of these intangible assets using the multi-period excess earnings method, the relief-from-royalty method, and the with and without method, where applicable. These assumptions are forward-looking and could be affected by future economic and market conditions.

Intangible assets, other than goodwill, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the undiscounted future cash flows expected to be derived from such asset or asset group.

Definite and indefinite-lived intangible assets primarily consist of customer relationships, customer lists, trademarks, trade names, product development and non-compete agreements. For long-lived assets used in operations, impairment losses are only recorded if the asset or asset groups carrying amount is not recoverable through its undiscounted future cash flows. We measure the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.

During the years ended December 27, 2025, December 28, 2024 and December 30, 2023, we recorded total impairment charges within the selling, general and administrative line of our consolidated statements of income on intangible assets of \$16 million, \$0 million and \$7 million, respectively, as more fully discussed in Note 9 – Goodwill and Other Intangibles, Net. During the years ended December 27, 2025, December 28, 2024 and December 30, 2023, we recorded impairment charges, within the restructuring and related costs line of our consolidated statements of income, of \$0 million, \$14, million, and \$12 million, respectively. See Note 16 – Plans of Restructuring and Related Costs for additional information.

*Income Taxes*

We account for income taxes under an asset and liability approach that requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than expected enactments of changes in tax laws or rates. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. We file a consolidated U.S. federal income tax return with our 80% or greater owned U.S. subsidiaries.

*Redeemable Noncontrolling Interests*

Some minority stockholders in certain of our consolidated subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Their interests in these subsidiaries are classified outside permanent equity on our consolidated balance sheets and are carried at the estimated redemption amounts. The redemption amounts have been estimated based on recent transactions and/or implied multiples of earnings and, if such earnings and cash flows are not achieved, the value of the redeemable noncontrolling interests might be impacted. Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are reflected at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

noncontrolling interests cannot go below the floor level. Adjustments to the carrying amount of noncontrolling interests to reflect a fair value redemption feature do not impact the calculation of earnings per share. Our net income is reduced by the portion of the subsidiaries' net income that is attributable to redeemable noncontrolling interests.

*Noncontrolling Interests*

Noncontrolling interest represents the ownership interests of certain minority owners of our consolidated subsidiaries. Our net income is reduced by the portion of the subsidiaries' net income that is attributable to noncontrolling interests.

*Comprehensive Income*

Comprehensive income includes certain gains and losses that, under accounting principles generally accepted in the United States, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders' equity. Our comprehensive income is primarily comprised of net income, foreign currency translation gain (loss), unrealized gain (loss) from hedging activities and unrealized pension adjustment gain (loss).

*Risk Management and Derivative Financial Instruments*

We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates, interest rates, and our unfunded non-qualified supplemental retirement plan ("SERP") and our deferred compensation plan ("DCP"). Our objective is to manage the impact that foreign currency exchange rate fluctuations could have on recognized asset and liability fair values, earnings and cash flows, as well as our net investments in foreign subsidiaries, the interest rate risk on variable rate debt, and the returns on our SERP and DCP. Our risk management policy requires that derivative contracts used as hedges be effective at reducing the risks associated with the exposure being hedged and be designated hedges at inception of the contracts. We do not enter into derivative instruments for speculative purposes. Our derivative instruments primarily include foreign currency forward contracts, total return swaps, and interest rate swaps.

Foreign currency forward agreements related to forecasted inventory purchase commitments with foreign suppliers, foreign currency swaps related to foreign currency denominated debt, and interest rate swaps related to variable rate debt are designated as cash flow hedges. For derivatives that are designated and qualify as cash flow hedges, the changes in the fair value of the derivatives are recorded as a component of Accumulated other comprehensive income in stockholders' equity and subsequently reclassified into earnings in the period(s) during which the hedged transactions affect earnings. We classify the cash flows related to our hedging activities in the same category in our consolidated statements of cash flows as the cash flows related to the hedged item.

Foreign currency forward contracts related to our euro-denominated foreign operations are designated as net investment hedges. For derivatives that are designated and qualify as net investment hedges, changes in the fair value of the derivatives are recorded in the foreign currency translation gain (loss) component of Accumulated other comprehensive income in stockholders' equity until the net investment is sold or substantially liquidated.

Interest swap agreements are entered into for the purpose of hedging the cash flow of our variable interest rate term loan.

Our foreign currency forward agreements related to foreign currency balance sheet exposure provide economic hedges but are not designated as hedges for accounting purposes.

For agreements not designated as hedges, changes in the value of the derivative, along with the transaction gain or loss on the hedged item, are recorded in other, net, within our consolidated statements of income.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

Total return swaps are entered into for the purpose of economically hedging our SERP and DCP. These swaps are expected to be renewed on an annual basis. Changes in the fair values of these total return swaps are recorded in selling, general, and administrative expenses within our consolidated statements of income and offset recognized changes in the fair values of our SERP and DCP liabilities.

*Foreign Currency Translation and Transactions*

The financial position and results of operations of our foreign subsidiaries are determined using local currencies as the functional currencies. Assets and liabilities of foreign subsidiaries are translated at the exchange rate in effect at each year-end. Income statement accounts are translated at the average rate of exchange prevailing during the year. Translation adjustments arising from the use of differing exchange rates from period to period are included in Accumulated other comprehensive income in stockholders' equity. Gains and losses resulting from foreign currency transactions are included in earnings.

*Accounting Pronouncements Recently Adopted*

During the year ended December 27, 2025, we adopted Accounting Standards Update (“ASU”) 2023-09, “*Income Taxes (Topic 740): Improvements to Income Tax Disclosures*,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, this ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. This ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. This ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of significantly increasing or decreasing in the 12 months following the reporting date. We adopted this ASU on a prospective basis, which resulted in the required additional disclosures included in Note 15 – Income Taxes.

During the year ended December 28, 2024, we adopted ASU 2023-07, “*Segment Reporting (Topic 280): Improvements to Reportable Segments*” (“Topic 280”), which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments in Topic 280 do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. We adopted Topic 280 on a retrospective basis, which resulted in the required additional disclosures included in our consolidated financial statements.

*Recently Issued Accounting Pronouncements*

In December 2025, the Financial Accounting Standards Board (“FASB”) issued ASU 2025-11, “*Interim Reporting (Topic 270): Narrow-Scope Improvements*,” which is intended to improve navigability of the guidance in Topic 270, Interim Reporting, and clarify when it applies. The ASU also addresses the form and content of such financial statements and interim disclosure requirements, and establishes a principle under which an entity must disclose events since the end of the last annual reporting period that have a material impact on the entity. This ASU is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods, with early adoption permitted. We are currently evaluating the impact that ASU 2025-11 will have on our consolidated financial statements and related disclosures.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

In December 2025, the FASB issued ASU 2025-10, “*Government Grants (Topic 832) - Accounting for Government Grants Received by Business Entities*,” which establishes guidance on the recognition, measurement, and presentation of government grants received by business entities. This ASU is effective for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods, with early adoption permitted. We are currently evaluating the impact that ASU 2025-10 will have on our consolidated financial statements and related disclosures.

In November 2025, the FASB issued ASU 2025-09, “*Derivatives and Hedging (Topic 815): Hedge Accounting Improvements*,” which is intended to more closely align financial reporting with the economics of entities’ risk management activities, including expanded eligibility of forecasted transactions, additional flexibility in measuring hedge effectiveness, and clarifications related to hedging non-financial items. This ASU is effective for annual reporting periods beginning June 1, 2027, and interim reporting periods within those annual reporting periods, with early adoption permitted, and should be applied prospectively. We are currently evaluating the impact that ASU 2025-09 will have on our consolidated financial statements and related disclosures.

In September 2025, the FASB issued ASU 2025-06, “*Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software*,” which removes all references to software development project stages. The ASU requires entities to begin capitalizing software costs when management authorizes and commits to funding the software project, and it is probable that the project will be completed and the software will be used for its intended purpose. This ASU is effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods, with early adoption permitted. Upon adoption, the guidance can be applied prospectively, retrospectively, or with a modified transition approach. We are currently evaluating the impact that ASU 2025-06 will have on our consolidated financial statements.

In July 2025, the FASB issued ASU 2025-05, “*Financial Instruments - Credit Losses (Subtopic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets*,” which introduces a practical expedient permitting an entity to assume that conditions at the balance sheet date remain unchanged throughout the remaining life of the asset when estimating expected credit losses on current accounts receivable and current contract asset under Topic 606 on revenue from contracts with customers. This ASU is effective for annual reporting periods beginning after December 15, 2025, with early adoption permitted. We do not expect ASU 2025-05 to have a material impact on our consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, “*Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure (Subtopic 220-40): Disaggregation of Income Statement Expenses*,” which requires additional disclosure about the specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements, but affect where this information appears in the notes to financial statements. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. We are currently evaluating the impact that ASU 2024-03 will have on our consolidated financial statements.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 2 – Cyber Incident**

In October 2023 Henry Schein experienced a cyber incident that primarily affected the operations of our North American and European dental and medical distribution businesses. Henry Schein One, our practice management software, revenue cycle management and patient relationship management solutions business, was not affected, and our manufacturing businesses were mostly unaffected. On November 22, 2023, we experienced a disruption of our ecommerce platform and related applications, which was remediated.

With respect to the October 2023 cyber incident, we had a \$60 million insurance policy, following a \$5 million retention. During the years ended December 27, 2025, December 28, 2024 and December 30, 2023, we incurred \$0 million, \$9 million and \$11 million, respectively, of expenses related to the cyber incident, mostly consisting of professional fees. During the year ended December 28, 2024, we received insurance proceeds of \$40 million, representing a partial insurance recovery of losses related to the cyber incident. During the year ended December 27, 2025, we received insurance proceeds of \$20 million under this policy, representing insurance recovery of losses related to the cyber incident. The expenses and insurance recoveries related to the cyber incident are included in the selling, general and administrative line in our consolidated statements of income.

**Note 3 – Net Sales from Contracts with Customers**

Net sales are recognized in accordance with policies disclosed in Note 1 – Basis of Presentation and Significant Accounting Policies.

*Disaggregation of Net Sales*

The following table disaggregates our net sales by reportable segment:

	<b>Years Ended</b>		
	<b>December 27, 2025</b>	<b>December 28, 2024</b>	<b>December 30, 2023</b>
<b>Net Sales:</b>			
Global Distribution and Value-Added Services			
Global Dental merchandise	\$ 4,831	\$ 4,723	\$ 4,783
Global Dental equipment	1,799	1,723	1,675
Global Value-added services	238	233	191
Global Dental	<u>6,868</u>	<u>6,679</u>	<u>6,649</u>
Global Medical	<u>4,270</u>	<u>4,081</u>	<u>3,912</u>
Total Global Distribution and Value-Added Services	11,138	10,760	10,561
Global Specialty Products	1,544	1,446	1,331
Global Technology	675	630	602
Eliminations	(173)	(163)	(155)
Total	<u>\$ 13,184</u>	<u>\$ 12,673</u>	<u>\$ 12,339</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

**Note 4 – Segment and Geographic Data**

We conduct our business through three reportable segments: (i) Global Distribution and Value-Added Services; (ii) Global Specialty Products; and (iii) Global Technology.

We aggregate operating segments into these reportable segments based on economic similarities, the nature of their products, customer base and methods of distribution.

Global Distribution and Value-Added Services includes distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting and other services. This segment also markets and sells under our own corporate brand a portfolio of cost-effective, high-quality consumable merchandise. Global Specialty Products includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other health care-related products and services. Global Technology includes development and distribution of practice management software, e-services and other products, which are distributed to health care providers.

Our organizational structure also includes Corporate, which consists primarily of income and expenses associated with support functions and projects.

Our chief operating decision maker (“CODM”) is our Chairman and Chief Executive Officer. Our CODM uses adjusted operating income as the profitability metric for purposes of making decisions about allocation of resources to each segment and assessing performance of each segment. Adjusted operating income provides a measure of our underlying segment results that is in line with our approach to risk and performance management. We define adjusted operating income as operating income adjusted to exclude (a) direct cybersecurity costs and related insurance recovery proceeds, (b) amortization of acquisition intangibles, (c) organizational restructuring and related expenses, (d) impairment of intangible assets, (e) changes in fair value of contingent consideration, (f) litigation settlements, and (g) costs associated with shareholder advisory matters and select value creation consulting costs. These adjustments are either: (i) non-cash or non-recurring in nature; (ii) not allocable or controlled by the segment; or (iii) not tied to the operational performance of the segment. Assets by segment are not a measure used to assess the performance of the Company by CODM and thus are not reported in our disclosures.

The accounting policies of the reportable segments are generally the same as those described in Note 1 – Basis of Presentation and Significant Accounting Policies. Sales and transfers between reportable segments are eliminated in consolidation.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

Segment adjusted operating income is presented in the following table to reconcile to operating income as presented on the consolidated statement of operations. The reconciliation from operating income to income before taxes and equity in earnings of affiliates is presented on our consolidated statements of income.

	Years Ended		
	December 27, 2025	December 28, 2024	December 30, 2023
<b>Gross Sales:</b>			
Global Distribution and Value-Added Services <sup>(1)</sup>	\$ 11,138	\$ 10,760	\$ 10,561
Global Specialty Products <sup>(2)</sup>	1,544	1,446	1,331
Global Technology <sup>(3)</sup>	675	630	602
Total Gross Sales	<u>13,357</u>	<u>12,836</u>	<u>12,494</u>
<b>Less: Eliminations:</b>			
Global Distribution and Value-Added Services	(18)	(31)	(36)
Global Specialty Products	(155)	(132)	(119)
Global Technology	-	-	-
Total Eliminations	<u>(173)</u>	<u>(163)</u>	<u>(155)</u>
<b>Net Sales:</b>			
Global Distribution and Value-Added Services	11,120	10,729	10,525
Global Specialty Products	1,389	1,314	1,212
Global Technology	675	630	602
Total Net Sales	<u>\$ 13,184</u>	<u>\$ 12,673</u>	<u>\$ 12,339</u>
<b>Segment Cost of Sales:</b> <sup>(4)</sup>			
Global Distribution and Value-Added Services	\$ 8,352	\$ 7,984	\$ 7,862
Global Specialty Products	697	644	611
Global Technology	218	206	185
<b>Segment Operating Expenses:</b> <sup>(5)</sup>			
Global Distribution and Value-Added Services	\$ 2,106	\$ 2,080	\$ 2,034
Global Specialty Products	605	624	545
Global Technology	277	272	275
<b>Operating Income:</b>			
Global Distribution and Value-Added Services	\$ 680	\$ 696	\$ 665
Global Specialty Products	242	178	175
Global Technology	180	152	142
Total Segment Operating Income	<u>1,102</u>	<u>1,026</u>	<u>982</u>
Corporate, net	(130)	(77)	(92)
Adjustments <sup>(6)</sup>	(319)	(328)	(275)
Total Operating Income	<u>\$ 653</u>	<u>\$ 621</u>	<u>\$ 615</u>
	Years Ended		
	December 27, 2025	December 28, 2024	December 30, 2023
<b>Depreciation and Amortization:</b>			
Global Distribution and Value-Added Services	\$ 27	\$ 25	\$ 26
Global Specialty Products	36	29	23
Global Technology	36	35	31
Total Segment Depreciation and Amortization	<u>99</u>	<u>89</u>	<u>80</u>
Corporate	33	24	18
Acquisition intangible amortization within adjustments <sup>(6)</sup>	179	184	150
Total Depreciation and Amortization	<u>\$ 311</u>	<u>\$ 297</u>	<u>\$ 248</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

- (1) Global Distribution and Value-Added Services: Includes distribution of infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, high-tech and digital restoration equipment, equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services. This segment also markets and sells under our own corporate brand a portfolio of cost-effective, high-quality consumable merchandise.
- (2) Global Specialty Products: Includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other health care-related products and services.
- (3) Global Technology: Includes development and distribution of practice management software, e-services and other products, which are distributed to health care providers.
- (4) Cost of goods sold in our Global Distribution and Value-Added Services segment and our Global Specialty Products segment includes product cost and inbound and outbound freight charges. Cost of goods sold in our Global Technology segment consists primarily of software development and third-party provider costs, including technology use and hosting fees.
- (5) Significant segment operating expenses for our reportable segments and Corporate include primarily compensation costs, and to a lesser extent, rent, depreciation and maintenance costs related to operating our facilities.
- (6) Adjustments represent items excluded from segment operating income to enable comparison of financial results between periods. The following table presents a breakdown of such adjustments:

	Years Ended		
	December 27, 2025	December 28, 2024	December 30, 2023
Adjustments:			
Restructuring and related costs	\$ (105)	\$ (110)	\$ (80)
Acquisition intangible amortization	(179)	(184)	(150)
Cyber incident-insurance proceeds, net of third-party advisory expenses	20	31	(11)
Change in contingent consideration	2	(45)	-
Litigation settlements	(5)	(6)	-
Impairment of capitalized assets	-	(12)	(27)
Impairment of intangible assets	(16)	-	(7)
Costs associated with shareholder advisory matters and select value creation consulting costs	(36)	(2)	-
Total adjustments	<u>\$ (319)</u>	<u>\$ (328)</u>	<u>\$ (275)</u>

The following table presents information about our operations by geographic area as of and for the years ended December 27, 2025, December 28, 2024 and December 30, 2023. Net sales by geographic area are based on the respective locations of our subsidiaries. No country, except for the United States, generated net sales greater than 10% of consolidated net sales. There were no material amounts of sales or transfers among geographic areas and there were no material amounts of export sales.

	2025		2024		2023	
	Net Sales	Long-Lived Assets	Net Sales	Long-Lived Assets	Net Sales	Long-Lived Assets
United States	\$ 9,096	\$ 4,033	\$ 8,825	\$ 3,683	\$ 8,662	\$ 3,479
Other	4,088	2,120	3,848	2,051	3,677	2,135
Consolidated total	<u>\$ 13,184</u>	<u>\$ 6,153</u>	<u>\$ 12,673</u>	<u>\$ 5,734</u>	<u>\$ 12,339</u>	<u>\$ 5,614</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 5 – Business Acquisitions**

Our acquisition strategy is focused on investments in companies, including high growth high margin businesses aligned with our BOLD+1 strategy, that add new customers and sales teams, increase our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we have already invested in businesses), and finally, those that enable us to access new products and technologies.

*2025 Acquisitions*

During the year ended December 27, 2025, we acquired companies within the Global Distribution and Value-Added Services, Global Specialty Products and Global Technology segments. Our acquired ownership interest in these companies range from 60% to 100%.

The following table aggregates the preliminary estimated fair value, as of the date of the acquisition, of consideration paid and net assets acquired for acquisitions during the year ended December 27, 2025:

	<b>Preliminary Allocation as of December 27, 2025</b>
Acquisition consideration:	
Cash	\$ 194
Deferred consideration	3
Estimated fair value of contingent consideration payable	19
Fair value of previously held equity method investments	91
Redeemable noncontrolling interests	85
Total consideration	\$ 392
Identifiable assets acquired and liabilities assumed:	
Current assets	\$ 59
Intangible assets	150
Other noncurrent assets	42
Current liabilities	(26)
Long-term debt	(1)
Deferred income taxes	(23)
Other noncurrent liabilities	(8)
Total identifiable net assets	193
Goodwill	199
Total net assets acquired	\$ 392

The accounting for acquisitions in the year ended December 27, 2025 has not been completed in several areas, including, but not limited to, pending assessment of certain assets, primarily including identifiable intangibles and certain equity method investments, and certain liabilities, primarily including deferred income taxes. During the year ended December 27, 2025, we did not record any material measurement period adjustments.

Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions are expected to provide for us, as well as the expected growth potential. The majority of the acquired goodwill is not deductible for tax purposes.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

The following table summarizes the intangible assets acquired during the year ended December 27, 2025:

	<u>2025</u>	<u>Weighted Average Useful Lives (in years)</u>
Customer relationships and lists	\$ 98	11
Trademarks / Tradenames	32	7
Product development	18	10
Non-compete agreements	2	5
Total	<u>\$ 150</u>	

During the year ended December 27, 2025, in connection with acquisitions of controlling interests of affiliates, we recognized gains of approximately \$38 million, related to the remeasurement to fair value of our previously held equity investments. Such gains were calculated using a discounted cash flow model based on Level 3 inputs, as defined in Note 11 – Fair Value Measurements, which was recorded in selling, general and administrative in the consolidated statements of income.

The impact of these acquisitions, individually and in the aggregate, was not considered material to our consolidated financial statements.

Pro forma financial information since the acquisition date has not been presented because the impact of these acquisitions was immaterial to our consolidated financial statements.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

*2024 Acquisitions*

*Acquisition of TriMed*

On April 1, 2024, we acquired a 60% voting equity interest in TriMed Inc. (“TriMed”), a global developer of solutions for the orthopedic treatment of lower and upper extremities, headquartered in California, for consideration of \$315 million. This acquisition is reported in our Global Specialty Products segment. The following table aggregates the final fair value, as of the date of the acquisition, of consideration paid and net assets acquired in the TriMed acquisition:

	<u>Final Allocation</u>
Acquisition consideration:	
Cash	\$ 141
Deferred consideration	21
Redeemable noncontrolling interests	153
Total consideration	<u>\$ 315</u>
Identifiable assets acquired and liabilities assumed:	
Current assets	\$ 35
Intangible assets	221
Other noncurrent assets	10
Current liabilities	(7)
Deferred income taxes	(62)
Other noncurrent liabilities	(6)
Total identifiable net assets	<u>191</u>
Goodwill	124
Total net assets acquired	<u>\$ 315</u>

Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of TriMed. The acquired goodwill is not deductible for tax purposes.

The intangible assets acquired consisted of product development of \$204 million, trademarks and tradenames of \$9 million, and in-process research and development of \$8 million. Weighted average useful lives for these acquired intangible assets were 9 years, 7 years and indefinite-lived, respectively. Except for in-process research and development (“IPR&D”), intangible assets acquired as a result of the TriMed acquisition are being amortized over their estimated useful lives using the straight-line method of amortization. IPR&D is accounted for as an indefinite-lived intangible asset and is not amortized until completion or abandonment of the associated research and development efforts. IPR&D is tested for impairment annually or periodically if an indicator of impairment exists during the period until completion.

Pro forma financial information and TriMed’s revenue and earnings since the acquisition date have not been presented because the impact of the TriMed acquisition was immaterial to our consolidated financial statements.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

*Other 2024 Acquisitions*

During the year ended December 28, 2024, we acquired companies within the Global Distribution and Value-Added Services and Global Specialty Products segments. Our acquired ownership interest in these companies range from 51% to 100%. Total consideration for these acquisitions was \$113 million (including cash paid of \$62 million, fair value of previously held equity investment of \$30 million, noncontrolling interest of \$18 million, estimated fair value of contingent consideration payable of \$2 million, and deferred consideration of \$1 million). Net assets acquired primarily consisted of \$60 million of goodwill and \$64 million of intangible assets. The intangible assets acquired consisted of customer relationships and lists of \$33 million, trademarks and tradenames of \$24 million, product development of \$5 million and non-compete agreements of \$2 million. Weighted average useful lives for these acquired intangible assets were 11 years, 7 years, 9 years and 5 years, respectively.

We completed the accounting for all other acquisitions that occurred during the year ended December 28, 2024 and we did not record any material measurement period adjustments related to these acquisitions during the year ended December 27, 2025.

Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions are expected to provide for us, as well as the expected growth potential. The majority of the acquired goodwill is not deductible for tax purposes.

During the year ended December 28, 2024, in connection with the acquisition of a controlling interest of an affiliate, we recognized a gain of approximately \$19 million related to the remeasurement to fair value of our previously held equity investment, using a discounted cash flow model based on Level 3 inputs, as defined in Note 11 – Fair Value Measurements, which was recorded in selling, general and administrative in the consolidated statements of income.

Pro forma financial information for our 2024 acquisitions has not been presented because the impact of the acquisitions was immaterial to our consolidated financial statements.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

*2023 Acquisitions*

*Acquisition of Shield Healthcare*

On October 2, 2023, we acquired a 90% voting equity interest in Shield Healthcare, Inc. (“Shield”), a supplier of homecare medical products delivered directly to patients in their homes, for consideration of \$348 million. This acquisition is reported in our Global Distribution and Value-Added Services segment. Shield expands our existing medical business by delivering a diverse range of products, including items such as incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes supplies. Additionally, Shield offers continuous glucose monitoring devices directly to patients in their homes.

The following table aggregates the final fair value, as of the date of the acquisition, of consideration paid and net assets acquired in the Shield acquisition:

	<u>Final Allocation</u>
Acquisition consideration:	
Cash	\$ 289
Deferred consideration	22
Redeemable noncontrolling interests	37
Total consideration	<u>\$ 348</u>
Identifiable assets acquired and liabilities assumed:	
Current assets	\$ 41
Intangible assets	166
Other noncurrent assets	16
Current liabilities	(24)
Deferred income taxes	(43)
Other noncurrent liabilities	(7)
Total identifiable net assets	<u>149</u>
Goodwill	199
Total net assets acquired	<u>\$ 348</u>

Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of Shield. The acquired goodwill is not deductible for tax purposes.

The following table summarizes the identifiable intangible assets acquired as part of the acquisition of Shield:

	<u>2023</u>	<u>Weighted Average Useful Lives (in years)</u>
Customer relationships and lists	\$ 156	12
Trademarks / Tradenames	10	5
Total	<u>\$ 166</u>	

Pro forma financial information and Shield’s revenue and earnings from the acquisition date have not been presented because the impact of the Shield acquisition was immaterial to our consolidated financial statements.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

*Acquisition of S.I.N. Implant System*

On July 5, 2023, we acquired a 100% voting equity interest in S.I.N. Implant System (“S.I.N.”) for consideration of \$329 million. This acquisition is reported in our Global Specialty Products segment. Based in São Paulo, S.I.N. manufactures an extensive line of products to perform dental implant procedures and is focused on advancing the development of value-priced dental implants. In 2023, S.I.N. expanded the distribution of its products into the United States and other international markets.

The following table aggregates the final fair value, as of the date of acquisition, of consideration paid and net assets acquired in the S.I.N. acquisition:

	<u>Final Allocation</u>
Acquisition consideration:	
Cash	\$ 329
Total consideration	<u>\$ 329</u>
Identifiable assets acquired and liabilities assumed:	
Current assets	\$ 73
Intangible assets	87
Other noncurrent assets	48
Current liabilities	(33)
Long-term debt	(22)
Deferred income taxes	(38)
Other noncurrent liabilities	<u>(27)</u>
Total identifiable net assets	88
Goodwill	<u>241</u>
Total net assets acquired	<u>\$ 329</u>

Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of S.I.N. The acquired goodwill is not deductible for tax purposes.

The following table summarizes the identifiable intangible assets acquired as part of the acquisition of S.I.N.:

	<u>2023</u>	<u>Weighted Average Useful Lives (in years)</u>
Customer relationships and lists	\$ 38	7
Product development	36	8
Trademarks / Tradenames	13	10
Total	<u>\$ 87</u>	

Pro forma financial information and S.I.N.’s revenue and earnings from the acquisition date have not been presented because the impact of the S.I.N. acquisition was immaterial to our consolidated financial statements.

*Acquisition of Biotech Dental*

On April 5, 2023, we acquired a 57% voting equity interest in Biotech Dental, a provider of dental implants, clear aligners, individualized prosthetics and innovative digital dental software based in France, for preliminary consideration of \$423 million. This acquisition is reported in our Global Specialty Products segment. Biotech Dental has several important solutions for dental practices and dental labs, including Nemotec, a comprehensive, integrated suite of planning and diagnostic software using open architecture that connects disparate medical devices to create a digital view of the patient, offering greater diagnostic accuracy and an improved patient experience.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

The following table aggregates the final fair value, as of the date of acquisition, of consideration paid and net assets acquired in the Biotech Dental acquisition:

	<u>Final Allocation</u>
Acquisition consideration:	
Cash	\$ 216
Fair value of contributed equity share in a controlled subsidiary	25
Redeemable noncontrolling interests	182
Total consideration	<u>\$ 423</u>
Identifiable assets acquired and liabilities assumed:	
Current assets	\$ 74
Intangible assets	189
Other noncurrent assets	69
Current liabilities	(60)
Long-term debt	(73)
Deferred income taxes	(53)
Other noncurrent liabilities	(20)
Total identifiable net assets	<u>126</u>
Goodwill	<u>297</u>
Total net assets acquired	<u>\$ 423</u>

Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of Biotech Dental. The acquired goodwill is not deductible for tax purposes.

The following table summarizes the identifiable intangible assets acquired as part of the acquisition of Biotech Dental:

	<u>2023</u>	<u>Weighted Average Useful Lives (in years)</u>
Product development	\$ 124	10
Customer relationships and lists	47	9
Trademarks / Tradenames	18	7
Total	<u>\$ 189</u>	

Pro forma financial information and Biotech's revenues and earnings from the acquisition date have not been presented because the impact of the Biotech Dental acquisition was immaterial to our consolidated financial statements.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

*Other 2023 Acquisitions*

During the year ended December 30, 2023, in addition to those noted above, we acquired companies within the Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments for total consideration of \$284 million. Our acquired ownership interest ranged between 51% to 100%. During the year ended December 30, 2023, in connection with the acquisition of a controlling interest of an affiliate, we recognized a gain of approximately \$18 million related to the remeasurement to fair value of our previously held equity investment, using a discounted cash flow model based on Level 3 inputs, as defined in Note 11 – Fair Value Measurements.

Goodwill of \$171 million from these acquisitions is a result of the synergies and cross-selling opportunities that these acquisitions are expected to provide for us, as well as the expected growth potential. The majority of the acquired goodwill is deductible for tax purposes. Intangible assets of \$116 million, consisting of \$79 million of customer relationships and lists, \$8 million of trademarks and tradenames, \$7 million of product development, and other of \$22 million are being amortized over their weighted average useful lives that range from two years to ten years.

Pro forma financial information for our 2023 acquisitions has not been presented because the impact of the acquisitions was immaterial to our consolidated financial statements.

*Acquisition Costs*

During the years ended December 27, 2025, December 28, 2024 and December 30, 2023 we incurred \$6 million, \$6 million and \$22 million in acquisition costs, respectively. These costs are included in selling, general and administrative in our consolidated statements of income.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 6 – Inventories, Net**

Inventories, net consisted of the following as of:

<u>Description</u>	<u>December 27, 2025</u>	<u>December 28, 2024</u>
Finished goods	\$ 1,889	\$ 1,710
Raw materials	70	61
Work-in process	<u>43</u>	<u>39</u>
Inventories, net	<u>\$ 2,002</u>	<u>\$ 1,810</u>

Our inventory reserve was \$131 million and \$132 million as of December 27, 2025 and December 28, 2024, respectively.

**Note 7 – Property and Equipment, Net**

Property and equipment, including related estimated useful lives, consisted of the following as of:

	<u>December 27, 2025</u>	<u>December 28, 2024</u>
Land	\$ 22	\$ 20
Buildings and permanent improvements	187	164
Leasehold improvements	125	109
Machinery and warehouse equipment	307	257
Furniture, fixtures and other	137	128
Computer equipment and software	<u>602</u>	<u>523</u>
	1,380	1,201
Less accumulated depreciation and amortization	<u>(759)</u>	<u>(670)</u>
Property and equipment, net	<u>\$ 621</u>	<u>\$ 531</u>

	<u>Estimated Useful Lives (in years)</u>
Buildings and permanent improvements	40
Machinery and warehouse equipment	5-15
Furniture, fixtures and other	3-10
Computer equipment and software	3-10

Leasehold improvements are amortized on a straight-line basis over the lesser of the useful life of the assets or the remaining lease term.

Property and equipment related depreciation expense for the years ended December 27, 2025, December 28, 2024 and December 30, 2023, was \$101 million, \$83 million and \$70 million, respectively. Please see Note 8 – Leases for finance lease amounts included in property and equipment, net within our consolidated balance sheets.

During the year ended December 30, 2023 we recorded a \$27 million impairment of capitalized software, related to the Global Distribution and Value-Added Services segment.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 8 – Leases**

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles and certain equipment. Our leases have remaining terms of less than one year to approximately 23 years, some of which may include options to extend the leases for up to 10 years. The components of lease expense were as follows:

	Years Ended		
	December 27, 2025	December 28, 2024	December 30, 2023
Operating lease cost:	\$ 94	\$ 107	\$ 99
Variable lease cost	11	12	12
Short-term lease cost	10	11	10
Total operating lease cost <sup>(1)</sup>	115	130	121
Finance lease cost	3	4	5
Total lease cost	\$ 118	\$ 134	\$ 126

(1) Total operating lease cost for the years ended December 27, 2025, December 28, 2024 and December 30, 2023, included costs of \$3 million, \$17 million and \$11 million, respectively, related to facility leases recorded in restructuring and related costs within our consolidated statements of income.

Further, for the year ended December 27, 2025 we recognized a gain of \$4 million on early lease termination related to facility leases which was recorded in restructuring and related costs within our consolidated statement of income. For the years ended December 28, 2024 and December 30, 2023, we recognized a net impairment of operating lease right-of-use assets of \$0 million and \$3 million respectively, related to facility leases recorded in restructuring and related costs within our consolidated statement of income.

Supplemental balance sheet information related to leases is as follows:

	Years Ended	
	December 27, 2025	December 28, 2024
Operating Leases:		
Operating lease right-of-use assets	\$ 301	\$ 293
Current operating lease liabilities	78	75
Non-current operating lease liabilities	251	259
Total operating lease liabilities	\$ 329	\$ 334
Finance Leases:		
Property and equipment, at cost	\$ 14	\$ 16
Accumulated depreciation	(7)	(9)
Property and equipment, net of accumulated depreciation	\$ 7	\$ 7
Current maturities of long-term debt	\$ 3	\$ 3
Long-term debt	4	3
Total finance lease liabilities	\$ 7	\$ 6
Weighted Average Remaining Lease Term in Years:		
Operating leases	5.6	5.9
Finance leases	2.9	2.7
Weighted Average Discount Rate:		
Operating leases	4.5%	4.2%
Finance leases	4.5%	4.4%

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

Supplemental cash flow information related to leases is as follows:

	<b>Years Ended</b>	
	<b>December 27, 2025</b>	<b>December 28, 2024</b>
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 99	\$ 94
Financing cash flows for finance leases	3	4
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	\$ 71	\$ 76
Finance leases	3	2

Maturities of lease liabilities are as follows:

	<b>December 27, 2025</b>	
	<b>Operating Leases</b>	<b>Finance Leases</b>
2026	\$ 91	\$ 3
2027	74	2
2028	59	1
2029	47	1
2030	37	-
Thereafter	63	-
Total future lease payments	371	7
Less imputed interest	42	-
Total	<u>\$ 329</u>	<u>\$ 7</u>

As of December 27, 2025, we have additional operating leases that have not yet commenced with total lease payments of \$23 million for buildings and vehicles. These operating leases will commence after December 27, 2025, with lease terms of less than one year to ten years.

Certain of our facilities related to our acquisitions are leased from employees and minority shareholders. These leases are classified as operating leases and have a remaining lease term ranging from less than a year to 12 years. As of December 27, 2025, current and non-current liabilities associated with related party operating leases were \$5 million and \$22 million, respectively. At December 27, 2025, related party leases represented 6.6% and 8.7% of the total current and non-current operating lease liabilities, respectively. As of December 28, 2024, current and non-current liabilities associated with related party operating leases were \$6 million and \$20 million, respectively. At December 28, 2024 related party leases represented 7.6% and 7.8% of the total current and non-current operating lease liabilities, respectively.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 9 – Goodwill and Other Intangibles, Net**

Changes in the carrying amounts of goodwill for the years ended December 27, 2025 and December 28, 2024 were as follows:

	<b>Global Distribution and Value-Added Services</b>	<b>Global Specialty Products</b>	<b>Global Technology</b>	<b>Total</b>
Balance as of December 30, 2023	\$ 2,007	\$ 1,077	\$ 791	\$ 3,875
Adjustments to goodwill:				
Acquisitions	41	107	-	148
Impairment	-	(11)	(2)	(13)
Foreign currency translation	(39)	(80)	(4)	(123)
Balance as of December 28, 2024	2,009	1,093	785	3,887
Adjustments to goodwill:				
Acquisitions	49	124	26	199
Disposal	(1)	-	(2)	(3)
Foreign currency translation	49	74	7	130
Balance as of December 27, 2025	<u>\$ 2,106</u>	<u>\$ 1,291</u>	<u>\$ 816</u>	<u>\$ 4,213</u>

In January 2025, we performed a geographical realignment within the Global Distribution and Value-Added Services reportable segment intended to provide increased transparency into the performance of our global distribution businesses and to reflect evolving management oversight and decision-making. As a result of the realignment and the change in reporting units, we reallocated goodwill to each of our new reporting units using a relative fair value approach. The relative fair values of the new reporting units were determined based on a quantitative valuation analysis that considered projected cash flows, market assumptions, and other relevant valuation inputs. Reporting units under the former and new structures of the Global Distribution and Value-Added Services reportable segment were tested for impairment as of January 1, 2025, and it was determined that the fair values of our reporting units more likely than not exceeded their carrying values, resulting in no impairment as of January 1, 2025 under both structures.

In connection with our restructuring initiatives, during the year ended December 28, 2024, we recorded an \$11 million impairment of goodwill in the Global Specialty Products segment, relating to the disposal of a portion of a business; such impairment was calculated based on the relative fair value of goodwill.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

Other intangible assets consisted of the following:

	<b>December 27, 2025</b>			
	<b>Cost</b>	<b>Accumulated Amortization</b>	<b>Net</b>	<b>Weighted Average Life (in years)</b>
Customer relationships and lists	\$ 971	\$ (408)	\$ 563	10
Trademarks / Tradenames	205	(96)	109	8
Product development	438	(120)	318	9
Non-compete agreements	18	(5)	13	5
Other	24	(9)	15	15
Total	<u>\$ 1,656</u>	<u>\$ (638)</u>	<u>\$ 1,018</u>	

	<b>December 28, 2024</b>			
	<b>Cost</b>	<b>Accumulated Amortization</b>	<b>Net</b>	<b>Weighted Average Life (in years)</b>
Customer relationships and lists	\$ 915	\$ (356)	\$ 559	10
Trademarks / Tradenames	188	(89)	99	8
Product development	403	(71)	332	9
Non-compete agreements	21	(6)	15	4
Other	28	(10)	18	15
Total	<u>\$ 1,555</u>	<u>\$ (532)</u>	<u>\$ 1,023</u>	

Trademarks, trade names, customer lists and customer relationships were established through business acquisitions and are amortized on a straight-line basis over their respective asset life. Non-compete agreements represent amounts paid primarily to prior owners of acquired businesses and certain sales persons, in exchange for placing restrictions on their ability to pose a competitive risk to us. Such amounts are amortized, on a straight-line basis over the respective non-compete period, which generally commences upon termination of employment or separation from us.

Amortization expense, excluding impairment charges, related to definite-lived intangible assets for the years ended December 27, 2025, December 28, 2024 and December 30, 2023, was \$180 million, \$185 million and \$152 million, respectively.

During the year ended December 27, 2025, we recorded \$16 million of impairment charges related to businesses in our Global Distribution and Value-Added Services segment. The impairment charges included \$14 million primarily related to customer lists and relationships attributable to lower than anticipated operating margins in these businesses. The remaining impairment charges of \$2 million related to trade names and non-compete agreements.

During the year ended December 28, 2024, we recorded \$4 million of impairment charges related to businesses in our Global Distribution and Value-Added Services segment. It included \$2 million of a trade name impairment, calculated using the relative fair value, related to a disposal of a business, and \$1 million related to trade name impairment due to business integration in connection with our restructuring initiatives. The remaining \$1 million impairment charges related to trade names and non-compete agreements.

During the year ended December 30, 2023, we recorded \$19 million of impairment charges related to businesses in our Global Distribution and Value-Added Services segment, consisting of \$7 million primarily related to customer lists and relationships attributable to lower than anticipated operating margins in certain businesses, and a \$12 million charge related to the planned exit of a business in connection with our restructuring initiatives.

The impairment charges for the years ended December 27, 2025, December 28, 2024, and December 30, 2023 were measured as the excess of the carrying values over the estimated fair values of the related intangible assets, determined using discounted estimates of future cash flows and the relief-from-royalty method.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

Please see Note 16 – Plans of Restructuring and Related Costs for additional details.

The above intangible asset impairment charges were recorded within selling, general and administrative expenses and in restructuring and related costs in our consolidated statement of income.

The annual amortization expense expected to be recorded for existing intangibles assets for the years 2026 through 2030 is \$172 million, \$159 million, \$142 million, \$128 million and \$118 million.

**Note 10 – Investments and Other**

Investments and other consisted of the following:

	<u>December 27,</u> <u>2025</u>	<u>December 28,</u> <u>2024</u>
Investments in unconsolidated affiliates	\$ 174	\$ 170
Non-current deferred foreign, state and local income taxes	92	47
Notes receivable <sup>(1)</sup>	56	63
Capitalized costs for software and cloud based applications for external use	112	90
Security deposits	4	4
Acquisition-related indemnification assets	39	39
Non-current pension assets	11	9
Non-current inventory	38	27
Other	72	52
Total	<u>\$ 598</u>	<u>\$ 501</u>

(1) Long-term notes receivable carry interest rates ranging from 3.0% to 11.8% and are due in varying installments through May 31, 2031.

Amortization expense, related to capitalized costs for software to be sold, leased or marketed to external users, and for cloud-based applications used to deliver our services, for the years ended December 27, 2025, December 28, 2024 and December 30, 2023, was \$30 million, \$29 million and \$26 million, respectively, and is included in the selling, general and administrative line within our consolidated statements of income.

During the year ended December 28, 2024 we recorded a \$12 million impairment of capitalized software costs, related to the Global Technology segment.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

**Note 11 – Fair Value Measurements**

The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values.

*Investments and notes receivable*

There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable. Certain of our notes receivable contain variable interest rates. We believe the carrying amounts of the notes receivable are a reasonable estimate of fair value based on the interest rates in the applicable markets. Our notes receivable fair value is based on Level 3 inputs within the fair value hierarchy.

*Debt*

The fair value of our debt (including bank credit lines, current maturities of long-term debt and long-term debt) is based on Level 3 inputs within the fair value hierarchy, and as of December 27, 2025 and December 28, 2024 was estimated at \$3,107 million and \$2,536 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads.

*Derivative contracts*

Derivative contracts are valued using quoted market prices and significant other observable inputs. Our derivative instruments primarily include foreign currency forward contracts, interest rate swaps and total return swaps.

The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which are based on market rates for comparable transactions that are classified within Level 2 of the fair value hierarchy.

The fair value of the interest rate swap, which is classified within Level 2 of the fair value hierarchy, is determined by comparing our contract rate to a forward market rate as of the valuation date.

The fair value of total return swaps is determined by valuing the underlying exchange traded funds of the swap using market-on-close pricing by industry providers as of the valuation date that are classified within Level 2 of the fair value hierarchy.

*Redeemable noncontrolling interests*

The values for redeemable noncontrolling interests are based on recent transactions and/or implied multiples of earnings that are classified within Level 3 of the fair value hierarchy. See Note 20 – Redeemable Noncontrolling Interests for additional information.

*Intangible Assets*

Assets measured on a non-recurring basis at fair value include intangibles. Inputs for measuring intangibles are classified as Level 3 within the fair value hierarchy. See Note 1 – Basis of Presentation and Significant Accounting Policies and Note 9 – Goodwill and Other Intangibles, Net for additional information.

*Defined Benefit Plans*

Assets of our defined benefit plans are measured on a recurring basis and are classified as Level 1 within the fair value hierarchy. See Note 19 – Employee Benefit Plans for additional information.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

*Contingent Consideration*

We estimate the fair value of contingent consideration payments as part of the acquisition price and record the estimated fair value of contingent consideration as a liability on our consolidated balance sheet. For transactions accounted for as business combinations, subsequent changes in the estimated fair value of contingent consideration payments are included in selling, general and administrative expenses in our consolidated statements of income (see Note 5 – Business Acquisitions). For transactions involving changes in our ownership in consolidated subsidiaries without a change in our control, subsequent changes in the estimated fair value of contingent consideration payments are recognized in additional paid-in capital in our consolidated balance sheet. We measure contingent consideration at the fair value on a recurring basis using significant unobservable inputs classified as Level 3 of the fair value hierarchy. We use various valuation techniques, including the Monte Carlo simulation and probability-weighted scenarios, to determine the fair value of the contingent consideration liabilities on the acquisition date and at each reporting period. Our fair value measurement inputs include expected operating performance, discount and risk-free rates, and credit spread.

Contingent consideration is remeasured to fair value at each reporting period. During the year ended December 27, 2025, we updated the fair value of contingent consideration in connection with 2025 and 2023 business acquisitions, which resulted in expense of \$9 million and income of \$11 million, respectively. During the year ended December 28, 2024, we updated the fair value of contingent consideration in connection with 2023 and 2022 business acquisitions, which resulted in expense of \$38 million and \$7 million, respectively. These changes were recorded in selling, general and administrative in the consolidated statements of income. During the year ended December 27, 2025, we also updated the fair value of contingent consideration related to changes in ownership. These changes were recorded within additional paid-in-capital in the consolidated balance sheets.

The components of the change in the fair value of contingent consideration for the year ended December 27, 2025 and December 28, 2024 are presented in the following table:

	<b>Years Ended</b>	
	<b>December 27, 2025</b>	<b>December 28, 2024</b>
Balance, beginning of period	\$ 30	\$ 6
Increase in contingent consideration due to business acquisitions and acquisitions of noncontrolling interests in subsidiaries	103	10
Decrease in contingent consideration due to payments	(19)	(31)
Change in fair value of contingent consideration in connection with business acquisitions	(2)	45
Change in fair value of contingent consideration in connection with changes in ownership in consolidated subsidiaries	(15)	-
Balance, end of period	<u>\$ 97</u>	<u>\$ 30</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 27, 2025 and December 28, 2024:

	<b>December 27, 2025</b>			
	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Assets:</b>				
Derivative contracts designated as hedges	\$ -	\$ 1	\$ -	\$ 1
Derivative contracts undesignated	-	1	-	1
Total return swap	-	1	-	1
Total assets	<u>\$ -</u>	<u>\$ 3</u>	<u>\$ -</u>	<u>\$ 3</u>
<b>Liabilities:</b>				
Derivative contracts designated as hedges	\$ -	\$ 23	\$ -	\$ 23
Derivative contracts undesignated	-	2	-	2
Contingent consideration	-	-	97	97
Total liabilities	<u>\$ -</u>	<u>\$ 25</u>	<u>\$ 97</u>	<u>\$ 122</u>
Redeemable noncontrolling interests	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 895</u>	<u>\$ 895</u>
<b>December 28, 2024</b>				
	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Assets:</b>				
Derivative contracts designated as hedges	\$ -	\$ 10	\$ -	\$ 10
Derivative contracts undesignated	-	7	-	7
Total assets	<u>\$ -</u>	<u>\$ 17</u>	<u>\$ -</u>	<u>\$ 17</u>
<b>Liabilities:</b>				
Derivative contracts designated as hedges	\$ -	\$ 5	\$ -	\$ 5
Derivative contracts undesignated	-	4	-	4
Total return swap	-	3	-	3
Contingent consideration	-	-	30	30
Total liabilities	<u>\$ -</u>	<u>\$ 12</u>	<u>\$ 30</u>	<u>\$ 42</u>
Redeemable noncontrolling interests	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 806</u>	<u>\$ 806</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

**Note 12 – Concentrations of Risk**

Certain financial instruments potentially subject us to concentrations of credit risk. These financial instruments consist primarily of cash equivalents, trade receivables, long-term investments, notes receivable and derivative instruments. In all cases, our maximum exposure to loss from credit risk equals the gross fair value of the financial instruments. We routinely maintain cash balances at financial institutions in excess of insured amounts. We have not experienced any loss in such accounts and we manage this risk through maintaining cash deposits and other highly liquid investments in high quality financial institutions. We continuously assess the need for reserves for such losses, which have been within our expectations. We do not require collateral or other security to support financial instruments subject to credit risk, except for long-term notes receivable.

We limit credit risk with respect to our cash equivalents, short-term and long-term investments and derivative instruments, by monitoring the credit worthiness of the financial institutions who are the counter-parties to such financial instruments. As a risk management policy, we limit the amount of credit exposure by diversifying and utilizing numerous investment grade counterparties.

With respect to our trade receivables, credit risk is somewhat limited due to a relatively large customer base and its dispersion across different types of health care professionals and geographic areas. No single customer accounted for more than 2% of our net sales in each of the years ended December 27, 2025, December 28, 2024 or December 30, 2023. With respect to our sources of supply, our top 10 Global Distribution and Value-Added Services suppliers and our single largest supplier accounted for approximately 24% and 4%, respectively, of our aggregate purchases for the year ended December 27, 2025 and approximately 25% and 4%, respectively, of our aggregate purchases for the year ended December 28, 2024.

Our long-term notes receivable primarily represent strategic financing arrangements with certain affiliates. Generally, these notes are secured by certain assets of the counterparty; however, in most cases our security is subordinate to the rights of other commercial financial institutions. While we have exposure to credit loss in the event of non-performance by these counterparties, we conduct ongoing assessments of their financial and operational performance.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

**Note 13 – Derivatives and Hedging Activities**

We are exposed to market risks and changes in foreign currency exchange rates against the U.S. dollar and each other, and changes to the credit risk of the derivative counterparties. We attempt to minimize these risks using foreign currency forward contracts and by maintaining counter-party credit limits. Our hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter are for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into foreign currency forward contracts for speculative purposes and we manage our credit risks by diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital. Our derivative instruments primarily include foreign currency forward contracts, total return swaps, and interest rate swaps.

During 2019 we entered foreign currency forward contracts that we designated as net investment hedges to hedge a portion of our euro-denominated foreign operations. These net investment hedges offset changes in the U.S. dollar value of our investments in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates. Gains and losses related to these net investment hedges are recorded in accumulated other comprehensive loss within our consolidated balance sheets. Amounts excluded from the assessment of hedge effectiveness are included in interest expense within our consolidated statements of income. The aggregate notional value of these net investment hedges, which matured on November 16, 2023, was approximately €200 million. On November 3, 2023 we entered into new foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. The aggregate notional value of this net investment hedge, which matures on November 3, 2028, is approximately €300 million. During the years ended December 27, 2025, December 28, 2024, and December 30, 2023, we recorded an increase/(decrease) of \$(33) million, \$10 million, and \$(32) million, respectively, within other comprehensive income related to these foreign currency forward contracts. See Note 11 – Fair Value Measurements for additional information.

On March 20, 2020, we entered a total return swap to economically hedge our unfunded non-qualified SERP and our DCP. This swap will offset changes in our SERP and DCP liabilities. At the swap's inception, the notional value of the investments in these plans was \$43 million. At December 27, 2025, the notional value of the investments in these plans was \$117 million. At December 27, 2025, the financing blended rate for this swap was based on the Secured Overnight Financing Rate ("SOFR") of 3.79% plus 0.75%, for a combined rate of 4.54%. For the years ended December 27, 2025, December 28, 2024, and December 30, 2023, we recorded within selling, general and administrative expenses in our consolidated statement of income, a gain of \$11 million, 8 million, and \$10 million, respectively, net of transaction costs, related to this undesignated swap. See Note 19 – Employee Benefit Plans for additional information.

On July 11, 2023, we entered into interest rate swap agreements to hedge the cash flow of our variable rate \$750 million floating debt term loan facility, with three years maturity, effectively changing the floating rate portion of our obligation to a fixed rate. Under the terms of the interest rate swap agreements, we receive variable interest payments based on the one-month Term SOFR rate and pay interest at a fixed rate. As of December 27, 2025, the notional value of the interest rate swap agreements was \$675 million. For the years ended December 27, 2025 and December 28, 2024, we recorded, within accumulated other comprehensive loss within our consolidated balance sheets, a loss of \$3 million and \$3 million, respectively, related to the change in the fair value of these interest rate swap agreements, since we have designated these swap agreements as cash flow hedges.

Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward contracts to protect against currency

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we consider foreign currency translation to be an accounting exposure, not an economic exposure. Amounts related to our hedging activities are recorded in prepaid expenses and other and/or accrued expenses: other within our consolidated balance sheets.

The following table summarizes the terms and fair value of our outstanding derivative financial instruments as of December 27, 2025 and December 28, 2024:

<b>December 27, 2025</b>				
	<b>Notional Amount</b>	<b>Classification</b>	<b>Fair Value</b>	<b>Maturity Date</b>
Derivatives used in cash flow hedges:				
Foreign currency forward contracts	\$ 98	Prepaid expenses and other	\$ -	December 24, 2026
Interest rate swaps	675	Accrued expenses, other	(3)	July 13, 2026
Derivatives used in net investment hedges:				
Foreign currency forward contracts	365	Accrued expenses, other	(19)	November 3, 2028
Undesignated hedging relationships:				
Total return swaps	116	Prepaid expenses and other	1	December 30, 2025
Total	\$ 1,254		\$ (21)	

<b>December 28, 2024</b>				
	<b>Notional Amount</b>	<b>Classification</b>	<b>Fair Value</b>	<b>Maturity Date</b>
Derivatives used in cash flow hedges:				
Foreign currency forward contracts	\$ 84	Prepaid expenses and other	\$ -	October 30, 2025
Interest rate swaps	713	Accrued expenses, other	(3)	July 13, 2026
Derivatives used in net investment hedges:				
Foreign currency forward contracts	336	Prepaid expenses and other	9	November 3, 2028
Undesignated hedging relationships:				
Total return swaps	106	Accrued expenses, other	(3)	December 30, 2024
Total	\$ 1,239		\$ 3	

The following table summarizes the effect of cash flow hedges and net investment hedges on our consolidated statements of income for the years ended December 27, 2025, December 28, 2024 and December 30, 2023:

	<b>Years Ended</b>		
	<b>December 27, 2025</b>	<b>December 28, 2024</b>	<b>December 30, 2023</b>
Derivatives used in cash flow hedges:			
Foreign currency forward contracts	\$ -	\$ -	\$ (1)
Interest rate swaps	-	6	(7)
Derivatives used in net investment hedges:			
Foreign currency forward contracts	(24)	7	(10)
Total	\$ (24)	\$ 13	\$ (18)

The amount of gains or losses reclassified from accumulated other comprehensive loss into income were not material for the years ended December 27, 2025, December 28, 2024, and December 30, 2023.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 14 – Debt**

*Bank Credit Lines*

Bank credit lines consisted of the following:

	<u>December 27, 2025</u>	<u>December 28, 2024</u>
Revolving credit agreement	\$ 100	\$ -
Other short-term bank credit lines	664	650
Total	<u>\$ 764</u>	<u>\$ 650</u>

*Revolving Credit Agreement*

On August 20, 2021, we entered into a \$1.0 billion revolving credit agreement (the “Revolving Credit Agreement”) which was amended and restated on July 11, 2023 to extend the maturity date to July 11, 2028 and update the interest rate provisions to reflect the current market approach for a multicurrency facility. On June 6, 2025, we amended and restated the Revolving Credit Agreement to, among other things, modify certain financial definitions and covenants. The interest rate on this revolving credit facility is based on Term Secured Overnight Financing Rate (“Term SOFR”) plus a spread based on our leverage ratio at the end of each financial reporting quarter. As of December 27, 2025 the interest rate on this revolving credit facility was 3.78% plus 1.08% for a combined rate of 4.86%. As of December 28, 2024 the interest rate on this revolving credit facility was 4.45% plus 1.18% for a combined rate of 5.63%.

The Revolving Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Revolving Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of December 27, 2025 and December 28, 2024, we had \$100 million and \$0 million in borrowings, respectively, under this revolving credit facility. During the year ended December 27, 2025, the average outstanding balance under the Revolving Credit Agreement was approximately \$203 million. As of December 27, 2025 and December 28, 2024, there were \$10 million and \$11 million of letters of credit, respectively, provided to third parties under the Revolving Credit Agreement.

*Other Short-Term Bank Credit Lines*

As of December 27, 2025 and December 28, 2024, we had various other short-term bank credit lines available, in various currencies, with a maximum borrowing capacity of \$787 million and \$790 million, respectively. As of December 27, 2025 and December 28, 2024, \$664 million and \$650 million, respectively, were outstanding. During the year ended December 27, 2025, the average outstanding balances under our various other short-term bank credit lines was approximately \$680 million. As of December 27, 2025 and December 28, 2024, borrowings under other short-term bank credit lines had weighted average interest rates of 4.68% and 5.35%, respectively.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

*Long-term debt*

Long-term debt consisted of the following:

	<b>December 27, 2025</b>	<b>December 28, 2024</b>
Private placement facilities	\$ 1,149	\$ 975
Term loan	749	712
U.S. trade accounts receivable securitization	390	150
Various collateralized and uncollateralized loans payable with interest, in varying installments through 2031 at interest rates from 0.00% to 6.75% at December 27, 2025 and from 0.00% to 9.42% at December 28, 2024	48	43
Finance lease obligations	7	6
Total	2,343	1,886
Less current maturities	(33)	(56)
Total long-term debt	\$ 2,310	\$ 1,830

As of December 27, 2025, the aggregate amounts of long-term debt, including finance lease obligations and net of deferred debt issuance costs, maturing in each of the next five years and thereafter are as follows:

2026		\$ 33
2027		534
2028		221
2029		143
2030		810
Thereafter		602
Total		\$ 2,343

*Private Placement Facilities*

Our private placement facilities provided by four insurance companies have a total facility amount of \$1.5 billion, and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through December 19, 2028. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness, and/or to fund potential acquisitions. On December 19, 2025, we amended and restated our private placement facilities to, among other things, (i) extend the scheduled facility termination dates to December 19, 2028 and (ii) modify certain financial definitions and covenants. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

The components of our private placement facility borrowings as of December 27, 2025, which have a weighted average interest rate of 3.93% are presented in the following table:

<u>Date of Borrowing</u>	<u>Amount of Borrowing Outstanding</u>	<u>Borrowing Rate</u>	<u>Due Date</u>
June 16, 2017	\$ 100	3.42%	June 16, 2027
September 15, 2017	100	3.52	September 15, 2029
January 2, 2018	100	3.32	January 2, 2028
September 2, 2020	100	2.35	September 2, 2030
June 2, 2021	100	2.48	June 2, 2031
June 2, 2021	100	2.58	June 2, 2033
May 4, 2023	75	4.79	May 4, 2028
May 4, 2023	75	4.84	May 4, 2030
May 4, 2023	75	4.96	May 4, 2033
May 4, 2023	150	4.94	May 4, 2033
December 15, 2025	100	5.23	December 15, 2032
December 15, 2025	75	5.28	December 15, 2032
Less: Deferred debt issuance costs	(1)		
Total	<u>\$ 1,149</u>		

The components of our private placement facility borrowings as of December 28, 2024, which have a weighted average interest rate of 3.70% are presented in the following table:

<u>Date of Borrowing</u>	<u>Amount of Borrowing Outstanding</u>	<u>Borrowing Rate</u>	<u>Due Date</u>
June 16, 2017	\$ 100	3.42%	June 16, 2027
September 15, 2017	100	3.52	September 15, 2029
January 2, 2018	100	3.32	January 2, 2028
September 2, 2020	100	2.35	September 2, 2030
June 2, 2021	100	2.48	June 2, 2031
June 2, 2021	100	2.58	June 2, 2033
May 4, 2023	75	4.79	May 4, 2028
May 4, 2023	75	4.84	May 4, 2030
May 4, 2023	75	4.96	May 4, 2033
May 4, 2023	150	4.94	May 4, 2033
Total	<u>\$ 975</u>		

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

*Term Loan*

On July 11, 2023, we entered into a three-year \$750 million term loan credit agreement (the “Term Credit Agreement”), which was originally scheduled to mature on July 11, 2026. On June 6, 2025, this agreement was amended and restated to, among other things, (i) extend the maturity date to June 6, 2030, and (ii) modify certain financial definitions and covenants. The interest rate on this term loan is based on the Term SOFR plus a spread based on our leverage ratio at the end of each financial reporting quarter. Beginning in June 2026 and continuing through June 2027, we are required to make quarterly payments of \$5 million. In September 2027, the quarterly payment amount increases to \$9 million, continuing through June 2030 with the remaining balance due June 6, 2030. As of December 27, 2025, the borrowings outstanding under this term loan were \$749 million. At December 27, 2025, the interest rate under the Term Credit Agreement was 3.76% plus 1.25% for a combined rate of 5.01%. As of December 28, 2024, the borrowings outstanding under this term loan were \$712 million. At December 28, 2024, the interest rate under the Term Credit Agreement was 4.45% plus 1.60% for a combined rate of 6.05%. However, at December 28, 2024, we had a hedge in place creating an effective fixed rate of 6.04%. After renewing the Term Credit Agreement in June of 2025, our hedged portion of the Term Credit Agreement is now approximately 90% of the notional total. As of December 27, 2025, the effective fixed rate was 5.69% and the floating rate was 5.01%, resulting in a weighted average rate of 5.62%. The Term Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Term Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements.

*U.S. Trade Accounts Receivable Securitization*

We have a facility agreement based on our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years. On December 6, 2024, we extended the expiration date of this facility agreement to December 6, 2027 (the previous maturity date was December 15, 2025). This facility agreement has a purchase limit of \$450 million with two banks as agents.

As of December 27, 2025 and December 28, 2024, the borrowings outstanding under this securitization facility were \$390 million and \$150 million, respectively. At December 27, 2025, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 4.06% plus 0.75%, for a combined rate of 4.81%. At December 28, 2024, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 4.73% plus 0.75%, for a combined rate of 5.48%.

If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced.

We are required to pay a commitment fee of 30 to 35 basis points depending upon program utilization.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 15 – Income Taxes**

Income before taxes and equity in earnings of affiliates was as follows:

	Years ended		
	December 27, 2025	December 28, 2024	December 30, 2023
Domestic	\$ 384	\$ 338	\$ 424
Foreign	149	175	118
Total	<u>\$ 533</u>	<u>\$ 513</u>	<u>\$ 542</u>

The provisions for income taxes were as follows:

	Years ended		
	December 27, 2025	December 28, 2024	December 30, 2023
Current income tax expense:			
U.S. Federal	\$ 42	\$ 100	\$ 72
State and local	15	33	28
Foreign	64	56	40
Total current	<u>121</u>	<u>189</u>	<u>140</u>
Deferred income tax expense (benefit):			
U.S. Federal	33	(29)	9
State and local	3	(12)	(3)
Foreign	(31)	(20)	(26)
Total deferred	<u>5</u>	<u>(61)</u>	<u>(20)</u>
Total provision	<u>\$ 126</u>	<u>\$ 128</u>	<u>\$ 120</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

The tax effects of temporary differences that give rise to our deferred income tax asset (liability) were as follows:

	Years Ended	
	December 27, 2025	December 28, 2024
Deferred income tax asset:		
Net operating losses	\$ 105	\$ 91
Other carryforwards	52	37
Inventory, premium coupon redemptions and accounts receivable valuation allowances	38	37
Operating lease liability	75	76
Capitalization of research and development costs	10	27
Other asset	62	49
Total deferred income tax asset	342	317
Valuation allowance for deferred tax assets <sup>(1)</sup>	(53)	(38)
Net deferred income tax asset	289	279
Deferred income tax liability		
Intangibles amortization	(266)	(260)
Operating lease right-of-use asset	(70)	(67)
Property and equipment	(7)	(7)
Total deferred tax liability	(343)	(334)
Net deferred income tax asset (liability)	\$ (54)	\$ (55)

(1) Primarily relates to operating losses, the benefits of which are uncertain. Any future reductions of such valuation allowances will be reflected as a reduction of income tax expense.

The assessment of the amount of value assigned to our deferred tax assets under the applicable accounting rules is judgmental. We are required to consider all available positive and negative evidence in evaluating the likelihood that we will be able to realize the benefit of our deferred tax assets in the future. Such evidence includes reversals of deferred tax liabilities and projected future taxable income. Since this evaluation requires consideration of events that may occur some years into the future, there is an element of judgment involved. Realization of our deferred tax assets is dependent on generating sufficient taxable income in future periods. We believe that it is more likely than not that future taxable income will be sufficient to allow us to recover substantially all of the value assigned to our deferred tax assets. However, if future events cause us to conclude that it is not more likely than not that we will be able to recover the value assigned to our deferred tax assets, we will be required to adjust our valuation allowance accordingly.

As of December 27, 2025, we had federal, state and foreign net operating loss carryforwards of approximately \$86 million, \$62 million and \$366 million, respectively. The federal, state and foreign net operating loss carryforwards will begin to expire in various years from 2026 through 2045. The amounts of federal, state and foreign net operating losses that can be carried-forward indefinitely are \$86 million, \$21 million and \$358 million, respectively.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

The effective income tax rate for the year ended December 27, 2025 differs from the statutory federal income tax rate as follows:

	<b>Year ended December 27, 2025</b>	
	\$	%
Income tax provision at federal statutory rate	\$ 112	21.0%
State income tax provision, net of federal income tax effect <sup>(1)</sup>	10	2.0
Foreign Tax effects		
Cayman Islands:		
Foreign partnership loss	8	1.5
Other	(1)	(0.1)
Other foreign jurisdictions:		
Equity investment remeasurement gain	(6)	(1.1)
Notional interest deduction	(6)	(1.1)
Other	19	3.5
Effects of changes in tax laws or rates enacted in current period	-	-
Cross-border tax laws	1	0.1
Tax credits	(2)	(0.4)
Changes in valuation allowance	3	0.6
Nontaxable and nondeductible items	3	0.5
Worldwide changes in unrecognized tax benefits	4	0.7
Other adjustments:		
Previously held non-controlling equity investment	(9)	(1.7)
Other	(10)	(1.8)
Effective tax rate	\$ 126	23.7%

(1) State taxes in California, Illinois, Massachusetts, New Jersey, and New York make up the majority (greater than 50%) of the tax effect in this category.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

As previously disclosed for the years ended December 28, 2024 and December 20, 2023, prior to the adoption of ASU 2023-09, the tax provisions differ from the amount computed using the federal statutory income tax rate as follows:

	Years ended	
	December 28, 2024	December 30, 2023
Income tax provision at federal statutory rate	\$ 108	\$ 114
State income tax provision, net of federal income tax effect	11	15
Foreign income tax provision	10	5
Pass-through noncontrolling interest	1	(8)
Valuation allowance	6	(3)
Unrecognized tax benefits and audit settlements	5	9
Interest expense related to loans	(14)	(13)
Effect of cross border tax laws	12	7
Other	(11)	(6)
Total income tax provision	<u>\$ 128</u>	<u>\$ 120</u>

For the year ended December 27, 2025 our effective tax rate was 23.7%, compared to 24.9% for the prior year period. In 2023, our effective tax rate was 22.1%. The difference between our effective and federal statutory tax rates primarily relates to state and foreign income taxes and interest expense, as well as the tax treatment associated with the acquisition of a controlling interest of a previously held non-controlling equity investment.

On July 4, 2025, President Trump signed the reconciliation tax bill, commonly known as the “One Big Beautiful Bill Act” (OBBBA), into law. Corporate provisions in the OBBBA include immediate expensing of domestic research and experimental expenditures, limitations on certain deductions and modifications to international tax provisions. The changes resulting from the OBBBA did not have a significant impact to the total tax provision.

The OECD issued technical and administrative guidance on Pillar Two rules in December 2021, which provides for a global minimum tax rate on the earnings of large multinational businesses on a country-by-country basis. Effective January 1, 2024, the minimum global tax rate is 15% for various jurisdictions pursuant to the Pillar Two rules. Future tax reform resulting from these developments may result in changes to long-standing tax principles, which may adversely impact our effective tax rate going forward or result in higher cash tax liabilities. As of December 27, 2025, the impact of the Pillar Two rules to our financial statements was immaterial.

Due to the one-time transition tax and the imposition of the GILTI provisions, all previously unremitted earnings will no longer be subject to U.S. federal income tax; however, there could be U.S., state and/or foreign withholding taxes upon distribution of such unremitted earnings. Determination of the amount of unrecognized deferred tax liability with respect to such earnings is not practicable.

ASC Topic 740 prescribes the accounting for uncertainty in income taxes recognized in accordance with other provisions contained within its guidance. This topic prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by the taxing authorities. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likelihood of being realized upon ultimate audit settlement. In the normal course of business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

and interest assessments by these taxing authorities for uncertain tax positions taken in respect of certain tax matters.

The total amount of unrecognized tax benefits, which are included in “other liabilities” within our consolidated balance sheets, as of December 27, 2025 and December 28, 2024 was \$112 million and \$108 million, respectively, of which \$104 million and \$100 million, respectively, would affect the effective tax rate if recognized.

All tax returns audited by the IRS are officially closed through 2021. The tax years subject to examination by the IRS include years 2022 and forward. In addition, limited positions reported in the 2017 tax year are subject to IRS examination.

The amount of tax interest expense included as a component of the provision for taxes was \$4 million, \$2 million and \$4 million during the years ended December 27, 2025, December 28, 2024 and December 30, 2023, respectively. The total amount of accrued interest is included in other liabilities within our consolidated balance sheets, and was \$22 million as of December 27, 2025 and \$18 million as of December 28, 2024. The amount of penalties accrued for during the periods presented was not material to our consolidated financial statements.

The following table provides a reconciliation of unrecognized tax benefits:

	<u>December 27,</u> <u>2025</u>	<u>December 28,</u> <u>2024</u>	<u>December 30,</u> <u>2023</u>
Balance, beginning of period	\$ 89	\$ 98	\$ 82
Additions based on current year tax positions	5	5	9
Additions based on prior year tax positions	5	10	26
Reductions based on prior year tax positions	(2)	(14)	(2)
Reductions resulting from settlements with taxing authorities	-	-	(3)
Reductions resulting from lapse in statutes of limitations	(7)	(10)	(14)
Balance, end of period	<u>\$ 90</u>	<u>\$ 89</u>	<u>\$ 98</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 16 – Plans of Restructuring and Related Costs**

On August 6, 2024, we committed to a restructuring plan (the “2024 Plan”) to integrate our acquisitions, right-size operations and further increase efficiencies. We currently expect this plan to be completed at the end of 2027. During the years ended December 27, 2025 and December 28, 2024, we recorded restructuring and related charges associated with the 2024 Plan of \$105 million and \$73 million, respectively. The restructuring and related costs for these periods primarily related to severance and employee-related costs, accelerated amortization of right-of-use assets and fixed assets, and other exit costs. We expect to record restructuring and related charges associated with the 2024 Plan through the end of 2027; however, an estimate of the amount of these charges for 2026 through 2027 has not yet been determined.

During the year ended December 27, 2025, in connection with the 2024 Plan, we recorded a loss of \$1 million and \$12 million related to the disposal of businesses in the Global Distribution and Value-Added Services and Global Specialty Product segments, respectively, and a net gain related to disposal of a business in the Global Technology segment. These amounts are included in the \$105 million of restructuring and related charges discussed above.

During the year ended December 28, 2024, in connection with the 2024 Plan, we recorded an impairment of goodwill and intangible assets of \$13 million related to the disposal of a portion of a business in the Global Specialty Products segment. This impairment is included in the \$73 million of restructuring and related charges discussed above.

On August 1, 2022, we committed to a restructuring plan (the “2022 Plan”) focused on funding the priorities of the BOLD+1 strategic plan, streamlining operations and other initiatives to increase efficiency. The 2022 Plan was completed as of July 31, 2024. During the years ended December 28, 2024 and December 30, 2023, in connection with our 2022 Plan, we recorded restructuring and related costs of \$37 million and \$80 million, respectively, which primarily related to severance and employee-related costs, accelerated amortization of right-of-use assets and fixed assets, and other exit costs.

During the year ended December 30, 2023, in connection with the 2022 Plan, we recorded an impairment of an intangible asset of \$12 million related to disposal of a U.S. business in the Global Specialty Products segment. This impairment is included in the \$80 million of restructuring and related costs discussed above. The disposal was completed during the first quarter of 2024.

Restructuring and related costs recorded for the fiscal years ended 2025, 2024 and 2023 in connection with the 2024 Plan and 2022 Plan, respectively, consisted of the following:

	<b>Year Ended December 27, 2025</b>				
	<b>Global Distribution and Value-Added Services</b>	<b>Global Specialty Products</b>	<b>Global Technology</b>	<b>Corporate</b>	<b>Total</b>
<u>2024 Plan</u>					
Severance and employee-related costs	\$ 40	\$ 22	\$ 4	\$ 20	\$ 86
Impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets	(3)	6	(1)	-	2
Exit and other related costs	5	4	-	-	9
Loss/(Gain) on disposal of a business	1	12	(5)	-	8
Restructuring and related costs-2024 Plan	<u>\$ 43</u>	<u>\$ 44</u>	<u>\$ (2)</u>	<u>\$ 20</u>	<u>\$ 105</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

	<b>Year Ended December 28, 2024</b>				
	<b>Global Distribution and Value-Added Services</b>	<b>Global Specialty Products</b>	<b>Global Technology</b>	<b>Corporate</b>	<b>Total</b>
<i>2024 Plan</i>					
Severance and employee-related costs	\$ 31	\$ 5	\$ 6	\$ 2	\$ 44
Impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets	5	3	4	-	12
Exit and other related costs	2	-	-	-	2
Loss on disposal of a business	-	15	-	-	15
Restructuring and related costs-2024 Plan	\$ 38	\$ 23	\$ 10	\$ 2	\$ 73
<i>2022 Plan</i>					
Severance and employee-related costs	\$ 18	\$ 5	\$ 1	\$ -	\$ 24
Accelerated depreciation and amortization	10	-	-	(3)	7
Exit and other related costs	2	2	-	2	6
Loss on disposal of a business	-	-	-	-	-
Restructuring and related costs-2022 Plan	\$ 30	\$ 7	\$ 1	\$ (1)	\$ 37
Total restructuring and related costs	\$ 68	\$ 30	\$ 11	\$ 1	\$ 110

	<b>Year Ended December 30, 2023</b>				
	<b>Global Distribution and Value-Added Services</b>	<b>Global Specialty Products</b>	<b>Global Technology</b>	<b>Corporate</b>	<b>Total</b>
<i>2022 Plan</i>					
Severance and employee-related costs	\$ 29	\$ 5	\$ 5	\$ 7	\$ 46
Impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets	13	-	2	-	15
Exit and other related costs	3	1	-	2	6
Loss on disposal of a business	-	13	-	-	13
Restructuring and related costs-2022 Plan	\$ 45	\$ 19	\$ 7	\$ 9	\$ 80

The following table summarizes, by plan year, the activity related to the liabilities associated with our restructuring initiatives under the 2022 Plan and the 2024 Plan for the year ended December 27, 2025. The remaining accrued balance of restructuring and related costs as of December 27, 2025, which primarily relates to severance and employee-related costs, is included in accrued expenses: other within our consolidated balance sheets. Liabilities related to exited leased facilities are recorded within our current and non-current operating lease liabilities within our consolidated balance sheets.

	<b>2022 Plan</b>	<b>2024 Plan</b>	<b>Total</b>
Balance, December 30, 2023	\$ 23	\$ -	\$ 23
Restructuring and related costs	37	73	110
Non-cash impairment, accelerated depreciation and amortization	(7)	(12)	(19)
Non-cash impairment on disposal of a business	-	(13)	(13)
Cash payments and other adjustments	(41)	(20)	(61)
Balance, December 28, 2024	12	28	40
Restructuring and related costs	-	105	105
Non-cash impairment, accelerated depreciation and amortization	-	(2)	(2)
Non-cash charges related to disposal of a business	-	(6)	(6)
Cash payments and other adjustments	(11)	(77)	(88)
Balance, December 27, 2025	\$ 1	\$ 48	\$ 49

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 17 – Commitments and Contingencies**

*Purchase Commitments*

In our Global Distribution and Value-Added Services business, we sometimes enter into long-term purchase commitments to ensure the availability of products for distribution. Future minimum annual payments for inventory purchase commitments as of December 27, 2025 were:

2026	\$	8
2027		1
2028		-
2029		-
2030		-
Thereafter		-
Total minimum inventory purchase commitment payments	<u>\$</u>	<u>9</u>

*Employment, Consulting and Non-Compete Agreements*

We have employment, consulting and non-compete agreements that have varying base aggregate annual payments for the years 2026 through 2030 and thereafter of approximately \$13 million, \$3 million, \$0 million, \$0 million, \$0 million, and \$0 million, respectively. We also have lifetime consulting agreements that provide for current compensation of four-hundred thousand dollars per year, with small scheduled increases every fifth year with the next increase in 2027. In addition, some agreements have provisions for additional incentives and compensation.

*Legal Proceedings*

Henry Schein, Inc. was named as a defendant in multiple opioid related lawsuits (currently less than ten (10); one or more of Henry Schein, Inc.'s subsidiaries was also named as a defendant in a number of those cases). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and its subsidiaries) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. The actions that remain have been consolidated within the MultiDistrict Litigation ("MDL") proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed. Of Henry Schein's 2025 net sales of approximately \$13.2 billion, sales of opioids represented less than four-tenths of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions.

From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations.

As of December 27, 2025, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

**Note 18 – Stock-Based Compensation**

Stock-based awards are provided to certain employees under our 2024 Stock Incentive Plan (formerly known as our 2020 Stock Incentive Plan) and to non-employee directors under our 2023 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board (the “Compensation Committee”). Historically, equity-based awards to our employees have been granted solely in the form of time-based and performance-based restricted stock units (“RSUs”) with the exception of our 2021 plan year in which non-qualified stock options were issued in place of performance-based RSUs and in 2022, when we granted time-based and performance-based RSUs, as well as non-qualified stock options. Our non-employee directors receive equity-based awards solely in the form of time-based RSUs with 12-month cliff vesting.

Starting with our 2023 plan year, we returned to granting our employees equity-based awards solely in the form of time-based RSUs (which vest solely based on the recipient’s continued service over time) and performance-based RSUs (which vest based on achieving specified performance measurements and the recipient’s continued service over time).

In our 2025 plan year, stock awards issued to our Chief Executive Officer were allocated 35% to time-based RSU awards with four-year cliff vesting and 65% to performance-based RSU awards with three-year cliff vesting. In our 2025 plan year, stock awards issued to members of our Executive Management Committee were allocated 50% to time-based RSU awards with four-year cliff vesting and 50% to performance-based RSU awards with three-year cliff vesting.

In our 2025 plan year, stock awards issued to our eligible vice-presidents were allocated 80% to time-based RSU awards and 20% to performance-based RSU awards with three-year cliff vesting. Our vice-president level time-based awards will vest 50% on the third anniversary of the grant date with the remaining 50% vesting on the fourth anniversary of the grant date.

In our 2025 plan year, we began granting only time-based RSU awards to our eligible director level employees. Our director level time-based RSU awards will vest 50% on the third anniversary of the grant date with the remaining 50% vesting on the fourth anniversary of the grant date.

For the performance-based RSUs and the time-based RSUs with cliff vesting (issued in 2022-2024 plan years), we recognize the cost as compensation expense on a straight-line basis. For the time-based RSUs with graded vesting (issued in the 2025 plan year), we recognize the cost as compensation expense on an accelerated basis.

As of December 27, 2025, there were 75,742,657 shares authorized and 9,081,164 shares available to be granted under the 2025 Stock Incentive Plan and 2,075,000 shares authorized and 324,753 shares available to be granted under the 2023 Non-Employee Director Stock Incentive Plan.

For all RSUs, we estimate the fair value based on our closing stock price on the grant date. With respect to performance-based RSUs, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant.

Each of the Plans provide for certain adjustments to the performance measurement in connection with awards under the Plans. With respect to the performance-based RSUs granted under our 2024 Stock Incentive Plan, such performance measurement adjustments relate to significant events, including, without limitation, acquisitions, divestitures, new business ventures, changes in fair value of contingent consideration (solely with respect to performance-based RSUs granted in the 2024 and 2025 plan years), certain capital transactions (including share repurchases), differences in budgeted average outstanding shares (other than those resulting from capital

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

transactions referred to above), restructuring and related costs, amortization expense recorded for acquisition-related intangible assets, certain litigation settlements or payments, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets, foreign exchange fluctuations, the financial impact either positive or negative, of the difference in projected earnings generated by COVID-19 test kits (solely with respect to performance-based RSUs granted in the 2023 plan year), intangibles impairment charges and costs related to shareholder advisory matters (solely with respect to performance-based RSUs granted in the 2025 plan year).

Over the performance period, the number of performance-based RSUs that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense is based on our actual performance against the pre-determined performance metrics (in each case as adjusted).

Stock options are awards that allow the recipient to purchase shares of our common stock after vesting at a fixed price set at the time of grant. Stock options were granted at an exercise price equal to our closing stock price on the date of grant. Stock options issued in 2021 and 2022 vest one-third per year based on the recipient's continued service, subject to the terms and conditions of the 2020 Stock Incentive Plan, are fully vested three years from the grant date and have a contractual term of ten years from the grant date, subject to earlier termination of term and term acceleration upon certain events. Compensation expense for stock options is recognized on an accelerated basis. We estimate grant date fair value of stock options using the Black-Scholes valuation model. During the year ended December 27, 2025, we did not grant any stock options.

Our consolidated statements of income reflect pre-tax share-based compensation expense of \$39 million, \$39 million and \$39 million for the years ended December 27, 2025, December 28, 2024 and December 30, 2023, respectively.

Total unrecognized compensation cost related to unvested awards as of December 27, 2025 was \$63 million, which is expected to be recognized over a weighted-average period of approximately 2.5 years.

The weighted-average grant date fair value of stock-based awards granted was \$75.78, \$75.12 and \$76.43 per share during the years ended December 27, 2025, December 28, 2024 and December 30, 2023, respectively.

We record deferred income tax assets for awards that will result in future income tax deductions based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction.

Our consolidated statements of cash flows present our stock-based compensation expense as a reconciling adjustment between net income and net cash provided by operating activities for all periods presented. There were no cash benefits associated with tax deductions in excess of recognized compensation for the years ended December 27, 2025, December 28, 2024 and December 30, 2023.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

The following table summarizes the stock option activity for the year ended December 27, 2025:

	Stock Options			
	Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value
Outstanding at beginning of year	963,491	\$ 72.16		
Granted	-	-		
Exercised	(24,945)	62.71		
Forfeited	(15,831)	81.75		
Outstanding at end of year	<u>922,715</u>	\$ 72.26	5.6 \$	7
Options exercisable at end of year	<u>922,715</u>	\$ 72.26	5.6 \$	7

The following tables summarize the activity of our unvested RSUs for the year ended December 27, 2025:

	Time-Based Restricted Stock Units		Performance-Based Restricted Stock Units	
	Shares/Units	Weighted Average Grant Date Fair Value Per Share	Shares/Units	Weighted Average Grant Date Fair Value Per Share
Outstanding at beginning of period	1,685,550	\$ 72.90	389,111	\$ 75.98
Granted	592,716	75.18	251,287	75.30
Performance adjustment	n/a	n/a	(31,313)	76.20
Vested	(564,037)	66.54	(14,499)	84.04
Forfeited	(107,687)	77.10	(206,626)	77.33
Outstanding at end of period	<u>1,606,542</u>	\$ 75.69	<u>387,960</u>	\$ 75.89

The fair value of time and performance RSUs that vested was \$38 million and \$1 million, respectively, for the year ended December 27, 2025; \$21 million and \$1 million, respectively, for the year ended December 28, 2024; and \$27 million and \$38 million, respectively, for the year ended December 30, 2023.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 19 – Employee Benefit Plans**

*Defined benefit plans*

Certain of our employees in our international markets participate in various noncontributory defined benefit plans. These plans are managed to provide pension benefits to covered employees in accordance with local regulations and practices. Our net unfunded liability for these plans are recorded in accrued expenses: other; and other liabilities within our consolidated balance sheets. The following table presents the changes in projected benefit obligations, plan assets, and the funded status of our defined benefit pension plans:

	<b>Years Ended</b>	
	<b>December 27, 2025</b>	<b>December 28, 2024</b>
Obligation and funded status:		
<b>Change in benefit obligation</b>		
Projected benefit obligation, beginning of period	\$ 129	\$ 125
Service costs	4	4
Interest cost	3	3
Past service cost (credit)	-	(1)
Actuarial gain (loss)	(2)	6
Benefits paid	1	-
Participant contributions	2	2
Settlements and curtailments	(7)	(1)
Effect of foreign currency translation	16	(9)
Projected benefit obligation, end of period	<u>\$ 146</u>	<u>\$ 129</u>
<b>Change in plan assets</b>		
Fair value of plan assets at beginning of period	\$ 90	\$ 86
Actual return on plan assets	1	3
Employer contributions	3	3
Plan participant contributions	2	2
Expected return on plan assets	3	3
Benefit received	4	1
Settlements	(6)	(2)
Effect of foreign currency translation	9	(6)
Fair value of plan assets at end of period	<u>\$ 106</u>	<u>\$ 90</u>
Unfunded status at end of period	<u>\$ 40</u>	<u>\$ 39</u>

The majority of our defined benefit plans are unfunded, with the exception of one plan in one country where the amount of assets exceeds the projected benefit obligation by approximately \$8 million and \$8 million as of December 27, 2025 and December 28, 2024, respectively. At December 27, 2025 and December 28, 2024 the accumulated benefit obligations were \$142 million and \$125 million, respectively.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

The following table provides the amounts recognized in our consolidated balance sheets for our defined benefit pension plans:

	Years Ended	
	December 27, 2025	December 28, 2024
Non-current assets	\$ 37	\$ 28
Current liabilities	(1)	(1)
Non-current liabilities	(76)	(68)
Accumulated other comprehensive loss, pre-tax	8	10

The following table provides the components of net periodic pension cost for our defined benefit plans:

	Years Ended		
	December 27, 2025	December 28, 2024	December 30, 2023
Service cost	\$ 4	\$ 4	\$ 3
Interest cost	3	3	3
Expected return on plan assets	(3)	(3)	(3)
Employee contributions	(1)	(1)	(1)
Settlements	(1)	-	-
Net periodic pension cost	<u>\$ 2</u>	<u>\$ 3</u>	<u>\$ 2</u>

The following tables present the weighted-average actuarial assumptions used to determine our pension benefit obligation and our net periodic pension cost for the periods presented:

	Years Ended	
	December 27, 2025	December 28, 2024
<b><u>Pension Benefit Obligation</u></b>		
Weighted average discount rate	2.75 %	2.23 %

	Years Ended		
	December 27, 2025	December 28, 2024	December 30, 2023
<b><u>Net Periodic Pension Cost</u></b>			
Discount rate-pension benefit	2.05 %	1.70 %	1.50 %
Expected return on plan assets	0.92 %	1.13 %	0.51 %
Rate of compensation increase	2.00 %	1.98 %	1.64 %
Pension increase rate	0.74 %	0.63 %	0.80 %

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

The following table presents the estimated pension benefit payments that are payable to the plan’s participants as of December 27, 2025:

<u>Year</u>		
2026	\$	8
2027		9
2028		9
2029		7
2030		8
2031 to 2035		<u>52</u>
Total	<u>\$</u>	<u>93</u>

*401(k) Plans*

We offer qualified 401(k) plans to substantially all domestic full-time employees. As determined by our Board, matching contributions to these plans generally do not exceed 100% of the participants’ contributions up to 5% of their base compensation, subject to applicable legal limits. Matching contributions are made in cash and are allocated consistent with the participants’ investment elections on file, subject to a 20% allocation limit to the Henry Schein Stock Fund. Forfeitures attributable to participants whose employment terminates prior to becoming fully vested are reallocated as part of our ongoing matching contributions and to offset administrative expenses of the 401(k) plans.

Assets of the 401(k) and other defined contribution plans are held in self-directed accounts enabling participants to choose from various investment fund options. Matching contributions related to these plans charged to operations during the years ended December 27, 2025, December 28, 2024 and December 30, 2023 amounted to \$42 million, \$48 million and \$50 million, respectively. Within our consolidated statements of income, \$36 million, \$40 million, and \$42 million, is included in selling, general and administrative; and \$6 million, \$8 million, and \$8 million is included in cost of goods sold for the years ended December 27, 2025, December 28, 2024, and December 30, 2023, respectively.

*Supplemental Executive Retirement Plan*

We offer an unfunded, non-qualified SERP to eligible employees. This plan generally covers officers and certain highly compensated employees after they have reached the maximum IRS allowed pre-tax 401(k) contribution limit. Our contributions to this plan are equal to the 401(k) employee-elected contribution percentage applied to base compensation for the portion of the year in which such employees are not eligible to make pre-tax contributions to the 401(k) plan. The amounts charged to operations during the years ended December 27, 2025, December 28, 2024 and December 30, 2023 amounted to \$3 million, \$2 million and \$3 million, respectively. The charges are included in selling, general and administrative within our consolidated statements of income. Please see Note 13 – Derivatives and Hedging Activities for additional information.

*Deferred Compensation Plan*

We offer DCP to a select group of management or highly compensated employees of the Company and certain subsidiaries. This plan allows for the elective deferral of base salary, bonus and/or commission compensation by eligible employees. The amounts charged to operations during the years ended December 27, 2025, December 28, 2024 and December 30, 2023 were approximately \$12 million, \$12 million and \$12 million, respectively. The charges are included in selling, general and administrative within our consolidated statements of income. Please see Note 13 – Derivatives and Hedging Activities for additional information.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 20 – Redeemable Noncontrolling Interests**

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. ASC Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the years ended December 27, 2025, December 28, 2024 and December 30, 2023, are presented in the following table:

	<u>December 27, 2025</u>	<u>December 28, 2024</u>	<u>December 30, 2023</u>
Balance, beginning of period	\$ 806	\$ 864	\$ 576
Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries	(76)	(273)	(19)
Increase in redeemable noncontrolling interests due to business acquisitions	86	171	326
Net income (loss) attributable to redeemable noncontrolling interests	(5)	(1)	6
Distributions declared, net of capital contributions	(18)	(50)	(19)
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	30	(24)	5
Change in fair value of redeemable securities	72	119	(11)
Balance, end of period	<u>\$ 895</u>	<u>\$ 806</u>	<u>\$ 864</u>

**Note 21 – Comprehensive Income**

Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income and are recorded directly to stockholders' equity.

The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of:

	<u>December 27, 2025</u>	<u>December 28, 2024</u>	<u>December 30, 2023</u>
Attributable to redeemable noncontrolling interests:			
Foreign currency translation adjustment	<u>\$ (26)</u>	<u>\$ (56)</u>	<u>\$ (32)</u>
Attributable to noncontrolling interests:			
Foreign currency translation adjustment	<u>\$ 1</u>	<u>\$ (1)</u>	<u>\$ (1)</u>
Attributable to Henry Schein, Inc.:			
Foreign currency translation adjustment	\$ (196)	\$ (371)	\$ (188)
Unrealized loss from hedging activities	(24)	-	(13)
Pension adjustment loss	(6)	(8)	(5)
Accumulated other comprehensive loss	<u>\$ (226)</u>	<u>\$ (379)</u>	<u>\$ (206)</u>
Total Accumulated other comprehensive loss	<u>\$ (251)</u>	<u>\$ (436)</u>	<u>\$ (239)</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

The following table summarizes the components of comprehensive income, net of applicable taxes as follows:

	<u>December 27, 2025</u>	<u>December 28, 2024</u>	<u>December 30, 2023</u>
Net income	\$ 419	\$ 398	\$ 436
Foreign currency translation gain (loss)	207	(207)	53
Tax effect	-	-	-
Foreign currency translation gain (loss)	<u>207</u>	<u>(207)</u>	<u>53</u>
Unrealized gain (loss) from hedging activities	(33)	18	(25)
Tax effect	9	(5)	7
Unrealized gain (loss) from hedging activities	<u>(24)</u>	<u>13</u>	<u>(18)</u>
Pension adjustment gain (loss)	5	(5)	(3)
Tax effect	(3)	2	-
Pension adjustment gain (loss)	<u>2</u>	<u>(3)</u>	<u>(3)</u>
Comprehensive income	<u>\$ 604</u>	<u>\$ 201</u>	<u>\$ 468</u>

Our financial statements are denominated in U.S. Dollars. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation gain (loss) during the years ended December 27, 2025, December 28, 2024 and December 30, 2023 was primarily due to changes in foreign currency exchange rates of the Brazilian Real, British Pound, Euro, Swiss Franc, Israel Shekel, Canadian Dollar, Australian Dollar, and New Zealand Dollar.

The hedging gain (loss) during the years ended December 27, 2025, December 28, 2024, and December 30, 2023 was attributable to a net investment hedge. See Note 13 – Derivatives and Hedging Activities for further information.

The following table summarizes our total comprehensive income, net of applicable taxes as follows:

	<u>December 27, 2025</u>	<u>December 28, 2024</u>	<u>December 30, 2023</u>
Comprehensive income attributable to Henry Schein, Inc.	\$ 551	\$ 217	\$ 443
Comprehensive income attributable to noncontrolling interests	28	9	14
Comprehensive income (loss) attributable to Redeemable noncontrolling interests	25	(25)	11
Comprehensive income	<u>\$ 604</u>	<u>\$ 201</u>	<u>\$ 468</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 22 – Earnings Per Share**

Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for unvested RSUs and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect.

A reconciliation of shares used in calculating earnings per basic and diluted share follows:

	<b>Years Ended</b>		
	<b>December 27, 2025</b>	<b>December 28, 2024</b>	<b>December 30, 2023</b>
Basic	120,813,977	126,788,997	130,618,990
Effect of dilutive securities:			
Stock options and restricted stock units	903,899	990,231	1,129,181
Diluted	<u>121,717,876</u>	<u>127,779,228</u>	<u>131,748,171</u>

The number of antidilutive securities that were excluded from the calculation of diluted weighted average common shares outstanding are as follows:

	<b>Years Ended</b>		
	<b>December 27, 2025</b>	<b>December 28, 2024</b>	<b>December 30, 2023</b>
Stock options	396,052	406,676	424,695
Restricted stock units	6,200	9,287	15,040
Total anti-dilutive securities excluded from earnings per share computation	<u>402,252</u>	<u>415,963</u>	<u>439,735</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)

**Note 23 – Supplemental Cash Flow Information**

Cash paid for interest and income taxes was:

	Years Ended		
	December 27, 2025	December 28, 2024	December 30, 2023
Cash paid for interest	\$ 151	\$ 132	\$ 84
Cash paid for income taxes, net of refunds:			
U.S. Federal	\$ 67		
U.S. State and local	15		
Foreign:			
Switzerland	8		
Other	38		
Total	\$ 128		

	Years Ended	
	December 28, 2024	December 30, 2023
Cash paid during the period for income taxes (prior to ASU 2023-09)	\$ 144	\$ 218

For the years ended December 27, 2025, December 28, 2024 and December 30, 2023, we had \$(33) million, \$18 million and \$(25) million of non-cash net unrealized gains (losses) related to hedging activities, respectively. See Note 13 – Derivatives and Hedging Activities for additional information related to our total return swap and our interest rate swap agreements.

There was approximately \$3 million, \$0 million and \$143 million of debt assumed as a part of the acquisitions for the years ended December 27, 2025, December 28, 2024 and December 30, 2023, respectively. Debt assumed during the year ended December 30, 2023 primarily relates to the acquisitions of Biotech Dental and S.I.N.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

**Note 24 – Related Party Transactions**

During 2018, we entered into a joint venture with Internet Brands to create Henry Schein One, LLC. Internet Brands initially held a 26% noncontrolling interest, which has since increased to a 33.6% noncontrolling interest in Henry Schein One, LLC, and a freestanding and separately exercisable right to put its noncontrolling interest to Henry Schein, Inc. for fair value following the fifth anniversary of the effective date of the formation of the joint venture. On January 29, 2025, Henry Schein, Inc. signed a Memorandum of Understanding with Internet Brands to extend the time-based trigger for the exercise of our call option to July 1, 2032 and to pause the exercise by Internet Brands of its put option for a period of four years, to January 29, 2029.

In connection with the formation of Henry Schein One, LLC we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately \$31 million annually for the use of their intellectual property. During the years ended December 27, 2025, December 28, 2024 and December 30, 2023, we recorded \$31 million, \$31 million and \$31 million, respectively, within selling, general and administrative in our consolidated statements of income, in connection with costs related to this royalty agreement. As of December 27, 2025 and December 28, 2024, Henry Schein One, LLC had a net payable balance to Internet Brands of \$9 million and \$1 million, respectively, comprised of amounts related to results of operations and the royalty agreement. The components of this payable are recorded within accrued expenses: other within our consolidated balance sheets.

We have interests in entities that we account for under the equity accounting method. In our normal course of business, during the years ended December 27, 2025, December 28, 2024 and December 30, 2023, we recorded net sales of \$56 million, \$52 million, and \$47 million respectively, to such entities. During the years ended December 27, 2025, December 28, 2024 and December 30, 2023, we purchased \$19 million, \$10 million and \$10 million respectively, from such entities. At December 27, 2025 and December 28, 2024, we had an aggregate \$39 million and \$35 million, respectively, due from our equity affiliates, and \$6 million and \$6 million, respectively, due to our equity affiliates.

Certain of our facilities related to our acquisitions are leased from employees and minority shareholders. Please see Note 8 – Leases for further information.

**HENRY SCHEIN, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**

**Note 25 – KKR Investment and Accelerated Share Repurchase Program**

On January 29, 2025, Henry Schein, Inc. announced a strategic investment by funds affiliated with KKR, a leading global investment firm, and entered into a Strategic Partnership Agreement with KKR (the “Agreement”). On May 16, 2025, we issued 3,285,151 shares of common stock to funds affiliated with KKR for an investment of \$250 million, at approximately \$76.10 per share. In addition, under the Agreement, two independent directors have joined our Board of Directors.

On May 19, 2025, we executed an accelerated share repurchase program to repurchase a total of \$250 million of our outstanding common stock based on volume-weighted average prices. In May 2025 we received 3,122,832 shares at an estimated fair value of \$224 million. In July 2025, we received an additional 368,651 shares at an estimated fair value of \$26 million, representing the final amount of shares to be received under this accelerated share repurchase program.

On November 4, 2025, the Company and KKR entered into an amendment to the Agreement that increased the beneficial ownership limit from 14.9% to 19.9% of the outstanding shares of the Company’s common stock that KKR is permitted to acquire during the standstill period. The standstill provisions, including the increased ownership limit, continue in effect for a period of six months following the later of the expiration of the term of the Agreement and the date on which no KKR director appointed pursuant to the Agreement is serving on the Board of Directors.

## **ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure**

None.

### **ITEM 9A. Controls and Procedures**

#### *Evaluation of Disclosure Controls and Procedures*

Under the supervision and with the participation of management, including our principal executive officer and principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this annual report as such term is defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our management, including our principal executive officer and principal financial officer, concluded that our disclosure controls and procedures were effective as of December 27, 2025, to ensure that all material information required to be disclosed by us in reports that we file or submit under the Exchange Act is accumulated and communicated to them as appropriate to allow timely decisions regarding required disclosure and that all such information is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and the rules of the Nasdaq stock exchange.

#### *Changes in Internal Control over Financial Reporting*

The combination of acquisitions, continued acquisition integrations and systems implementation activity undertaken during the quarter ended December 27, 2025, and carried over from prior quarters, when considered in the aggregate, represents a material change in our internal control over financial reporting. The full integration of certain acquisitions completed in the current and prior quarters will extend beyond year-end and, therefore, we excluded these acquisitions, which represents approximately 0.10% of our total net sales, from our annual assessment of internal control over financial reporting as of December 27, 2025, as permitted by related SEC staff interpretive guidance for newly acquired businesses.

During the quarter ended December 27, 2025, we completed the acquisition of a controlling interest of a Global Distribution and Value-Added Services segment affiliate in Canada as well as the acquisition of a Global Specialties Products segment business in Brazil. Also, post-acquisition integration related activities continued for businesses acquired during prior quarters within our Global Specialties Products segment. These acquisitions, the majority of which utilize separate information and financial accounting systems, have been included in our consolidated financial statements since their respective dates of acquisition.

Additionally, during the quarter ended December 27, 2025, we continued systems implementation activities for the phased roll-out of a new e-commerce system for our Global Distribution and Value-Added Services segment in the U.S. and Canada. Also, we completed systems implementation activity for migrating many of our Global Distribution and Value-Added Services, Global Specialty Products and Global Technology segment businesses Company-wide onto an existing Human Capital Management system. Finally, we continued systems implementation activities for upgrading the ERP business system for our Global Distribution and Value-Added Services segment in Australia and New Zealand.

All acquisitions, continued acquisition integrations, and systems implementation activities involve necessary and appropriate change-management controls that are considered in our quarterly assessment of the design and operating effectiveness of our internal control over financial reporting.

#### *Management’s Report on Internal Control over Financial Reporting*

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control system is designed to provide reasonable assurance to our management and Board regarding the preparation and fair presentation of published financial statements. Under the supervision and with the participation of our management, including our principal

executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control-Integrated Framework (2013), updated and reissued by the Committee of Sponsoring Organizations, or the COSO Framework. Based on our evaluation under the COSO Framework, our management concluded that our internal control over financial reporting was effective at a reasonable assurance level as of December 27, 2025.

The effectiveness of our internal control over financial reporting as of December 27, 2025, has been independently audited by BDO USA, P.C., an independent registered public accounting firm and their attestation is included herein.

*Limitations of the Effectiveness of Internal Control*

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the internal control system are met. Because of the inherent limitations of any internal control system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

## **Report of Independent Registered Public Accounting Firm**

Shareholders and Board of Directors  
Henry Schein, Inc.  
Melville, New York

### **Opinion on Internal Control over Financial Reporting**

We have audited Henry Schein, Inc.'s (the "Company's") internal control over financial reporting as of December 27, 2025, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the "COSO criteria"). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 27, 2025, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 27, 2025 and December 28, 2024, the related consolidated statements of income and comprehensive income, changes in stockholders' equity, and cash flows for each of the three years in the period ended December 27, 2025, and the related notes and our report dated February 24, 2026 expressed an unqualified opinion thereon.

### **Basis for Opinion**

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Item 9A, Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

As indicated in the accompanying Item 9A, Controls and Procedures, management's assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of certain entities acquired in 2025 ("the 2025 Acquisitions"), which are included in the consolidated balance sheet of the Company as of December 27, 2025, and the related consolidated statements of income and comprehensive income, changes in stockholders' equity, and cash flows for the year then ended. The 2025 Acquisitions constituted approximately 0.10% of total net sales for the year ended December 27, 2025. Management did not assess the effectiveness of internal control over financial reporting of the 2025 Acquisitions because of the timing of the acquisitions which were completed during the 2025 fiscal year. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of the 2025 Acquisitions.

### **Definition and Limitations of Internal Control over Financial Reporting**

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable

assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ BDO USA, P.C.  
New York, New York  
February 24, 2026

## **ITEM 9B. Other Information**

Not applicable.

## **ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections**

Not applicable.

### **PART III**

## **ITEM 10. Directors, Executive Officers and Corporate Governance**

Information required by this item regarding our directors and executive officers and our corporate governance is hereby incorporated by reference to the Section entitled “Election of Directors,” with respect to directors, and the first paragraph of the Section entitled “Corporate Governance - Board of Directors Meetings and Committees - Audit Committee,” with respect to corporate governance, in each case in our definitive 2026 Proxy Statement to be filed pursuant to Regulation 14A and to the Section entitled “Information about our Executive Officers” in Part I of this report, with respect to executive officers.

There have been no changes to the procedures by which stockholders may recommend nominees to our Board since our last disclosure of such procedures, which appeared in our definitive 2025 Proxy Statement filed pursuant to Regulation 14A on April 9, 2025.

Information required by this item concerning compliance with Section 16(a) of the Securities Exchange Act of 1934 is hereby incorporated by reference to the Section entitled “Delinquent Section 16(a) Reports” in our definitive 2026 Proxy Statement to be filed pursuant to Regulation 14A, to the extent responsive disclosure is required.

We have adopted a Code of Ethics that applies to our Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer and Controller. We make available free of charge through our Internet website, [www.henryschein.com](http://www.henryschein.com), under the “About Henry Schein--Corporate Governance Highlights” caption, our Code of Ethics. We intend to disclose on our Web site any amendment to, or waiver of, a provision of the Code of Ethics.

The Company has adopted an insider trading policy, and accompanying procedures, applicable to all of our TSMs and members of our Board of Directors, which we believe is reasonably designed to promote compliance with insider trading laws, rules and regulations, and Nasdaq listing standards. Our insider trading policy, which is filed as Exhibit 19.1 to this Annual Report on Form 10-K, prohibits our TSMs from trading in securities of the Company while in possession of material, non-public information, and, among other things, requires that designated individuals holding certain positions only transact in Company securities during an open window period (with appropriate preclearance for members of our Executive Management Committee and Board of Directors), subject to limited exceptions. The Company also requires periodic training for certain senior officers and others likely to learn material, non-public information in the course of their job duties. The Company also has a practice that requires that any transactions by the Company in its securities are pre-cleared by appropriate members of its General Counsel’s office.

## **ITEM 11. Executive Compensation**

The information required by this item is hereby incorporated by reference to the Sections entitled “Compensation Discussion and Analysis,” “Compensation Committee Report” (which information shall be deemed furnished in this Annual Report on Form 10-K), “Executive and Director Compensation” and “Compensation Committee Interlocks and Insider Participation” in our definitive 2026 Proxy Statement to be filed pursuant to Regulation 14A.

## ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

We maintain several stock incentive plans for the benefit of certain officers, directors and employees. All active plans have been approved by our stockholders. Descriptions of these plans appear in the notes to our consolidated financial statements. The following table summarizes information relating to these plans as of December 27, 2025:

<u>Plan Category</u>	<u>Number of Common Shares to be Issued Upon Exercise of Outstanding Options and Rights</u>	<u>Weighted- Average Exercise Price of Outstanding Options</u>	<u>Number of Common Shares Available for Future Issuances</u>
Plans Approved by Stockholders	-	\$ -	9,405,917
Plans Not Approved by Stockholders	-	-	-
Total	-	\$ -	9,405,917

The other information required by this item is hereby incorporated by reference to the Section entitled “Security Ownership of Certain Beneficial Owners and Management” in our definitive 2026 Proxy Statement to be filed pursuant to Regulation 14A.

## ITEM 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this item is hereby incorporated by reference to the Section entitled “Certain Relationships and Related Transactions” and “Corporate Governance – Board of Directors Meetings and Committees – Independent Directors” in our definitive 2026 Proxy Statement to be filed pursuant to Regulation 14A.

## ITEM 14. Principal Accounting Fees and Services

The information required by this item is hereby incorporated by reference to the Section entitled “Independent Registered Public Accounting Firm Fees and Pre-Approval Policies and Procedures” in our definitive 2026 Proxy Statement to be filed pursuant to Regulation 14A.

## PART IV

### ITEM 15. Exhibits, Financial Statement Schedules

#### (a) List of Documents Filed as a Part of This Report:

1. Financial Statements:  
Our Consolidated Financial Statements filed as a part of this report are listed on the index on Page 69.
2. Index to Exhibits:  
See exhibits listed under Item 15(b) below.

## (b) Exhibits

- 3.1 Second Amended and Restated Certificate of Incorporation of Henry Schein, Inc. (Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on June 1, 2018.)
- 3.2 Fifth Amended and Restated By-Laws of Henry Schein, Inc., effective January 10, 2026. (Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on January 12, 2026.)
- 4.1 Third Amended and Restated Multicurrency Master Note Purchase Agreement, dated as of October 20, 2021, by and among us, Metropolitan Life Insurance Company, MetLife Investment Management, LLC and each MetLife affiliate which becomes party thereto. (Incorporated by reference to Exhibit 4.4 to our Current Report on Form 8-K filed on October 21, 2021.)
- 4.2 First Amendment to the Third Amended and Restated Multicurrency Master Note Purchase Agreement, dated as of December 19, 2025, by and among us, Metropolitan Life Insurance Company, MetLife Investment Management, LLC and each affiliate thereof party thereto. (Incorporated by reference to Exhibit 4.3 to our Current Report on Form 8-K filed on December 23, 2025.)\*
- 4.3 Third Amended and Restated Master Note Facility, dated as of October 20, 2021, by and among us, NYL Investors LLC and each New York Life affiliate which becomes party thereto. (Incorporated by reference to Exhibit 4.3 to our Current Report on Form 8-K filed on October 21, 2021.)
- 4.4 First Amendment to the Third Amended and Restated Master Note Facility, dated as of December 19, 2025, by and among us, NYL Investors LLC and each affiliate thereof party thereto. (Incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on December 23, 2025.)\*
- 4.5 Third Amended and Restated Multicurrency Private Shelf Agreement, dated as of October 20, 2021, by and among us, PGIM, Inc. and each Prudential affiliate which becomes party thereto. (Incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on October 21, 2021.)
- 4.6 First Amendment to the Third Amended and Restated Multicurrency Private Shelf Agreement, dated as of December 19, 2025, by and among us, PGIM, Inc. and each affiliate thereof party thereto. (Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on December 23, 2025.)\*
- 4.7 Multicurrency Private Shelf Agreement, dated as of October 20, 2021, by and among us, AIG Asset Management (U.S.), LLC and each AIG affiliate which becomes party thereto. (Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on October 21, 2021.)
- 4.8 First Amendment to the Multicurrency Private Shelf Agreement, dated as of December 19, 2025, by and among us, Corebridge Institutional Investors (U.S.), LLC (formerly AIG) and each affiliate thereof party thereto. (Incorporated by reference to Exhibit 4.4 to our Current Report on Form 8-K filed on December 23, 2025.)\*
- 4.9 Description of Securities. (Incorporated by reference to Exhibit 4.5 to our Annual Report on Form 10-K for the fiscal year ended December 25, 2021 filed on February 15, 2022.)
- 10.1 Henry Schein, Inc. 2020 Stock Incentive Plan, as amended and restated effective as of May 21, 2020. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 26, 2020.)\*

- 10.2 Form of 2021 Stock Option Agreement pursuant to the Henry Schein, Inc. 2020 Stock Incentive Plan (as amended and restated effective as of May 21, 2020). (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on March 8, 2021.)\*\*
- 10.3 Form of 2021 Restricted Stock Unit Agreement for time-based restricted stock unit awards pursuant to the Henry Schein, Inc. 2020 Stock Incentive Plan (as amended and restated effective as of May 21, 2020). (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 26, 2022 filed on May 3, 2022.)\*\*
- 10.4 Form of 2022 Restricted Stock Unit Agreement for performance-based restricted stock unit awards pursuant to the Henry Schein, Inc. 2020 Stock Incentive Plan (as amended and restated effective as of May 21, 2020). (Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 26, 2022 filed on May 3, 2022.)\*\*
- 10.5 Form of 2024 Restricted Stock Unit Agreement for time-based restricted stock unit awards pursuant to the Henry Schein, Inc. 2020 Stock Incentive Plan (as amended and restated effective as of May 21, 2020). (Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 30, 2024 filed on May 7, 2024.)\*\*
- 10.6 Form of 2024 Restricted Stock Unit Agreement for performance-based restricted stock unit awards pursuant to the Henry Schein, Inc. 2020 Stock Incentive Plan (as amended and restated effective as of May 21, 2020). (Incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 30, 2024 filed on May 7, 2024.)\*\*
- 10.7 Henry Schein, Inc. 2024 Stock Incentive Plan, as amended and restated effective as of May 21, 2024. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 24, 2024.)\*\*
- 10.8 Henry Schein, Inc. 2015 Non-Employee Director Stock Incentive Plan. (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended June 27, 2015 filed on July 29, 2015.)\*\*
- 10.9 Form of 2018 Restricted Stock Unit Agreement for time-based restricted stock unit awards pursuant to the Henry Schein, Inc. 2015 Non-Employee Director Stock Incentive Plan (as amended and restated effective as of June 22, 2015). (Incorporated by reference to Exhibit 10.6 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2018 filed on May 8, 2018.)\*\*
- 10.10 Henry Schein, Inc. 2023 Non-Employee Director Stock Incentive Plan, as amended and restated effective as of May 23, 2023. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 25, 2023.)\*\*
- 10.11 Form of 2024 Restricted Stock Unit Agreement for time-based restricted stock unit awards pursuant to the Henry Schein, Inc. 2023 Non-Employee Director Stock Incentive Plan (as amended and restated effective as of May 23, 2023). (Incorporated by reference to Exhibit 10.4 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 30, 2024 filed on May 7, 2024.)\*\*
- 10.12 Henry Schein, Inc. Supplemental Executive Retirement Plan, amended and restated effective September 1, 2025. (Incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q for the fiscal quarter ended June 28, 2025 filed on August 5, 2025.)\*\*
- 10.13 Henry Schein, Inc. 2004 Employee Stock Purchase Plan, effective as of May 25, 2004. (Incorporated by reference to Exhibit D to our definitive 2004 Proxy Statement on Schedule 14A, filed on April 27, 2004.)\*\*

- 10.14 Henry Schein, Inc. Non-Employee Director Deferred Compensation Plan, amended and restated effective as of January 1, 2005. (Incorporated by reference to Exhibit 10.11 to our Annual Report on Form 10-K for the fiscal year ended December 27, 2008 filed on February 24, 2009.)\*\*
- 10.15 Henry Schein, Inc. Deferred Compensation Plan, as amended and restated effective as of November 14, 2023. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on November 16, 2023.)\*\*
- 10.16 Henry Schein, Inc. Incentive Plan and Plan Summary, effective as of January 1, 2025. (Incorporated by reference to Exhibit 10.4 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2025 filed on May 5, 2025.)\*\*
- 10.17 Amended and Restated Employment Agreement dated as of November 28, 2022, by and between Henry Schein, Inc. and Stanley M. Bergman. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on November 29, 2022.)\*\*
- 10.18 Letter Agreement dated December 23, 2025 to the Amended and Restated Employment Agreement dated as of November 28, 2022, by and between Henry Schein, Inc. and Stanley M. Bergman. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on December 23, 2025.)\*\*
- 10.19 Employment Agreement dated as of January 10, 2026, by and between Henry Schein, Inc. and Frederick M. Lowery. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on January 12, 2026.)\*\*
- 10.20 Form of Restricted Stock Unit Agreement (CEO Sign-On RSU Award), by and between Henry Schein, Inc. and Frederick M. Lowery, pursuant to the Henry Schein, Inc. 2024 Stock Incentive Plan. (Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on January 12, 2026.)\*\*
- 10.21 Form of Amended and Restated Change in Control Agreement dated December 12, 2008 between us and certain executive officers who are a party thereto (Michael S. Ettinger and Mark Mlotek, respectively). (Incorporated by reference to Exhibit 10.15 to our Annual Report on Form 10-K for the fiscal year ended December 27, 2008 filed on February 24, 2009.)\*\*
- 10.22 Form of Amendment to Amended and Restated Change in Control Agreement effective January 1, 2012 between us and certain executive officers who are a party thereto (Michael S. Ettinger and Mark Mlotek, respectively). (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on January 20, 2012.)\*\*
- 10.23 Amended and Restated Henry Schein, Inc. Executive Change in Control Plan (Andrea Albertini and Ronald N. South). (Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on April 15, 2025.)\*\*
- 10.24 Form of Indemnification Agreement between us and certain directors and executive officers who are a party thereto (Mohamed Ali, William K. “Dan” Daniel, Deborah Derby, Carole T. Faig, Joseph L. Herring, Robert J. Hombach, Kurt P. Kuehn, Philip A. Laskawy, Max Lin, Anne H. Margulies, Scott P. Serota, Bradley T. Sheares, Ph.D., Reed V. Tuckson, M.D., FACP, Andrea Albertini, Stanley M. Bergman, Michael S. Ettinger, Mark E. Mlotek and Ronald N. South, respectively). (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended September 26, 2015 filed on November 4, 2015.)\*\*

- 10.25 Third Amended and Restated Revolving Credit Agreement, dated as of June 6, 2025, among us, the several lenders parties thereto, and JPMorgan Chase Bank, N.A., as administrative agent, U.S. Bank National Association, as syndication agent, and The Toronto-Dominion Bank, New York Branch, Bank of America, N.A., UniCredit Bank, A.G., the Bank of New York Mellon, ING Bank, N.V. and HSBC Bank USA, N.A., as co-documentation agents. (Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on June 9, 2025.)
- 10.26 Amended and Restated Term Loan Credit Agreement, dated as of June 6, 2025, among us, the several lenders parties thereto, JPMorgan Chase Bank, N.A., as administrative agent and joint lead arranger, U.S. Bank National Association, as syndication agent and joint lead arranger, and The Toronto-Dominion Bank, New York Branch, and Bank of America, N.A., as co-documentation agents and joint lead arrangers and ING Bank, N.V. and BNP Paribas, as co-documentation agents. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on June 9, 2025.)
- 10.27 Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., as agent and the various purchaser groups from time to time party thereto. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on April 19, 2013.)
- 10.28 Amendment No. 1 dated as of September 22, 2014 to the Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, LTD., New York Branch, as agent and the various purchaser groups from time to time party thereto. (Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on September 26, 2014.)
- 10.29 Amendment No. 2 dated as of April 17, 2015 to Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as performance guarantor, HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as agent and the various purchaser groups party thereto. (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended June 25, 2016 filed on August 4, 2016.)
- 10.30 Amendment No. 3 dated as of June 1, 2016 to Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as performance guarantor, HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as agent and the various purchaser groups party thereto. (Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q for the fiscal quarter ended June 25, 2016 filed on August 4, 2016.)
- 10.31 Amendment No. 4 dated as of July 6, 2017 to Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as performance guarantor, HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as agent and the various purchaser groups party thereto. (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2017 filed on November 6, 2017.)
- 10.32 Amendment No. 5 dated as of May 13, 2019 to Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as performance guarantor, HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as agent and the various purchaser groups party thereto. (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended June 29, 2019 filed on August 6, 2019.)
- 10.33 Limited Waiver dated as of May 22, 2020 to Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, lender, as agent and the various purchaser groups from time to time party thereto, as amended. (Incorporated by reference to Exhibit 10.7 to our Quarterly Report on Form 10-Q for the fiscal quarter ended June 27, 2020 filed on August 4, 2020.)

- 10.34 Amendment No. 6 dated as of June 22, 2020 to the Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, lender, as agent and the various purchaser groups from time to time party thereto. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on June 25, 2020.)
- 10.35 Amendment No. 7 dated as of October 20, 2021 to Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, lender, as agent and the various purchaser groups from time to time party thereto. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on October 21, 2021.)
- 10.36 Amendment No. 8 dated as of December 15, 2022 to Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, lender, as agent and the various purchaser groups from time to time party thereto. (Incorporated by reference to Exhibit 10.45 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed on February 21, 2023.)
- 10.37 Omnibus Amendment No. 1, dated July 22, 2013, to Receivables Purchase Agreement dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., as agent, and the various purchaser groups from time to time party thereto and Receivables Sales Agreement, dated as of April 17, 2013, by and among us, certain of our wholly-owned subsidiaries and HSFR, Inc., as buyer. (Incorporated by reference to Exhibit 10.5 to our Quarterly Report on Form 10-Q for the fiscal quarter ended June 29, 2013 filed on August 6, 2013.)
- 10.38 Omnibus Amendment No. 2, dated April 21, 2014, to Receivables Purchase Agreement dated as of April 17, 2013, as amended, by and among us, as servicer, HSFR, Inc., as seller, The Bank of Tokyo-Mitsubishi UFJ, Ltd., as agent, and the various purchaser groups from time to time party thereto and Receivables Sales Agreement, dated as of April 17, 2013, by and among us, certain of our wholly-owned subsidiaries and HSFR, Inc., as buyer. (Incorporated by reference to Exhibit 10.8 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2014 filed on May 6, 2014.)
- 10.39 Receivables Sale Agreement, dated as of April 17, 2013, by and among us, certain of our wholly-owned subsidiaries and HSFR, Inc., as buyer. (Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on April 19, 2013.)
- 10.40 Strategic Partnership Agreement, dated January 29, 2025, by and between us and KKR Hawaii Aggregator L.P. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on January 29, 2025.)
- 10.41 Letter Agreement on Voting Commitment by and between us and KKR Hawaii Aggregator L.P. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on April 9, 2025.)
- 10.42 Letter Agreement to Remove Voting Commitment by and between us and KKR Hawaii Aggregator L.P. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 2, 2025.)
- 10.43 Amendment No. 1 to the Strategic Partnership Agreement, dated November 4, 2025, by and between us and KKR Hawaii Aggregator L.P. (Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended September 27, 2025 filed on November 4, 2025.)
- 10.44 Form of Registration Rights Agreement by and between us and KKR Hawaii Aggregator L.P. (Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on January 29, 2025.)
- 10.45 Form of Offer Letter (Ronald N. South).\*\*+

- 10.46 Employment Agreement dated as of August 23, 2023, by and between Henry Schein, Inc. and Andrea Albertini.\*\*+
- 10.47 Global Mobility Letter dated as of August 23, 2023, by and between Henry Schein, Inc. and Andrea Albertini.\*\*+
- 10.48 Restrictive Covenant, Confidentiality and Inventions Agreement dated as of August 23, 2023, by and between Henry Schein, Inc. and Andrea Albertini.\*\*+
- 19.1 Henry Schein, Inc. Insider Trading Policy (amended and restated as of January 1, 2025). (Incorporated by reference to Exhibit 19.1 to our Annual Report on Form 10-K for the fiscal year ended December 28, 2024 filed on February 25, 2025.)
- 21.1 List of our Subsidiaries.+
- 23.1 Consent of BDO USA, P.C.+
- 31.1 Certification of our Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+
- 31.2 Certification of our Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+
- 32.1 Certification of our Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.+
- 97.1 Henry Schein, Inc. Dodd-Frank Clawback Policy, effective as of December 1, 2023. (Incorporated by reference to Exhibit 97.1 to our Annual Report on Form 10-K for the fiscal year ended December 30, 2023 filed on February 28, 2024.)\*\*
- 99.1 Amendment No. 9 dated as of December 20, 2023 to Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, lender, as agent and the various purchaser groups from time to time party thereto. (Incorporated by reference to Exhibit 99.8 to our Annual Report on Form 10-K for the fiscal year ended December 30, 2023 filed on February 28, 2024.)
- 99.2 Amendment No. 10 dated as of February 23, 2024 to Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, lender, as agent and the various purchaser groups from time to time party thereto. (Incorporated by reference to Exhibit 99.9 to our Annual Report on Form 10-K for the fiscal year ended December 30, 2023 filed on February 28, 2024.)
- 99.3 Amendment No. 11 dated as of May 17, 2024 to Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, lender, as agent and the various purchaser groups from time to time party thereto. (Incorporated by reference to Exhibit 99.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended June 29, 2024 filed on August 6, 2024.)
- 99.4 Amendment No. 12 dated as of December 6, 2024 to Receivables Purchase Agreement, dated as of April 17, 2013, by and among us, as servicer, HSFR, Inc., as seller, lender, as agent and the various purchaser groups from time to time party thereto. (Incorporated by reference to Exhibit 99.4 to our Annual Report on Form 10-K for the fiscal year ended December 28, 2024 filed on February 25, 2025.)
- 99.5 Amendment No. 1 to the Henry Schein, Inc. Supplemental Executive Retirement Plan, amended and restated effective September 1, 2025.\*\*+

- 99.6 Form of 2025 Restricted Stock Unit Agreement for time-based restricted stock unit awards pursuant to the Henry Schein, Inc. 2024 Stock Incentive Plan (as amended and restated on May 21, 2024). (Incorporated by reference to Exhibit 99.2 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2025 filed on May 5, 2025.)\*\*
- 99.7 Form of 2025 Restricted Stock Unit Agreement for performance-based restricted stock unit awards pursuant to the Henry Schein, Inc. 2024 Stock Incentive Plan (as amended and restated on May 21, 2024). (Incorporated by reference to Exhibit 99.3 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2025 filed on May 5, 2025.)\*\*
- 99.8 Letter Agreement on Share Repurchases by and between us and KKR Hawaii Aggregator L.P. (Incorporated by reference to Exhibit 99.1 to our Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2025 filed on May 5, 2025.)
- 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.+
- 101.SCH Inline XBRL Taxonomy Extension Schema Document+
- 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document+
- 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document+
- 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document+
- 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document+
- 104 The cover page of Henry Schein, Inc.'s Annual Report on Form 10-K for the year ended December 27, 2025, formatted in Inline XBRL (included within Exhibit 101 attachments).+

---

+ Filed or furnished herewith.

\* Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

\*\* Indicates management contract or compensatory plan or agreement.

## **ITEM 16. Form 10-K Summary**

None.

## SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Henry Schein, Inc.

By: /s/ STANLEY M. BERGMAN

Stanley M. Bergman

Chairman and Chief Executive Officer

February 24, 2026

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

<u>Signature</u>	<u>Capacity</u>	<u>Date</u>
<u>/s/ STANLEY M. BERGMAN</u> Stanley M. Bergman	Chairman, Chief Executive Officer and Director (principal executive officer)	February 24, 2026
<u>/s/ RONALD N. SOUTH</u> Ronald N. South	Senior Vice President, Chief Financial Officer (principal financial and accounting officer)	February 24, 2026
<u>/s/ MOHAMAD ALI</u> Mohamad Ali	Director	February 24, 2026
<u>/s/ WILLIAM K. DANIEL</u> William K. Daniel	Director	February 24, 2026
<u>/s/ DEBORAH DERBY</u> Deborah Derby	Director	February 24, 2026
<u>/s/ CAROLE T. FAIG</u> Carole T. Faig	Director	February 24, 2026
<u>/s/ JOSEPH L. HERRING</u> Joseph L. Herring	Director	February 24, 2026
<u>/s/ ROBERT J. HOMBACH</u> Robert J. Hombach	Director	February 24, 2026
<u>/s/ KURT P. KUEHN</u> Kurt P. Kuehn	Director	February 24, 2026
<u>/s/ PHILIP A. LASKAWY</u> Philip A. Laskawy	Director	February 24, 2026
<u>/s/ MAX LIN</u> Max Lin	Director	February 24, 2026
<u>/s/ ANNE H. MARGULIES</u> Anne H. Margulies	Director	February 24, 2026
<u>/s/ SCOTT SEROTA</u> Scott Serota	Director	February 24, 2026
<u>/s/ BRADLEY T. SHEARES, PH.D.</u> Bradley T. Sheares, Ph.D.	Director	February 24, 2026
<u>/s/ REED V. TUCKSON, M.D., FACP</u> Reed V. Tuckson, M.D., FACP	Director	February 24, 2026



FOLLOW HENRY SCHEIN ON

-  @HenrySchein
-  @HenrySchein
-  @HenrySchein
-  @Henry Schein
-  @HenryScheinInc

Henry Schein, Inc.  
135 Duryea Road  
Melville, New York 11747  
U.S.A.  
(631) 843-5500  
[www.henryschein.com](http://www.henryschein.com)

